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ABSTRACT 
As a strategy to enhance immune response against tumours by a "danger signal", the 
Mycobacterium tuberculosis Ag38 gene encoding an highly immunogenic protein has 
been transduced in tumour cells. The gene was stably expressed on tumour cell surface 
by using a retroviral vector modified to express the leader and transmembrane 
sequences of the Nerve Growth Factor Receptor. Transduced cells have been used as a 
cellular vaccine in syngeneic mice and their ability to elicit an anti-tumour response has 
been evaluated against both a transplanted tumour model and against a spontaneous 
tumour model. 
In the transplanted melanoma model, vaccination with transduced cells induced a 
significant protection against subcutaneous or intravenous challenge with non-
transduced cells. In Ag38-transduced vaccinated mice a preferential Thl response was 
observed. Moreover, after challenge, a high titre of antibodies directed against tumour 
cells was detected in protected mice. Most of these antibodies were directed against 
endogenously expressed viral antigens, while no reactivity against melanocyte lineage-
specific antigens was observed. 
In the HER2/Neu transgenic mice model, which spontaneously develop stochastic 
mammary tumours after a long latency period, the onset of tumour development was 
significantly delayed in mice vaccinated with Ag38-transduced cells. The delay in 
tumour development was increased when mice were vaccinated with the Ag38-
transduced vaccine plus ·a systemic administration of IL-12 at . ~ low dose. Consistent 
with melanoma model, a preferential Thl profile was observed in mice in response to 
vaccination with Ag38-transduced cells and a CD3+CD8+ population able to respond to 
the tumour with IFN-y production was derived from these mice. No humoral response 
2 
was induced in protected mice, while an activated CD4+ T cell population producing IL-
4 was obtained from long-survived mice. 
These findings show the efficacy of a short-term protocol of vaccinations exploiting the 
adjuvant potency of a Mycobacterium tuberculosis gene. This adjuvant ·approach may 
·represent a promising immunotherapeutic strategy for cancer immunisation. 
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volume per volume 
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CHAPTER ONE 
INTRODUCTION 
1.1 TUMOUR ANTIGENS 
Malignant transformation is the end result of altered expression of genes related to 
normal cell growth control and differentiation. Altered expression results from a variety 
of mechanisms including gene amplification, somatic DNA mutation and gene 
translocation. Each mechanism results in the expression of proteins ·that have the 
potential to serve as tumour antigens and thus as targets for immune therapy. 
The molecular identification of tumour antigens, their immunodominant peptides, and 
the receptors that recognize them have placed studies of tumour immunology and 
immunotherapy in the mainstream of immunological research. 
In the past decade different immunotherapeutical protocols have provided the first 
demonstration that immune reactions against cancer antigens can lead to the regression 
of invasive tumours in selected patients. 
1.1.1 METHODS FOR THE DETECTION OF TUMOUR ANTIGENS 
Three major techniques have been used to identify cancer antigens capable of eliciting 
cellular immune reactions in humans. 
- The majority of human tumour antigens now known have been identified by a genetic 
approach based on the transfection of genomic DNA or cDNA libraries into cells 
expressing .the appropriate MHC molecule. Positive clones expressing tumour antigens 
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are identified on the basis of the ability to stimulate cytokine release by human T cells 
with specific anti-tumour reactivity (Boon, 1993; Rosenberg, 1996) (Fig. 1.1). 
- Biochemical approach have had more limited success in the identification of human 
cancer antigens. Attempts have been made to elute peptides from tumour cells or from 
MHC molecules purified from tumour cells and to detect fractions capable of 
stimulating anti-tumour T cells after pulsing purified fractions onto antigen-presenting 
cells. Triple quadrapole mass spectrometric techniques have then been used to 
sequence the minute quantities of peptides obtained (Cox et al., 1994). This approach 
has been severely limited by the need for custom-made, highly specialised equipment 
and the requirement that peptides be present in sufficient quantity to enable their 
identification by these physical techniques (Fig. 1.1 ). 
- Each of the two techniques mentioned above is dependent on the prior availability of T 
cells capable of recognising tumour antigens, a requirement that often cannot be met. 
A third approach to the identification of tumour antigens has involved attempts to 
develop, by in vitro sensitisation techniques, T cells against candidate tumour antigens 
(Parkhurst et al., 1998). Genes encoding candidate tumour antigens have been 
transfected or transduced into antigen-presenting cells or synthesised peptides from 
candidate antigens based on known MHC-binding motifs have been pulsed onto 
antigen-presenting cells and used for in vitro sensitisation's of peripheral blood 
lymphocytes (PBLs) from cancer patients. T cells successfully generated in vitro 
against candidate antigens have then been tested for their ability to recognise intact 
tumour cells, the presence of such reactivity providing evidence that these candidate 
proteins represent tumour antigens (Fig. 1.2). 
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Fig. 1.1: Genetic and biochemical approaches to identify tumour antigens 
Antigen-specific T cells are used to screen COS cells expressmg a tumour-derived 
cDNA library (genetic approach) or peptides eluted from the tumour cells are pulsed 
onto APCs (biochemical approach) (from Greten et al. , 1999). 
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Fig. 1.2: Generation of tumour antigens-specific CTL clones 
Peripheral blood lymphocytes (PB Ls) from cancer patients are in vitro sensitised by co-
culture with peptides from candidate antigens, based on known MHC-binding motifs, 
pulsed onto antigen presenting cells. Single T cells from these cultures are expanded 
into clonal CTL lines (modified from Abbas et al.). 
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For the identification of antibody-defined tumour antigens a technique has recently been 
described. This approach, called serological analysis of recombinant cDNA expression 
libraries (SEREX), uses the antibody repertoire of cancer patients for the systematic 
search for human tumour antigens. A cDNA library is constructed from fresh tumour . 
specimens, packaged into lambda-phage vectors and expressed recombinantly in 
Eschericha coli. Recombinant proteins are transferred onto nitrocellulose membranes 
and identified as antigens by their reactivity with high-titre IgG antibodies present in the 
patient's serum. Reactive clones, detected using an enzyme-conjugated secondary 
antibody specific for human IgG, are recovered and subcloned to monoclonality. The 
nucleotide sequence of the inserted cDNA, which encodes the serological-defined 
tumour antigen, is determined by sequencing (Sahin et al., 1995; Chen et al., 1997) (Fig. 
1.3). 
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Fig. 1.3: Molecular definition of tumour antigens by the SEREX technique 
A cDNA library is established from fresh tumour tissue and expressed in Escherichia coli 
using a A.-phage expression vector. The bacteria are grown in colonies and the lytic 
plaques are transferred by blotting to a nitrocellulose membrane. The diluted autologous 
serum is then incubated with the membrane and those antibodies that bind to tumour-
derived antigens expressed in lytic plaques are made visible by enzyme-conjugated goat 
anti-human IgG antibodies (from Tiireci et al. , 1997). 
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1.1.2 CHARACTERISTICS AND CLASSIFICATION OF T CELL-DEFINED 
TUMOUR ANTIGENS 
Based on the pattern of expression of the parent protein, tumour antigens can be 
classified into five major groups. 
1.1.2.1 Tumour-specific shared antigens 
This first group of tumour antigens represents those antigens encoded by genes that are 
completely silent in most normal tissues but are activated in a number of tumours of 
various histological types. 
Prototype antigens of this group are those encoded by the gene PIA in the mouse (Van 
den Eynde et al., I99Ia) and by the MAGE genes in humans (De Plaen et al., I994). 
MAGE-I and MAGE-3 genes were isolated as melanoma antigens recognised by CTL 
clones established from a single melanoma patient who was repeatedly immunised with 
mutagenized autologous tumour cells (Van der Bruggen et al., I 99 I; Gaugler et al., 
I994; Van den Eynde et al., I997). These genes belonged to a multigene family 
containing at least I2 different genes expressed not only in melanoma, but also in a 
variety of cancers, including breast, lung, prostate, bladder, laryngeal, head and neck 
cancers, and sarcomas. They are not detected in normal human tissues with the 
exception of testis (Takahashi et al., 1995). 
By screening cDNA libraries utilising T cell clones from the same patient used to 
identify the MAGE gene family, another series of multigene families called BAGE 
(Boel et. al., I 995) and GAGE (Van den Eynde et al., l 995b) have been identified. 
These gene products appear to have similar expression distributions to the MAGE gene 
family. 
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These proteins are nucleoproteins, whose biological function is not yet known. Their 
expression in cancer cells usually results from a demethylation of their promoters (de 
Smet et al., 1996). Epitopes from the MAGE, GAGE, and BAGE genes have been 
identified that are restricted by HLA-Al, -A2, -B44, and -CW16 (Traversari et al., 
1992; Gaugler et al., 1994; Van der Bruggen et al., 1994; Van der Bruggen et al., 1994; 
Fleischhauer et al., 1996; Tanaka et al., 1997). 
1.1.2.2 Tissue-specific differentiation antigens 
Tissue-specific shared tumour antigens, such as tyrosinase, MART-1/Melan-A, gplOO, 
TRP-1/gp75 and TRP-2, have been identified. These antigens are expressed in 
melanoma, normal melanocytes and retina, but not in other normal human tissues. They 
are localised in the melanosomes, which are specific organelles produced only by 
melanocytes and wherein melanin pigments are synthesised and deposited. It is not 
known why melanosomal proteins are highly immunogenic. The presence of precursors 
capable of reacting with normal non-mutated self-antigens within the tumour has 
suggested that the inflammatory microenvironment at the site of the tumour has resulted 
in the breaking of peripheral tolerance of these antigens. The role of CTLs against 
melanocyte differentiation antigens in melanoma rejection is not clear, but it is 
supported by the reported association of vitiligo, a local depigmentation of the skin 
resulting from melanocyte destruction, with prolonged patient survival and with 
spontaneous regression of melanoma (Rosenberg et al., 1996). The administration of 
TIL specifically recognising these tumour antigens to autologous patients along with IL-
2 induced tumour regression. Thus, they may represent tumour rejection antigens. 
Tyrosinase is the first member of differentiation antigens identified; it is a melanosomal 
protein with tyrosine hydroxylase, 3,4-dihydroxyindole (DOPA) oxidase and 5,6-
dihydroxyindole (DHI) oxidase activity and represents a principal enzyme involved in 
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melanin synthesis. Tyrosinase was demonstrated to give rise to different peptides 
recognised by HLA-Al-, -A2-, -A24-, -B44-, and DR4- restricted T cells (Robbins et 
al., 1994; Anichini et al., 1993; Brichard et al., 1993; Wolfel et al., 1994; Kang et al., 
1995; Brichard et al., 1996) and also to peptides that are presented by class II molecules 
to CD4+ T cells (Topalian et al., 1996). Interestingly, one of the naturally occurring 
epitopes recognised by HLA-A2-restricted CTL was found to have posttranslational 
deamidation of an asparagine residue (Skipper et al., 1996a). Adoptive transfer of one of 
the HLA-A24-restricted TIL into an autologous patient resulted in complete regression 
of tumour (Robbins et al., 1994), and, in addition, tumour regression was observed after 
immunisation with HLA-A2-binding tyrosinase epitopes (Jager et al., 1996). 
MART-1/Melan-A presents in melanosomes of melanocytes and melanoma cells, but its 
biological function has not yet been identified (Kawakami et al., 1994a; Coulie et al., 
1994; Kawakami et al., 1997). MART-1 was found to be an immunodominant 
melanoma antigen recogyised by the majority of HLA-A2-restricted melanoma-reactive 
TIL (Kawakami et al., 1994b). The peptide MART-1 27_35 was found to be the 
immunodominant common T-cell epitope recognised by CTL. The high 
immunogenicity of this epitope may be explained by its low HLA-binding affinity, 
resulting in less expression on the cell surface and less induction of tolerance to this 
epitope (Kawakami et al., 1996). It has also been suggested that crossreactive peptides 
on b~cterial or viral proteins may be responsible for the high immunogenicity of 
MART-1 (Loftus et al., 1996). Although tumour regression was not observed in several 
patients who received the MART-I-reactive TIL, evidence of tumour regression was 
observed in some patients who were immunised with the MART-1 peptide in 
incomplete Freund's adjuvant in a clinical trial (Cormier et al., 1997). 
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GplOO is a membrane glycoprotein in melanosomes and may be involved in the late 
steps of melanin synthesis. Gp 100 was found to be recognised by the murine 
monoclonal antibody HMB45 that is commonly used for the diagnosis of melanoma in 
pathology laboratories (Kawakami et al., 1994a; Adema et al., 1993a). GplOO appears 
to represent an immunodominant antigen recognised by many HLA-Al-, -A2-, -A3-, -
A24-restricted CTL (Kawakami et al., 1994a; Bakker et al., 1994; Cox et al., 1994; 
Kawakami et al., 1995; Bakker et al., 1995; Tsai et al., 1997; Skipper et al., 1996b). 
Interestingly, in contrast to other gplOO epitopes which are nonmutated self peptides, an 
epitope presented by HLA-A24 was found to be derived from an incompletely spliced 
transcript present in melanoma cells as well as in normal cultured rrielanocytes (Robbins 
et al., 1997). A significant correlation between the clinical response to adoptive transfer 
of TIL therapy and the recognition of gp 100 by TIL has been observed (Kawakami et 
al., 1995). 
TRP1/GP75 is a melanosomal glyco-membrane protein with DHI-2-carboxylic acid 
oxidase activity involved in melanin synthesis. TRP-1 was previously identified as an 
antigen recognised by IgG antibodies in the serum of a melanoma patient (Mattes et al., 
1983), suggesting the existence of CD4+ T-cells specific for this protein. TRPl was 
demonstrate_d to be recognised by HLA-A31-restricted melanoma reactive TIL (Wang et 
al., 1995). Transfer of this TIL plus IL-2 to the autologous patient resulted in tumour 
regression (Topalian et al., 1987). In the murine B 16 melanoma model, administration 
of antibody specific for TRPl was shown to result in the rejection of B16 melanoma as 
well as the development of vitiligo (Hara et al., 1995). 
TRP2 is a melanosomal enzyme with DOP Achrome tautomerase activity involved in 
melanin synthesis. TRP2 is a member of the tyrosinase-related gene family and shares 
40% amino acid sequence identity with both tyrosinase and TRPl. A TRP-2 epitope of 
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the normal TRP2 protein was found to be recognised by both HLA-A31- and HLA-
A33-restricted CTL (Wang et al., 1996). Interestingly, a mouse TRP2 was also 
identified as tumour antigen recognised by CTL reactive with the murine B 16 
melanoma (Bloom et al., 1997). Studies of the TRP2 protein represent an example of 
the use of the in vitro sensitisation techniques to identify new tumour antigenic 
epitopes. To identify· HLA-A2-restricted TRP2 epitopes, multiple peptides were 
synthesised from the TRP2 protein based on HLA-A2-binding motifs. An HLA-A2-
restricted T cell was in vitro generated against one of these TRP2 peptides, that was also 
capable ofrecognising HLA-A2+ melanomas (Parkhurst et al., 1998). 
1.1.2.3 Tumour-specific mutated antigens 
This third group of antigens correspond to peptides. derived from regions of ubiquitous 
proteins that are mutated in tumour cells. 
Three such antigens have been identified in melanomas. An HLA-B44-restricted T cell 
was identified that recognised the product of a gene termed MUM-1 (melanoma-
ubiquitous mutated) (Coulie et al., 1995). The epitope recognised ·by this T cell spanned 
an intron/exon boundary and contained a single base mutation. Since both the normal 
and mutated peptides bound efficiently to the class I HLA-B44 molecule, but only the 
mutated form could be recognised by T cells, this indicated that the mutation appeared 
to have an effect on T cell recogni~ion. 
An HLA-A2-restricted CTL clone was found to recognise the mutated product of the 
cyclin-dependent kinase 4 (CDK4) gene (Wolfel et al., 1995). A single base mutation in 
this gene resulted in the substitution of a cysteine for an arginine in an anchor position 
of this peptide and altered the binding properties of this peptide to HLA-A2. One-
hundred-fold lower concentrations of the mutant peptide were recognised, as compared 
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to the recognition of normal peptide. The CDK4 interacts with cyclin D and plays an 
important role in regulating cell cycle progression. The mutated CDK4 identified by the 
CTL had decreased kinase activity as well as decreased binding to the CDK4 inhibitor 
p 16 (Wolfe! et al., 1995), suggesting the involvement of this mutation in 
tumourigenesis. 
A TIL that recognised an HLA-A24 melanoma antigen was found to recognise a 
mutated P-catenin gene product. A single point mutation that substituted a 
phenylalanine for a serine residue gave rise to a peptide epitope that was recognised at 1 
milion times lower concentration than the normal peptide (Robbins et al., 1996). The 
same mutation in P-catenin was found in about 10% of all melanomas examined 
(Rubinfeld et al., 1997). The P-catenin mutation results in the stabilisation of the 
mutated protein, which favours the constitutive formation of complexes with 
transcription factors such as Lef-1. Constitutive P-catenin-Lef-1 complexes may result 
in persistent transactivation of as yet unidentified target genes, thereby stimulating cell 
proliferation or inhibiting apoptosis (Rubinfeld et al., 1997; Peifer, 1997). 
Another mutation which may antagonise apoptosis was identified with CTLs specific 
for a human squamous-cell carcinoma (Mandruzzato et al., 1997). The antigen is 
encoded by a mutated form of the CASP-8 gene, which product is required for the 
induction of apoptosis through Fas and the tumour necrosis factor receptor 1 (Boldin et 
al., 1996; Muzio et al., 1996). A single point mutation in the normal stop codon resulted 
in the extension of the normal open reading frame of this gene by a region of 88 amino 
acids containing a T cell epitope. The ability of the altered protein to trigger apoptosis 
appears to be reduced relative to wild-type caspase-8. 
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It is surprising that none of the frequently mutated oncogenes or tumour-suppressor 
genes, such as Ras or p53, have been picked up as targets of CTLs raised against 
tumour cells, although antibody against the proteins was detected in cancer patients. 
Synthetic Ras or p53 mutant peptides have, however, been used to generate CTL or 
rejection responses against tumours carrying the corresponding mutant genes (Skipper 
et al., 1993; Peace et al., 1994; Noguchi et al., 1994; Abrams et al., 1996). 
1.1.2.4 Overexpressed and ubiquitous tumour antigens 
A number of CTLs raised against autologous tumour cells have been found to recognise 
antigens encoded by nonmutated genes expressed in both normal and tumoural tissues, 
although the CTLs appeared to lyse the tumour cells specifically (Robbins et al., 1995; 
Ikeda et al., 1997). 
An HLA-A24-restricted TIL line reactive with HLA-A24 melanomas was used to 
isolate a previously undescribed gene called p 15 (Robbins et al., 1995). Although 
Northern blots revealed that pl5 was expressed in normal tissues, only tumour was 
recognised by this TIL. The mechanisms involved in this unique tumour recognition 
have not yet been elucidated. 
The PRAME gene encoded an antigen overexpressed in many tumours and expressed in 
low levels in a variety of normal tissues. In this case, reactive HLA-A24- restricted T 
cells were identified only against tumours that have lost the appropriate HLA-Cw7 class 
I molecule. Indeed, further studies demonstrated that these T cells expressed natural 
killer (NK) inhibitory receptors that prevent lysis of HLA class I positive cells (Ikeda et 
al., 1997). 
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Another antigen that is expressed in some normal tissues and overexpressed in tumours 
is HER-2/neu, which is found at high levels in about 30% of breast and ovarian 
carcinomas. Her-2 is a transmembrane glycoprotein with tyrosine kinase activity and 
homology to the epidermal growth factor (EGF) receptor. In breast cancer, HER-2/neu 
overexpression was reported to be associated with aggressive disease (Slamon et al., 
1987)~ IgG antibodies specific for Her2/neu and T-cell proliferative responses to 
Her2/neu proteins were detected in breast cancer patients, however the details of CD4+ 
T-cell recognition, including HLA restriction and involved epitopes, have not yet been 
determined (Disis et al., 1994). A peptide derived from HER-2/neu was found to be the 
target of lymphocytes infiltrating some HLA-A2 ovarian carcinomas (Fisk et al., 1995; 
Lustgarten et al., 1997). Recognition and lysis of ovarian cancer cells by CTLs were 
functional events also shown to correlate with the expression level of HER-2/neu in the 
tumour cells (Yoshino et al., 1994). Interestingly, breast and ovarian cancer-specific 
CTLs recognised the same epitope peptide (GP2) derived from the HER-2/neu protein 
in the context ofHLA-A2 (Peoples et al., 1995). 
Some CTLs directed against breast, ovarian and pancreatic carcinomas recognise an 
epitope of mucin (Jerome et al., 1993; Barratt-Boyes, 1996), a surface protein composed 
of multiple tandem repeats of 20 amino acids. Whereas in normal cells mucin is heavily 
glycosylated, in these tumours the peptide repeats are unmasked by underglycosylation, 
resulting in CTL recognition. Remarkably, this recognition, which depends on the 
presence of the multiple repeats, occurs in the absence of HLA restriction. 
1.1.2.5 Viral antigens 
Antigens derived from oncogenic viruses constitute another category of potentially 
useful tumour antigens. A number of viral antigens have been studied in detail on 
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virally-induced mouse tumours (Klamet et al., 1989; Tanaka et al., 1988; Kast et al., 
1989; Plata et al., 1987; Kast et al., 1991) and shown to be relevant for tumour rejection. 
In humans, more than 90% of cervical squamous cancers are Human Papilloma Virus 
(HPV)-positive (50% were HPV16-positive). HPV proteins E6 and E7 that are 
persistently expressed in these cancer cells and play an important role in oncogenesis, 
are attractive tumour-specific targets. Tumour-specific CTLs have been elicited by in 
vitro sensitisation with E7 peptides presented by HLA-A2 (Ressing et al., 1995). 
Epstein-Barr Virus (EBV) appears to be involved in oncogenesis of some cancers, a 
subset of Hodgkin's disease and immunoblastic B-cell lymphoma that develops in 
immunocompromised patients. CTL specific for EBV proteins including EBNA-2, -3A, 
-3B, -3C, -4, -6, and LMP2 have been demonstrated (Gavioli et al., 1992; Murray et al., 
1992). 
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1.1.3 NATURE OF SEROLOGICALLY-DEFINED TUMOUR ANTIGENS 
During the past few years, SEREX has been applied to a range of tumour types, 
including melanoma, renal cancer, astrocytoma, Hodgkin's disease, esophageal cancer, 
lung cancer, colon cancer, gastric cancer, breast cancer and prostate cancer. This survey 
has identified a large number of tumour antigens, more than 400, only a small fraction 
of which has been analysed beyond the initial sequencing stage. Approximately one 
third of the SEREX-defined genes are novel. Different categories of tumour antigens 
have been identified (Old et al., 1998). 
1.1.3.1 Mutational antigens 
. Antigens encoded by mutated genes have been demonstrated only rarely by the 
serological approach. An example is a mutated p53 isolated from a case of colon cancer 
(Scanlan et al., 1998). 
1.1.3.2 3p antigens 
Three SEREX-defined antigens are encoded by the p21 region on chromosome 3, a 
region known to be a hot spot of genetic abnormalities in many cancer types. An 
example is the NY-LU-12 gene, defined as human lung cancer antigen recognised by 
autologous antibodies (Giire et al., 1998). Although mutation may likely be the 
underlying mechanism for the immunogenicity of these antigens, no mutations have 
been detected yet in the coding sequences of the 3p antigens. 
1.1.3.3 Differentiation antigens 
The classic differentiation antigen tyrosinase has been detected in SEREX (Sahin et al., 
1997), demonstrating that some of the serologically identified antigens are also targets 
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for CTLs. Another example in this category is represented by the gastrointestinal tract-
related ·differentiation antigen galectin 4, defined as human colon cancer antigen 
recognised by autologous antibodies (Scanlan et al., 1998). 
1.1.3.4 Amplified and overexpressed antigens 
Several antigens coded by amplified and overexpressed genes have been identified, 
indicating that antigen overexpression can led to ·immunogenicity by overriding 
thresholds critical for the maintenance of tolerance. Examples in this category are a new 
isoform of carbonic anhydrase in renal cancer (Sahin et al., 1995), aldolase A (Gure et 
al., 1998) and the translation initiation factor elF-4y (Brass et al., 1997) in lung cancer 
and the new human galectin, galectin 9, in Hodgkin's disease (Tureci et al., 1997). 
1.1.3.5 Viral antigens 
A virus-encoded antigen that elicits an autologous antibody response is the env protein 
of the human endogenous retrovirus HERV-KlO, which was found in a renal cell cancer 
(Ono et al., 1986; Tureci et al., 1997). 
1.1.3.6 Splice-variant antigens 
Splice variants are also likely to be an immunogenic trigger as has been shown for the 
Hodgkin's disease associated antigen, restin (Sahin et al., 1995) and the colon cancer 
associated antigen, NY-C0-38 (Scanlan et al., 1998). 
1.1.3. 7 Cancer-testis antigens 
Cancer-testis antigens (CTA) represent an expanding family of tumour antigens that are 
expressed selectively in a varying proportion, 10-40%, of different cancers. In normal 
tissues expression is highly restricted, with testis being the sole or predominant site of 
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CTA expression. Three antigens in this category, MAGE, BAGE and GAGE initially 
were identified as targets for cytotoxic T cells. HOM-MEL-40/SSX2 (Sahin et al., 1995; 
Gure et al., 1997), NY-ES0-1 (Chen et al., 1997; Chen et al., 1997), SCPI (Tureci et 
al., 1998) and CT7 (Chen et al., 1998) were uncovered by SEREX analysis. Seven 
genes or gene families now belong to the CTA category and, interestingly, four of them 
have ~een shown to be coded for by the X chromosome (MAGE, GAGE, SSX and NY-
ESP-1 ). Since no evidence has been obtained for mutation or other gene rearrangements 
involving CTA-coding genes, with a single exception that involves SSX genes in a 
single case of synovial sarcoma (Crew et al., 1995), the likely explanation for 
expression of CT A in cancer cells is gene activation or derepression. MAGE expression 
has been correlated with the state of global hypomethylation generally associated with 
cancer and spermatogenesis (de Smet et al., 1996). However, this cannot be the whole 
explanation because CT A are not coordinately expressed and certain tumour types, such 
as colon cancer, rarely express known CTA. SCPI, the only CTA with a known 
function, is a synaptonemal complex protein involved in chromosome reduction during 
meiosis; it is intriguing to speculate what role aberrant expression of a meiotic protein 
in a somatic cell plays in the origins and progression of cancer. CT7 is the most recent 
CTA defined by SEREX. The CT7 gene encodes a protein with the COOR terminus 
highly homologous to the MAGE-IO and other MAGE genes over a 200 amino acid 
stretch. To find new members of the CTA family, SEREX analysis is being extended to 
screening expression libraries derived from normal testis and tumour cell lines 
expressing one or more of the known CT A. 
In conclusion, a great number of tumour antigens have been identified on the basis of 
their recognition by immune system through both T cell and/or humoral responses. The 
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identification of such large number of antigens demonstrates that immune system 
potentially has the ability to recognise and destroy tumours. 
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1.2 IMMUNE RESPONSE AGAINST TUMOUR CELLS 
The "immune surveillance" theory of Thomas (1959) was refined by Burnett in 1970, 
who formally postulated that the immune system constantly monitors the body for 
abnormal cells and destroys the majority of tumours before they become clinically 
manifest (Burnet, 1970). 
Several lines of evidence of tumour-specific immunity have been provided. In animal 
models it has convincingly been demonstrated that the immune system can recognise 
and eliminate tumour cells, especially by induction of tumour-specific T cells in cases 
where viruses play a role in the transformation event (Bernards et al., 1983; Kast et al., 
1989). Also from several types of human malignancies, T cells directed against 
autologous tumour cells have been isolated (Boon et al., 1994). In patients, spontaneous 
regression of tumours has been observed, most frequently in renal cell carcinoma and 
malignant mela~oma (Oliver et al., 1992). Furthermore, in immunocompromised 
patients, such as patients with organ transplants or HIV-infected patients, an increased 
frequency of tumours is observed (Bouwes et al., 1991; Oliver et al., 1992). 
1.2.1 SELF AND NON-SELF THEORY 
Host immune surveillance was suggested a long time ago to play a crucial role in the 
control of tumour growth on the assumption that tumour cells are seen as foreign by the 
host (Thomas, 1959; Burnet, 1970). As tumours arise after embryogenesis, negative 
thymic selection of T cells, based on self-discrimination, does not occur. Newly arising 
tumours are eliminated as they originate and only the few lacking. "neo-antigens" can 
escape immune surveillance and become clinically detectable. This theory, therefore, 
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postulated that most newly arising cancer cells are destroyed by a vigorous immune 
system. Only occasionally tumour cells, which do not express neo-antigens, escape 
immune surveillance. Therefore, these cells can divide undisturbed by the immune 
system and develop into observable tumour masses. 
The original concept of immune surveillance is no longer accepted since the molecular 
characterisation of tumour associated antigens (T AA) has shown that, for the most part, 
they are nonmutated self-molecules. Furthermore, at this point the role of immune 
suppression in the development of various cancers has not been conclusively 
established. Therefore, complex interactions between host and tumour cells that could 
lead to tumour rejection through breaks of self-tolerance similar to those which develop 
in auto-immune pathology need to be considered (Marincola, 1997). Thus, because 
most TAA are represented by nonmutated self-molecules and TM-specific CTL 
responses have been identified in patients, the growth of tumours in spite of this 
immune response represents a phenomenon of peripheral tolerance. This view assumes 
that a host TM-specific CTL response plays a predominant role in the control of 
tumour growth. Such a predominant role is still controversial and other immune 
mechanisms are likely to participate in the control of tumour growth (Sogn, 1998). 
1.2.2 DANGER MODEL 
Fuchs and Matzinger (Fuchs et al., 1996) proposed an alternative model to explain the 
coexistence in some case of effectors and target cells in tissues without the development 
of tumour rejection. In contrast with the theory that immunological recognition of 
cancer cells reflects the capacity of the immune system to discriminate between self and 
nonself molecules, this model envisions that the immune system starts an immune 
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response by detecting tissue distress (danger). It is possible that cancer cells cannot 
effectively provide danger signals and consequently the default response of T cells in 
the tumour microenvironment is turned off. 
This model best fits with the characteristics of melanoma associated antigens (MAA), 
most of which are nonmutated self-molecules (differentiation antigens) and with the 
indolent immune response to them in patients with melanoma. Furthermore, self-MAA 
specific CTL are easily generated in vitro from PBMC and TIL of patients with 
melanoma but not always do they significantly affect tumour cell growth in vivo. This 
discrepancy may reflect the lack in vivo of a second signal, which in vitro is provided in 
addition to a primary specific stimulus to induce MAA-specific CTL. 
In this view, the majority of tumours do not "escape" immune recognition but simply 
survive in a favourable environment without triggering a response. In circumstances 
where some cells undergo damage, irrespective of an immunisation protocol, the host 
immune response switches from self-tolerance to self-recognition; "tumour 
autoimmunity" occurs and malignant lesions regress. Availability of HLA class I 
antigen restricted T AA epitopes, while adequate to allow recognition and lysis of 
tumour cells by activated CTL, may not be sufficient to induce CTL activation and 
proliferation in the absence of a second stimulus provided either by costimulatory 
molecules or by stimulatory cytokines (Matzinger, 1994). Because the requirement for 
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secretion by CTL of IL-2 or other cytokines promoting their activation and proliferation 
are relatively high (Tsuji et al., 1992; Valitutti et al., 1996), CD4+ T cells may have to 
provide additional stimulation which could lead to amplification of CTL response and 
to tumour rejection. 
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1.2.3 EFFECTOR MECHANISMS IN ANTI-TUMOUR IMMUNITY 
Virtually all of the effector components of the immune system have the potential to 
contribute to the eradication of tumour cells. It is likely that each of these effector 
mechanism plays a role in the control of tumour growth, but a particular mechanism 
may be more or less important, depending on the tumour and setting. 
1.2.3.1 Antibodies 
Two major mechanisms potentially might be involved in antibody-dependent tumour 
lysis. Complement-fixing antibodies bind to the tumour cell membrane and promote 
attachment of complement components that create pores in the membrane, resulting in 
cell disruption. An alternative mechanism is antibody-dependent cell-mediated 
cytotoxicity (ADCC) in which antibodies, usually of IgG class, form an intercellular 
bridge by binding via the variable region to a specific determinant on the target cell and 
via the Fe region to effector cells expressing Fe receptors. 
The observation that sera from some tumour patients specifically recognise structures 
selectively expressed on autologous tumour, but not normal, cells provided strong 
evidence for the existence of a specific antibody response against tumour in cancer 
patients. Recently, by the SEREX approach a large number of tumour antigens have 
been identified using the antibody repertoire of cancer patients (Old et al., 1998). 
The clinical significance of antitumour antibodies in cancer patients is largely unknown. 
The presence of p53 antibodies has been reported to be associated with a poor prognosis 
(Houbiers. et al., 1995; Coomber et al., 1996), while the clinical significance of anti-
HER-2/neu antibodies and antibodies to mutated Ras oncogenes remains to be 
determined (Disis et al., 1996). More patients must be analysed to determine whether 
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the development of antibodies to tumour antigens is associated with clinically relevant 
features. 
1.2.3.2 T cells 
The T cell response is unquestionably the most important host response for the control 
of growth of antigenic tumour cells; it is responsible for both the direct killing of 
tumour cells and the activation of other components of the immune system. 
T-cell immunity to tumours reflects the function of the two T-cell subsets: class II-
restricted T cells, which largely represent CD4 helper T (Th) cells that mediate their 
effect by the secretion of lymphokines to activate other effectors cells and induce 
inflammatory responses, and class I-restricted T cells, which largely represent CD8 
cytotoxic T (Tc) cells that can also secrete lymphokines but mediate their effect mostly 
by direct lysis of tumour cells (Fig. 1.4). 
The precise contribution of each T cell subset and T cell function to the antitumour 
response appears quite variable, but tumour-specific T cells from each subset are 
capable of mediating tumour eradication and have been detected in the peripheral blood 
of individual patients and in the cells infiltrating human tumours. 
1.2.3.2 (1) Antigen presentation pathways and recognition by T cells 
The classical MHC class I pathway allows endogenous ·proteins within the cytosol to be 
presented on the cell surface to immune cells. Proteins are processed within the 
cytoplasm by degradative enzymes, probably within proteolytic complexes termed 
proteasomes. These peptides are then ferried into the lumen of the endoplasmic 
reticulum (ER) by the transporter proteins associated with antigen presentation (TAP). 
The TAP also ensures that the peptides are of a suitable size, of about 8 to 10 amino 
acid residues, for binding with class I molecules within the ER. 
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Fig. 1.4: T-cell immunity to tumours 
Tumour cells present their antigens on the surface to CD8+ T cells or release the antigen 
so that it can be taken up by professional APCs. These cells process the antigen and 
present it to CD4+ and CD8+ T cells by a mechanism called cross-priming. CD4+ T cells 
provide cytokine help for CD8+ T cells (from Greten et al. , 1997). 
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The assembled peptide-MHC complex then proceeded to the cell's surface (Fig. 1.5). 
This pathway was first characterised for viral proteins synthesised by infected host cells 
(Germain, 1994). Most of the peptides presented in this manner are self peptides to 
which the immune system is tolerant; tumour antigens may be presented in a ~imilar 
way on the tumour cell surface. 
Recognition of the tumour antigen-MHC class I complex by a naive CD8+ T cell 
bearing an appropriate TCR constitutes a signal for activation, but in order for the T cell 
to proliferate and mature into effective cytolytic T cells, the cell is dependent on various 
cytokines released by activated CD4+ T helper cells. 
A minority of tumours that express class II MHC molecules may directly activate 
tumour-specific CD4+ helper T cells. More commonly, class II-expressing· professional 
antigen-presenting cells (APCs) process and present internalised proteins derived from 
dying or phagocytosed tumour cells. APC cells include dendritic cells, which represent 
a widely-distributed heterogenous population of bone-marrow derived cells that have 
exquisite abilities of antigen presentation (Janeway, Jr. et al., 1994; Caux et al., 1995; 
Sprent, 1995), macrophages and activated B cells. 
The MHC class II pathway of antigen presentation differs from that of MHC class I 
(Germain, 1994). In the ER, MHC class II molecules are precluded from binding 
peptides by the invariant chain. The MHC class II molecule proceeds to proteolytic 
intracellular compartments, such as lysosomes and endosomes, where the invariant 
chain is removed to allow binding of peptides derived from exogenous proteins which 
have been internalised from the extracellular space (Fig. 1.6). 
1.2.3.2 (2) MHC, adhesion and accessory molecules 
The major histocompatibility complex, MHC, as described above, 1s required for 
antigen presentation. 
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Processing and presentation of peptides by MHC class I antigen processing machinery 
requires three major steps: a) the generation of antigenic peptides by the proteasome and 
other cytosolic proteases; b) peptide transport mediated by the TAP dimer from the 
cytosol into the ER; and c) the assembly of peptides with HLA class I molecules, which 
is assisted by various chaperones, such as calnexin, calreticulin, ER60 and tapasin. The 
trimeric complex comprising HLA class I H chains, P2m and peptide is then transported 
through the Golgi directly to the cell surface for presentation to CD8+ T cells (from 
Seliger et al.,2000). 
4 1 
{a) Exoge ous antigen,,.,,.{~ 
/ Cell su ace 
_ _ _ \ "'."~ ( 
\·~ .. ~/1·---------------l 
~~,. 
., En focytosis 
"""-::=-- :--... 
MllC-comp· artrnent '1f ~=~ J) ~~-!:/ 
.... 
1 . 
~ -- c . ,,. 
(<x . )3 i3 
limite J 
Gol ... i 
lr .. 
..... _ ..... 
0 I 
Pepti e 
11 
0 
(c) 
<xj~-CLIP 
. ,,,. ... · 
',. 
HLA .. DM .B (gmen) 
.a-~>SOCiated wi h LA-0-0 . lu > 
r i 
0 
(d) 
CLIP 
0 
.J ' 
/ / 
(b) E 
f Synthes is o · l1e 
l"wariant 'til c class I 
chain tieterodimer 
Q () 
Ribooorr 
Fig. 1.6: The lVIHC class II antigen-processing pathway 
..\, 
MHC class II molecules present peptides derived from exogenous antigens internalized 
in the endocytic pathway (a). HLA class II heterodimers assemble in the ER (b) with the 
invariant chains (Ii) to form nonameric a/~-Ii complexes [(a~)3Ih] , which are targeted 
to MHC class II compartments (MIIC) in the endocytic pathway. The HLA class II-
associated Ii is degradated in distinct steps, leaving class II-associated Ii peptide (CLIP) 
within the HLA class II binding groove ( c ). CLIP can then be exchanged for antigenic 
peptides and this exchange is catalysed by HLA-DM molecules (d). The HLA-DM-
dependent peptide loading is regulated by HLA-DO molecules. Peptide-loaded HLA 
class II molecules are then transported to the cell surface for presentation to CD4+ T 
cells (from Seliger et al., 2000). 
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MHC class II molecule is formed by polypeptides a and p, similar in size and both 
anchored in the surface membrane at their carboxy termini; each class I molecule, by 
contrast, consists of a structurally distinct a chain associated with a second shorter 
polypeptide, called P2-microglobulin. It is a polymorphic antigenic system initially 
recognised in transplantation experiments in tumour-bearing mice. These antigens, 
designated as HLA, are highly polymorphic membrane glycoproteins. The genetically 
inherited HLA alleles of an individual will determine the nature of the peptides capable 
of binding to these molecules. Thus, no immune response will occur against proteins 
which lack binding motifs for the HLA molecules of the host. 
The level of expression of the HLA molecules by individual tumour cells is therefore 
important in determining the outcome of an immune response. Recently, a correlation 
between the level of expression of MHC on tumour cells and the presence of T cells in 
tumour tissue was observed. In a cervical carcinoma a decreased expression of 
monomorphic HLA class I expression correlated with a significant decrease of CD8+ T 
cells within tumour cell areas (Hilders et al., 1993). 
For an effective elimination of tumour cells by cells of the immune system intercellular 
contact between the target and effector cell is required. These contacts involve, besides 
structures such as HLA or antigens for target cell recognition, structures for cell-cell 
binding (adhesion molecules) and for activation of immune cells (accessory molecules). 
One of the important interactions between effector cell and target cell is mediated by 
contact between LFA-1 and ICAM-1 (Melero et al., 1993). Tumour cells with relatively 
low expression ofICAM-1 are less susceptible to lysis by most effector cells (Braakman 
et al., 1990). 
An important costimulatory signal is represented by the activation of CD28 receptor on 
the T cell by interaction with the B7 family of accessory molecules, expressed on APC 
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cells. This interaction is required for activation of lymphocytes and its proliferation, 
leading to clonal expansion (June et al., 1994). 
1.2.3.2 (3) Thl and Th2 paradigm 
T helper cells serve an important function in the regulation of the immune respon~e by 
the production of a variety of cytokines with autocrine and paracrine effects. 
Many murine CD4+ T cell clones secrete either of two profiles of cytokines which is 
reflected in the functions of these subsets (Paul et al., 1994; Mosmann et al., 1996). Thl 
cells produce interleukin-2 (IL-2), interferon-y (IFN-y) and lymphotoxin, that enhance 
the development of cell-mediated inflammatory responses, including cytotoxic 
functions. Thus, a Thl-type reaction might be expected to favour an immune reaction 
against tumour cells. In contrast, Th2 cells produce IL-4, IL-5, IL-6, IL-9, IL-10 and IL-
13, that promote an antibody response. Such a reaction would not be expected to 
promote a cytotoxic response against tumour cells, although antibodies may mediate an 
anti-tumour effect by sensitising tumour cells to macrophage attack. 
One of the main factors that determine whether a Thl or Th2 response develops is the 
nature of the cytokines themselves. A Th 1 response is stimulated by IFN-y and IL-12, 
while IL-4 favours a Th2 response. In addition, IFN-y represses a Th2 response while 
IL-4 inhibits a Thl reaction. Therefore, once a response starts proceeding in one pattern, 
it receives positive feedback along the same direction. However, early in the response, T 
cells are probably dependent on cytokines produced by other cells. For example, 
macrophages and dendritic cells produce IL-12, and NK cells produce IFN-y when 
stimulated by IL-12, thus contributing to a Thl response. In contrast, a Th2 reaction is 
favoured by mast cells and basophils, which secrete IL-4 (Fig. 1. 7). 
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A naive CD4+ T cell is activated via the TCR when it encounters antigen (for example, 
derived from a microbe or allergen) presented by an antigen presenting cell. Once 
activated, the Th cell starts to proliferate and secrete IL-2, and expresses the IL-12 
receptor (IL-12R). On encountering IL-12 secreted by macrophages a.rid/or on contact 
with CD8a + dendritic cells (DCs), a Thl differentiation program is initiated: the IL-
12R~2 chain is upregulated in the developing Thl cell and ligation of the IL-12R by IL-
12 leads to activation of a specific transcription factor (Stat4) which initiates the Thl 
differentiation process. IL-4 produced intrinsically by the T helper precursor and 
extrinsically by several cell types as well as contact with CD8a- DCs induces 
differentiation into the Th2 subset: downregulation of IL-12R~2 expression and ligation 
of the IL-4R (expressed on the naive CD4+ T-cell surface) by IL-4 activates a specific 
transcription factor (Stat6) which initiates the Th2 differentiation process (from 
Rengarajan et al. , 2000). 
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The dose of the antigen also represents a determining factor of Thl/Th2 polarisation. 
With few exceptions, low antigen concentrations and low dose infections tend 
preferentially to induce Thl responses, whereas high doses induce Th2 development 
(Bretscher et al., 1992; Hosken et al., 1995). 
The mechanism underlying these effects of antigen dose is not well understood. It is 
possible that, at low doses of antigen, the principal antigen-presenting cells (APCs) are 
dendritic cells, or macrophages if the antigen is a particulate microbe. Both dendritic 
cells and macrophages produce IL-12 and tilt the balance of the specific T-cell response 
towards Thl differentiation. Conversely, when the antigen concentration is high, it may 
be presented by APCs that do not secrete IL-12, thus favouring Th2 development. It is 
also possible that high concentrations of antigen lead to repeated T cell stimulation, thus 
increasing IL-4 production and Th2 development, or induce a state of immunological 
tolerance, which often preferentially shuts offThl cells (De Wit et al., 1992). 
1.2.3.3 Natural killer (NK) cells 
NK cells are a subset of lymphocytes, characterised morphologically as large granular 
lymphocytes, which are phenotypically CD3-negative, TCR ( af3 and y8)-negative and 
CD16 positive (Abbas et al.). 
A role for NK cells in tumour immunity in vivo is suggested by indirect evidence: 
experimentally induced and transplanted tumours grow more rapidly in NK-deficient 
animals (Talmadge et al., 1980; Karre et al., 1980). 
NK cells can kill a wide range of tumour targets in vitro. The mechanism by which NK 
cells preferentially recognise and lyse transformed, rather than normal, targets is not 
well defined. In marked contrast to killing by CTLs, whose ability to recognise targets 
depends on antigen presentation by MHC class I molecules, natural killing is inhibited 
by MHC class I molecules and is enhanced by their absence. NK cells recognise but 
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receive an off-signal from class I molecules and thus preferentially lyse target cells with 
diminished expression of self-class I MHC molecules. 
Studies of human NK cells have led to the identification of a set of NK cell inhibitory 
·molecules: the killer cell inhibitory receptor (KIR) family. KIR molecules are members 
of the immunoglobulin supergene family and are expressed as monomers on NK cell 
membrane, oriented with their amino termini extracellularly. These molecules interact 
with MHC class I molecules and, as a result of this interaction, inhibit natural killing. 
Individual KIR molecules, which appear to consist of at least 10 members of the family, 
differ in the particular class I molecules they recognise. Differential expression of KIR 
molecules may therefore generate subsets of NK cells with differing abilities to kill 
targets. The ability ofNK cells to kill MHC class r cells clearly implies the existence of 
an "on signal" whenever NK cells interact with potential target cells. The surface 
receptor(s) responsible for NK-cell triggering in the process of natural cytotoxicity 
remained unknown until recently. These surface receptor(s), are collectively termed 
"natural cytotoxicity receptor" (NCRs) (Abai et al., 1999). Moreover, some data suggest 
the existence of other molecules which function as co-receptors in human NK cell 
triggering. A suitable candidate for this function is the 2B4 molecule (Moretta et al., 
2000) (Fig. 1.8). 
Cytolysis by NK cells is mediated by the release of a cytotoxic factor(s) and the use of 
perforins to puncture holes in the target cell membrane. 
The cytotoxic activity of NK cells can be augmented both in vitro and in vivo with the 
lymphokines interleukin-2 (IL-2) and interferon, and thus NK activity can be amplified 
by immune T cell response. Therefore, NK cells may represent a first line of host 
defense against the growth of transformed cells at both the primary and metastatic sites, 
as well as providing an effector mechanism recruited by T cells to supplement specific 
antitumour response. 
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Upon interaction with potential target cells, activating receptors expressed at the NK-
cell surface, including constitutively expressed (NKp46 ai1d NKp30) and inducible 
(NKp44) natural cytotoxicity receptors (NCRs), interact with their ligands on target 
cells. In the absence of concomitant inhibitory signals (in the case of HLA class r cells), 
this leads to NK-cell triggering and target cell lysis. In the case of normal cells 
expressing HLA class I molecules, the interaction between inhibitory receptors and 
HLA class I molecules delivers inhibitory signals that overcome NK-cell triggering, 
thus preventing target-cell lysis. The activation function of the 2B4 coreceptor is 
dependent upon the simultaneous engagement of the NCRs (from Moretta et al., 2000). 
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An interesting subpopulation of NK cells has been defined over the past 10 years. This 
population, defined NK 1.1 + T cells, co expresses an invariant T cell antigen receptor 
(TCR) a chain, encoded by the Va14 and 1a281 gene segments, associated with 
polyclonal V p8, V p 7 and V p2 TCR B chains, and receptors of the NK lineage. 
These cells have the unique potential to very rapidly secrete large amounts of 
cytokines, providing early help for effector cells and regulating the Thl or Th2 
differentiation of some immune responses. NK 1.1 + T cells recognise the products of the 
conserved family of MHC class I-like CDl genes, which represent a family of non-
polymorphic molecules able to bind and present lipid-containing antigens derived from 
intracellular pathogens. 
NKl .1 T cells were found to be an essential target of IL-12-mediated tumour rejection. 
Indeed, interleukin-12-induced rejection of tumours were not observed in NKl.1 cell-
deficient mice, characterised by a specific deletion of Ja281 gene segment and thus 
lacking of NKl .1 subpopulation (Cui et al., 1997). 
1.2.3.4 Macrophages 
Macrophages are potentially important in anti-tumour immunity as antigen-presenting 
cells to initiate the immune response and as potential effector cells to mediate tumour 
lysis. Resting macrophages are not cytolytic to tumour cells in vitro but can become 
cytolytic if activated with macrophage-activating factors (MAF). MAF are commonly 
secreted by T cells following antigen-specific stimulation; T-cell lymphokines with 
MAF activity include interferon gamma, TNF, IL-4 and granulocyte-macrophage 
colony-stimulating factor (GM-CSF). The mechanisms by which macrophages 
recognise tumour cells and mediate lysis are not defined, but activated macrophages 
bind to and lyse transformed cells in marked preference to normal cells. Several distint 
lytic mechanism may be operative, depending on the MAF responsible for activating the 
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macrophages. These include intercellular transfer of lysosomal products, superoxide · 
production, release of neutral proteinases and secretion of the mono kine TNF (Abbas et 
al.). Macrophages express Fey receptors; thus, a further mechanism may be represented 
by their targeting to tumour cells coated with antibody. 
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1.1.4 MECHANISMS OF TUMOUR ESCAPE 
Malignant melanoma has been the human tumour system most extensively studied, 
because of the greater availability of TAA-specific T cells that can be isolated from 
patients with this disease. Several CTL-defined melanoma-associated antigens (MAA) 
have been identified. Some of the identified human MAA have already undergone 
testing in patients and a large amount of data has been rapidly accumulated ·on the 
immune and clinical responses these MAA elicit (Nestle et al., 1998; Rosenberg et al., 
1998). These studies have shown that in the majority of patients immunisation with 
MAA does not yield the clinical responses predicted by murine models. Furthermore, 
progression or recurrence of disease has been observed in spite of the induction or 
persistence of MAA-specific CTL response. The utilisation of defined MAA or 
peptides, derived from their sequence, for vaccination of patients with advanced 
melanoma has yielded an opportunity to analyse the dynamics of in vivo interactions 
between the host immune system and tumour cells in human and to analyse in detail the 
molecular mechanism utilised by tumour cells to escape from CTL recognition. 
Many potential mechanisms permitting escape from immune destruction have been 
identified. 
1.1.4.1 Inadequacy of tumour cells as targets 
The recognition oftumour cells by CTL requires a sufficient presentation to TCR of 
tumour associated antigen (T AA) derived peptides in association with the restricting 
HLA class I allele. Defects in expression of either T AA or HLA class I molecules, as 
well as those molecules involved in generation of peptides from TAA and transport 
through the tumour cell, can provide tumour cells with an escape mechanism from CTL 
recognition. 
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1.1.4.1 (1) TAA loss or down-regulation 
Alteration in TAA expression is one of the mechanisms .by which tumour cells may 
escape CTL recognition in vivo. Changes in TAA expression range from down-
modulation to total loss. 
Using the murine mastocytoma P815 tumour model, Biddison and Palmer (Biddison et 
al., 1977; Uyttenhove et al., 1983) presented the first evidence that tumour escape may 
be due to the emergence of stable antigen-loss variants. Tumour cells of the subline 
P815-Y that were collected from the peritoneal cavity of tumour bearing animals a few 
days after the partial rejection phase were less sensitive to CTL lysis than the original 
tumour cells. The molecular basis for this finding subsequently was elucidated by Boon 
and his colleagues (Van den Eynde et al., 1991a; Boon et al., 1992; Lethe et al., 1992). 
These authors identified the gene P 1 A, silent in normal tissues with the exception of 
testes, which encodes the mastocytoma's tumour rejection antigen. This antigen is 
composed of two distinct CTL epitopes. Because of deletions within the P 1 A gene, both 
epitopes are undetectable in P815 mastocytoma cells that escape tumour rejection in 
vivo. This finding provided convincing evidence that tumour cells can escape from CTL 
recognition because of the development of variants that no longer express the rejection 
antigen(s) recognised by TAA-specific CTL. 
Most knowledge about alterations in antigen expression in human tumours comes from 
studies performed with melanoma cells, which demonstrated an heterogeneity in both 
CTL-defined and antibody-defined MAA expression. For example, among members of 
the MAGE family, studies utilising reverse transcriptase polymerase chain reaction 
(RT-PCR) showed that MAGE-1 was not expressed in a significant proportion of 
melanoma. lesions, while MAGE-3 had a wide distribution in melanoma and in other 
malignancies (Van der Bruggen et al., 1991 ). The differences in degree of expression 
among members of the MAGE family and other cancer testis antigens appear to reflect 
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different susceptibility to a genome-wide demethylation process associated with tumour 
progression (de Smet et al., 1996). Furthermore, studies using mAb specific for gp 100, 
Mart-1/MelanA and tyrosinase have revealed that most primary melanoma lesions 
express these tumour differentiation antigens (De Vries et al., 1997; Busam et al., 
1998), while metastases are quite heterogenous in their expression (Scheibenbogen et 
al., 1996; De Vries et al., 1997; Cormier et al., 1998; Riker et al., 1999). In particular, 
gplOO and Mart-1/MelanA have not been detected in about 10-20% of metastatic 
lesions, whereas tyrosinase appears to be less frequently lost (Chen et al., 1995; 
Cormier et al., 1998). 
1.1.4.1 (2) HLA class I antigen loss or down-regulation 
Selective loss of MHC class I alleles was first described in several mouse tumours, 
including the TL leukaemia cell line, the Tl 0 sarcoma, the 3LL Lewis lung carcinoma 
and the B 16 melanoma. It was soon realised that this phenotypic alteration may permit 
tumour cells to avoid and to survive attack by the immune system. This notion was 
supported by the enhanced growth of mouse tumour cells which had down-regulated 
MHC class I antigen expression following transfection with antisense DNA (Hui, 1989) 
and by the loss of tumourigenicity of aggressive MHC class I-negative mouse tumour 
cells following transfection with MHC class I genes (Hui et al., 1984a). 
HLA class I antigens are lost or down-regulated in many types of human tumours. The 
most common types of solid tumours analysed for HLA class I antigen expression 
include melanoma and carcinoma of the breast, cervix, colon, head and neck squamous 
cell, kidney and prostate. 
The altered HLA class I expression is summarised from these studies as loss or down-
regulation of monomorphic determinants or selective down-regulation of one or more 
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allospecificity(ies). Several distinct molecular mechanism that underlie the vanous 
phenotypes have been identified. 
Total HLA class I antigen loss in tumour cells is caused by mutations in the p2m gene 
that result in loss of functional P2microglobulin expression. Mutations in the p2m gene 
have been described in colon and lung carcinoma and in malignant melanoma (D'Urso 
et al., 1991; Wang et al., 1993; Bicknell et al., 1994; Chen et al., 1996; Hicklin et al., 
1997; Hicklin et al., 1998; Benitez et al., 1998). 
In contrast to total loss, HLA class I antigen down-regulation on tumour cells can reflect 
a defect in the regulatory mechanism responsible for the expression of HLA class I 
heavy chains. For example, tumour cell lines with HLA class I antigen down-regulation 
were shown to have altered binding of regulatory factors to HLA class I heavy chain 
gene enhancer elements (Henseling et al., 1990; Blanchet et al., 1991; Blanchet et al., 
1992). 
Abnormalities in HLA class I antigens may selectively affect only some of the HLA 
class I allospecificities encoded in malignant cells. Loss of an HLA class I haplotype 
has been described in malignant melanoma and pancreatic carcinoma (Marincola et al., 
1994; Torres et al., 1996), and a selective down-regulation of a gene product of the 
HLA-A or HLA-B locus has been found frequently in tumour cell lines (Marincola et 
al., 1994; Hicklin et al., 1998) and in surgically removed lesions (Kim et al., 1996a). 
1.1.4.1 (3) Defects in HLA class I-dependent antigen processing 
HLA class I antigen down-regulation frequently is associated with defects in antigen 
processing. Correct assembly of HLA class I molecules and efficient presentation of 
antigenic peptides is dependent on the generation of peptides by the proteasome 
complex and the transport of these peptides into the endoplasmic reticulum, where they 
are assembled with HLA class I heavy chains and p2_microglobulin. Tumour cells may 
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alter expression of components of the HLA class I antigen processing pathway leading 
to abnormal processing and presentation of T AA. 
Several studies have demonstrated abnormal expression of the proteasome subunits 
LMP2 and LMP7 and/or the transporter subunits TAPl and TAP2 in cell lines of 
hepatocellular, lung, prostate and renal carcinomas, lymphoma, malignant melanoma 
and neuroblastoma (Seigler et al., 1971; Ferrone et al., 1995; Rowe et al., 1995; Sanda 
et al., 1995, Alpan et al., 1996; Kurokohchi et al., 1996; Seliger et al., 1996; Singal et 
al., 1996; Johnsen et al., 1998; White, 1998). Simultaneous down-regulation of multiple 
components has been detected in several cell lines. The LMP and/ or TAP gene 
transfection of these cell lines restores HLA class I presentation of antigens and tumour 
cell recognition by antigen-specific CTL. 
Little information is available about the molecular basis of LMP and/or TAP down-
regulation in malignant cells. Synchronous loss of LMP and TAP subunits in some 
tumour cell lines suggests that various mechanisms of gene regulation are defective in 
these cells; in support of this hypothesis, this phenotype can be corrected by treatment 
with IFN-y (Restifo et al., 1993; Seliger et al., 1996; Johnsen et al., 1998; White, 1998). 
To date only one study has described a genetic mutation in tumour cells involving an 
antigen processing molecule, represented by a point mutation in the TAP 1 gene in a 
lung carcinoma cell line (Chen et al., 1996). This mutation introduces a premature stop 
codon which results in a nonfunctional TAPl protein (Chen et al., 1996). 
1.1.4.2 Potential role of HLA class I polymorphism in tumour cell escape 
Many melanoma-associated antigens (MAA) contain multiple peptide sequences that 
can function as T cell epitopes in the context of the same or different HLA class I 
alleles. Bulk TIL populations include subpopulations of T cells specific for more than 
one MAA. Thus, the host immune response against cancer cells potentially is broad. 
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Contrasting with this potential wealth of T cell/tumour cell interactions is, however, the 
practical observation that most often MAA immunodominance is restricted to few HLA 
class I alleles and TIL recognise predominantly one MAA epitope for each tumour. This 
phenomenon, which is referred to as epitope immunodominance, reflects discrepancies 
between the number of peptides within an antigenic protein that could bind to a 
particular HLA class I allele and the number of epitopes actually recognised in a CTL 
response to that protein (Kim et al., 1998b). 
Most MAA preferentially function as immunogens m association with particular 
restriction elements. For example, clonal analysis of MART-1/MelanA-specific CTL 
showed that MART-1/MelanA immunodominance is strongly restricted to the epitope 
resulting from the MART-127_35 peptide in association specifically with the HLA-A0201 
allele (Kawakami et al., 1994b; Rivoltini et al., 1995). Thus, autologous induction of 
MART-1/MelanA-specific CTL by whole antigen processing and presentation is 
restricted to a unique HLA class I allele/ligand combination and is excluded by minimal 
changes in HLA class I allele structure. 
Thus, this strong restriction to a unique HLA class I allele/ligand combination may have 
important implications in relation to escape mechanisms. Indeed, the loss of the specific 
combination, if due to a limited defect in only ohe of the two molecules could result in 
the lack of presentation of the tumour antigen. 
1.1.4.3 Inhibitory signals provided by the tumour microenvironment 
Other mechanisms, which do not involve the direct interaction of T cells with the MHC 
class I-restricted tumour associated antigen, can independently affect tumour-host 
interactions and represent alternative means of tumour escape. 
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1.1.4.3 (1) Immunoregulatory cytokines 
Within the microenvironment, host defenses against the tumour are controlled by 
immunological mediators, particularly cytokines. 
Secreted cytokines can have a stimulatory or an inhibitory role in immune response. 
Tumour cells, as well as normal cells, indeed, can spont~eously release in the tumour 
microenvironment immunosuppressive cytokines, that inhibit host immune function 
(Chouaib et al., 1997), as well as stimulatory factors, that make tumour cells more 
susceptible to recognition. 
Several lines of evidence have demonstrated the presence of different cytokines in the 
tumour microenvironment. 
For example, recently, IL-6 has been shown to be expressed specifically in the tumour 
microenvironment in 83% of patients with colorectal carcinoma (Piancatelli et al., 
1999); this cytokine, which is known to have multiple effects on T cell function may 
play a significant role in modulating T cell reactivity at the tumour site. 
IL-10 has pleiotropic effects on T-cell functions. These include suppression of 
granulocyte macrophage colony stimulating factor, IFN-y and IL-2 production by T 
helper cells, inhibition of T cell proliferation, downregulation of expression of adhesion 
molecules and HLA class I and class II antigens. Although immune cells represent the 
. major source of IL-10, this cytokine can also be secreted by melanoma cell lines and 
can be found in tissue samples from patients with metastatic melanoma (Dummer et al., 
1996). 
TGF-p, which has a predominant role as suppressor of CTL function, has been 
demonstrated to be secreted by different tumour cell lines (Dummer et al., 1996; Gorsch 
et al., 1992). 
In situ expression of TGF-P is common in tumours and correlates with progression of 
melanoma (Schmid et al., 1995; Van Belle et al., 1996; Moretti et al., 1997) and other 
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skin tumours (Schmid et al., 1996). Particularly TGF-P2 and TGF-P3 are expressed in 
melanoma lesions but are not detectable in melanocytes. Furthermore, the level of TGF-· 
P tends to increase with tumour progression because it is lower in thin primary 
melanoma lesions than in thick primary melanoma lesions and in metastases (Moretti et 
al., 1997). It has been proposed that the presence of TGF-P in situ is due to the paracrine 
secretion of this cytokine by tumour cells, as occurs in cell lines from melanoma 
metastases (Rodeck et al., 1991 ). 
Cytokines present in the tumour microenvironment may modulate local interactions 
between CTL and tumour cells via many different mechanisms. For example, cytokines 
can alter the expression of adhesion molecules on the peritumoural endothelium (Yoong 
et al., 1998) and on target tumour cells (Vanky et al., 1990; Cao et al., 1997; Lefor et 
al., 1998). The presence of adhesion molecules facilitates trafficking of T cells to the 
tumour site and reinforces the physical interaction of T cells with tumour cells. For 
example, ICAM-1, which is known to reinforce CTL/tumour interactions, can be 
induced or enhanced in normal and malignant cells in vitro and in vivo by IFN-y, 
interleukin (IL)-10 and tumour necrosis factor-a (TNF-a) (Temponi et al., 1988; Maio 
et al., 1989; Maio et al., 1989; Mortarini et al., 1990; Yue et al., 1997). 
Expression of adhesion molecules, such as ELAM-1, ICAM-1 and VCAM-1, may 
influence tumour progression (Johnson, 1991; Dyer, 1999; Maurer et al., 1998; Terol et 
al., 1998) and various malignant cell lines or tissues, including melanoma, have been 
demonstrated to have heterogeneous and often decreased expression of adhesion 
molecules (Mortarini et al., 1990; Braendstrup et al., 1996; Budinsky et al., 1997). 
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1.1.4.3 (2) Sulface expression of apoptotic signals 
Cancer cells are frequently resistant to apoptosis mediated through Fas. It has been 
reported "that high levels of Fas ligand (FasL) are expressed in a high percentage of 
melanoma cell lines and surgically removed melanoma tumours. Furthermore, high 
levels of FasL were also reported to be present in sera from patients with melanoma 
(Hahne et al., 1996). 
These findings suggested a novel mechanism utilised by tumour cells to escape from T 
cell recognition. Through interaction with Fas on the surface of TIL, FasL could 
counterattack and extinguish TAA-specific CTL at the tumour site. This model provides 
a mechanism for the lack of tumour regression in spite of the presence of T AA-specific 
CTL in malignant lesions. 
Besides melanoma, detection of FasL in a number of cell lines and a variety of 
surgically removed malignant lesions has been reported. The tumours include 
astrocytoma (Saas et al., 1997), glioblastoma (Gratas et al., 1997), esophageal (Bennett 
et al., 1998), lung (Niehans et al., 1997), hepatocellular (Strand et al., 1996) and colon 
(O'Connell et al., 1996; Shiraki et al., 1997) carcinoma. 
In addition to the expression of high level of FasL, other mechanisms have been 
demonstrated to be responsible for cancer cells resistance to apoptosis. This might be a 
result of downregulation of Fas or the release of soluble Fas, or abnormalities in the 
level of several proteins involved in the signal transduction cascade. Moreover, there is 
some evidence that some oncogene and tumour suppressor gene mutations, commonly 
found in tumours, could potentially impair Fas signalling (O'Connell et al., 1999) (Fig. 
1.9). 
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Fig. 1.9: Mechanisms of resistance to apoptosis 
Cancer cells are frequently resistant to apoptosis mediated through Fas. This might be a 
result of downregulation of Fas or release of soluble Fas, or abnommlities in the level of 
several proteins involved in the signal transduction cascade ( downregulation of caspase 
1, Bax or Bak, and upregulation of FLIP, FAP-1 or Bcl2). In addition, mutations have 
been identified in some components of the pathway, including Fas itself and caspase 8. 
There is evidence that some oncogene and tumour suppressor gene mutations, 
commonly found in tumours, could potentially impair Fas signaling (p53 and Ras) or 
cooperate to Fas resistance (c-Myc). Many cancer cells also express FasL and can 
therefore counterattack and kill Fas-sensitive tumour-infiltrating lymphocytes (TILs) 
(from O'Connel et al. , 1999). 
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1.3 CANCER IMMUNOTHERAPY APPROACHES 
It has been more than 100 years since the first reported attempts to activate a patient's 
immune system to eradicate developing cancers. In the 1890s, William Coley began to 
treat cancer patients with bacterial extract's (Coley' toxins) to activate general systemic 
immunity, a portion of which might be directed against the tumour. 
The molecular understanding of immune recognition and the molecular identification of 
tumour specific antigens provided opportunities to create immunotherapy approaches 
with much greater potency and specificity for tumour cells and diminished toxicity for 
normal tissues (Fig. 1.10). 
Three basic approaches have been used to treat patients with cancer usmg 
immunotherapy: 
passive or adoptive immunotherapy, in which anti-tumour immune response 1s 
augmented by infusion in patient of tumour-reactive immune cells or antibodies; 
therapy with cytokines, in which immune response is amplified by administration of 
one or more cytokines; 
active immunotherapy or vaccination, in which the immune system is stimulated to 
respond to tumour antigens, by administration of antigens, presented in variable 
forms, as vaccines. 
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Fig 1.10: Overview of current strategies in experimental immunotherapy of 
tumours 
Tumour-specific mAbs can mediate cytolysis either by engagmg NK cells via Fe 
receptors (ADCC) or by complement activation. Bispecific antibody construct are 
designed to bring immune effector cells into contact with tumour cells and to 
simultaneously stimulate their cytotoxic activity. Recombinant fusion products of 
antitumour antibodies and cytokines can concentrate immune effector functions at the 
tumour site. CTLs can be activated against tumour antigens by tumour cells rendered 
immunogenic by expression of either costimulatory molecules or cytokines. Effective 
stimulation of tumour-specific CTLs is achieved by dendritic cells loaded with peptides 
or exposed to tumour-cell lysates, tumour proteins, DNA, or transfected with cDNA 
coding for tumour protein in an expression vector (from Ockert et al. , 1999). 
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1.3.1 PASSIVE OR ADOPTIVE IMMUNOTHERAPY 
1.3.1.1 Cellular adoptive immunotherapy 
Cellular adoptive immunotherapy of malignancies involves the passive transfer of 
antitumour-reactive cells into a host in order· to mediate tumour regression. T cell 
populations that recognise tumour can be derived from cancer patients expanded in vitro 
to large numbers and used for the adoptive immunotherapy of cancer. 
The in vitro expansion and subsequent infusion of tumour-specific T cells into tumour-
bearing hosts has proven efficacious in a variety of murine tumour models (Cheever et 
al., 1986; Greenberg et al., 1985; Greenberg, 1991). Both CD4- and CDS-positive T 
cells have activity, apparently independent of the MHC status of the tumour, suggesting 
that multiple antitumour effector mechanisms can be recruited. In addition to rejecting 
the neoplasm, these animals developed a long lasting systemic immunity (Fass et al., 
1972; Colombo et al., 1985). 
However, clinical studies in patients usmg cellular adoptive immunotherapy 
demonstrated variable results and limited success and its potential efficacy is still under 
debate. 
Tumour-reactive T cells have been generated from several sources including peripheral 
blood, the site of growing tumour and lymph nodes draining tumours. 
The first clinical protocols describing the use of cellular adoptive immunotherapy in 
patients with renal cell carcinoma and melanomas reported that more than 30% of 
patients with advanced melanoma had an objective clinical response (Rosenberg et al., 
1987). These results were obtained with the use of peripheral blood lymphocytes (PBL ), 
activated in vitro in the presence of high doses of recombinant interleukin-2. These 
cells, named lymphokine activated killer (LAK) cells, have the capability of lysing not 
only autologous, but also allogeneic cancer cells. The clinical results obtained were 
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interesting but the severe toxicity of the approach, associated with a number of 
treatment-related deaths, limited its application in clinical trials: 
Tumour infiltrating lymphocytes subsequently were used. These cells are concentrated 
in vivo at the tumour site and can be isolated and expanded in culture in the presence of 
recombinant IL-2. At least a fraction of TIL was shown to kill human tumour cells in an 
HLA class I-restricted fashion, suggesting specific recognition of tumour antigens. 
These cells were used in adoptive cellular immunotherapy of advanced melanoma 
patients with promising clinical results (Rosenberg et al., 1988). Indeed, a variable 
percentage of patients (up to 40% in ·some studies) had objective clinical responses with 
the use of intravenous infusion of several billions (100-700) of in vitro-expanded TIL, 
in combination with high doses of rIL-2. However, further clinical studies using lower 
doses of IL-2 to reduce the very severe toxicities observed in the original trials, reported 
lower percentage of responses (Dillman et al., 1991; Arienti et al., 1993; Goedegebuure 
et al., 1995). 
Methods to genetically modified TIL to enhance their antitumour abilities and optimise 
adoptive immunotherapy have been developed by gene transfer techniques (see chapter 
1.4). 
1.3.1.2 Antibody therapy 
Monoclonal antibodies (MoAb) developed against tumour associated antigens have 
been tested in a variety of forms in different clinical settings. 
Antibodies can activate immune effector functions. Antibody that binds to the target 
antigen can mediate cell killing by complement fixation, opsonization or antibody-
dependent cell-mediated cytotoxicity. 
In the last few years, the availability of recombinant engineering techniques to 
manipulate the structures of antibody-based proteins has revolutionised their use in 
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cancer therapy. In order to reduce immunogenicity, humanised antibodies have been 
constructed by engineering chimeric antibodies· with a human backbone (Winter et al., 
1991) or by production from transgenic mice (Jakobovits et al., 1995). Chemically 
digested and recombinantly prepared antibody fragments have been created to improve 
tumour penetration and rapid systemic clearance (Adams et al., 1998). 
Multiple antibody-based strategies have been developed and used in therapy of cancer. 
1.3.1.2 (1) Unconjugated antibodies 
The effectiveness of unconjugated monoclonal antibody depends on the ability of these 
molecules to accumu_late at tumour sites and then stimulate the biological response. 
Several clinical trials have been conducted using unconjugated antibodies and their 
derivatives. 
In a randomised trial, 189 colorectal cancer patients, who had undergone curative 
resection for Duke's C cancer, received either monclonal antibody to the tumour-
associated antigen 17-lA, a 34-KDa glycoprotein of the cell membrane of epithelial 
cells, or were assigned to an observation arm (Riethmi.iller et al., 1994). At a median 
follow-up of 5 years, the mortality rate and recurrence were reduced by 30% and by 
27%, respectively, in the treatment group compared to controls. By 7 years of follow-
up, the survival benefits were maintained (Riethmi.iller et al., 1994). 
Encouraging results have also been demonstrated with antibody-based therapy in 
leukaemias and lymphomas (Kaminski et al., 1996). A chimeric monoclonal antibody to 
CD20 recently was licensed for use in relapsed low grade or follicular non-Hodgkins B 
cell lymphoma (Maloney et al., 1998). 
In patients with metastatic breast cancer, who had received extensive prior anti-cancer 
therapy, treatment with anti-pl85 HER2, Herceptin, produced response rates 
comparable to third or fourth-line chemotherapy, but with minimal toxicity (Baselga et 
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al., 1996). The antibody binds to HER2/c-erbB2, a transmembrane tyrosine kinase 
receptor overexpressed in approximately 30% of primary breast cancers. A multicentre 
controlled trial of 469 women with HER2-positive metastatic breast cancer was 
randomised so the women received doxorubicin and cyclophosphamide or paclitaxel 
with or without Herceptin. At a median follow-up of 25 months, a significant survival 
benefit for women receiving concurrent Herceptin was observed (Slamon et al., 1998). 
1.3.1.2 (2) Conjugated antibodies 
In contrast to immunologically oriented strategies, antibodies used in 
immunoconjugates are designed to provide targeting specificity to cytotoxic moieties. 
Monoclonal antibodies have been conjugated to catalytic toxins, chemotherapeutic 
agents and radionuclides. 
Several plant and bacterial catalytic toxins have been used (Fitzgerald et al., 1989; 
O'Toole et al., 1998). These toxins require internalisation and intracellular processing to 
exert their effect by inhibiting protein synthesis. The internalisation is mediated by a 
cell-binding chain, which, in the construction of immunotoxins, is substituted by 
specific anti-tumour monoclonal antibody, able to target the toxin to the tumour cell. 
Clinical trials have been performed using immunotoxins in patients with breast cancer, 
ovarian cancer, colorectal cancer, melanoma and lymphoproliferative disorders. In a 
study on 14 patients with B-cell lymphoma, five clinical responses were observed after 
treatment with an anti-CD22, a B cell marker, monoclonal antibody conjugated to ricin 
A chain (Vitetta et al., 1991 ). 
Monoclonal antibodies are also used to deliver conventional chemotherapy agents to 
tumour sites. Preclinical results were obtained using the immunoconjugated BR96-
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doxorubicin (Trail et al., 1993) in rodent models; however, a dose-limiting toxicity was 
observed in a series of phase I clinical trials. 
In contrast to toxin- and drug-conjugates, radioimmunoconjugates can exert their toxic 
effect over several cell diameters from the radiation source and do not require 
internalisation for their activity. Stable labelling techniques have been developed to 
prevent radionuclides from dissociating in vivo, and improved linkers have been 
obtained for appropriate monoclonal antibody stability. 
A radiolabelled conjugate of the anti-CD20 monoclonal antibody was used in clinical 
trials in highly pretreated patients with recurrent low-grade lymphoma. A complete 
response rate of greater than 80% and a 62% rate of progression-free survival at 2 years 
was observed (Wahl et al., 1998). 
Novel immunoconjugates composed of antibodies and cytokines have been recently 
created. These molecules can establish cytokine/chemotactic gradients to encourage 
. cytotoxic leukocyte accumulation and proliferation at tumour site (Sabzevari et al., 
1994; LeBerthon et al., 1991). 
1.3.1.2 (3) Bispecific antibodies 
Bispecific antibodies are double-specific monoclonal antibodies, designed to activate a 
cellular immune response by cross-linking immune cells to tumour cells. The 
simultaneous recognition of a target antigen and of a cytotoxicity trigger on 
lymphocytes, mediated by the same antibody molecule, can induce the destruction of 
tumour cells by the effector cells (Segal et al., 1988). Such molecules can be prepared 
by chemical conjugation, hybridoma fusion or by creation of recombinant molecules. 
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Clinical trials have been conducted using bispecific antibodies targeting T cells via 
CD3. Intraperitoneal administration of a bispecific antibody directed against the a-
folate receptor, which is overexpressed on 90% of ovarian carcinoma, and CD3 in 
combination with autologous lymphocytes and interleukin-2 induced a high proportion 
of clinical responses in patients with stage III ovarian carcinoma (Canevari et al., 1995). 
Bispecific antibodies targeting HER2/neu and the high-affinity Fey receptor (Valone et 
al., 1995), expressed by monocytes and activated neutrophils, or the low affinity Fey 
receptor (Weiner et al., 1995), expressed by natural killer cells and mature 
macrophages, exhibited some clinical activity in a phase I trial. 
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1.3.2 CYTOKINE THERAPY 
Cytokines have been used to enhance MHC-restricted and unrestricted tumour 
cytotoxicity. 
1.3.2.1 Interferons 
Interferon-a (IFNa) is perhaps the most widely· studied biologic response modifier in 
current use. By upregulating the expression of MHC class I and class II, as well as 
tumour-associated antigens, IFNa renders tumour cells more susceptible to destruction 
by T lymphocytes. It also stimulates the cytolytic activity of natural killer cells and 
cytotoxic T lymphocytes. 
IFN-a has been used in the treatment of malignant melanoma patients. Early reports 
showed evidence of activity for IFNa in the treatment of metastatic disease (Nethersell 
et al., 1985). However, the overall response rates were no better than the most active 
cytotoxic drugs. 
Clinical trials with high doses of IFNa in patients with high-risk node-positive stage III 
resected melanoma (Creagan et al., 1995) or low dose of IFNa in patients with 
intermediate-risk melanoma (Grob et al., 1998; Pehamberger et al., 1998) demonstrated 
a prolongation in relapse-free survival, but no benefit in overall survival from treatment. 
Recent evidence suggests a possible benefit for high-dose IFNa as an adjuvant therapy. 
In a randomised controlled trial, adjuvant therapy with IFNa significantly increased 5-
year disease-free and overall survival in patients with high-risk resected malignant 
melanoma (Kirkwood et al., 1996), although toxicity from high-dose IFNa was 
observed. 
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Studies using IFNa have been also performed in renal cancer treatment. Patients with 
metastatic renal cancer showed benefit in survival by treatment with IFNa, but the 
benefit was achieved at the cost of substantial toxicity (MRC Collaborators, 1999). A 
study of patients with progressive metastatic disease suggested a benefit for 
combination therapy with IL-2 and IFNa (Negrier et al., 1998). 
1.3.2.2 Interleukin-2 
Interleukin-2 (IL-2) has virtually no direct effect on cancer cells and its anti-tumour 
activity in vivo is immunologically mediated. Physiologically, IL-2 serves as an 
important growth and activation factor for T lymphocytes. It also stimulates 
macrophages, NK cells and B lymphocytes and, at very high concentrations, IL-2 can 
induce NK cells and some T cells to become cytolytic against a variety of tumour cells 
in a non-specific and non-MHC-restricted manner. 
The intravenous infusion of IL-2 combined with autologous lymphokine activated killer 
(LAK) cells resulted in objective responses in over 30% of melanoma patients 
(Rosenberg et al., 1987). Subsequent studies showed that LAK cells could be omitted 
from the treatment schedule without affecting the response rate (Law et al., 1995). 
In a multicentre study, 14% of complete or partial responses lasting for a median of 23 
months were observed in 255 patients with metastatic renal cancer treated with high-
dose IL-2 (Fyfe et al., 1995; Fyfe et al., 1996). More recently, similar response rates 
were obtained with lower dose IL-2 given subcutaneously, with considerably less 
toxicity (Law et al., 1995). 
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· 1.3.2.3 Tumour necrosis factor 
Tumour necrosis factor-a (TNF-a ), a cytokine secreted by activated T lymphocytes and 
macrophages, has both direct and indirect antitumour effects. Although it is cytotoxic to 
some types of transformed cells in vitro, much of its effects are on the vascular 
endothelium, platelets, and the coagulation cascade, which lead to a rapid hemorrhagic 
necrosis of tumours, hence its name. TNF-a also potentiates the activation of CTL by 
its effects on T cells and tumour cell targets. Unfortunately, despite impressive activity 
in murine tumour models, the toxicity of systemic TNF-a at therapeutic doses has been 
prohibitive in humans (Mueller, 1998). 
1.3.2.4 Interleukin-12 
Interleukin-12 (IL-12) induces IFN-y secretion, promotes growth of activated T and NK 
cells and induces commitment from the T helper 0 (ThO) to the Thl phenotype. 
A number of presentations addressed the potent antitumour effects of IL-12 in murine 
tumour models (Salgaller et al., 1998; Trinchieri, 1997). This activity appears to be 
largely IFN-y dependent and synergistic responses are obtained when IL-12 is combined 
with. IL-2, IFN-a or chemotherapeutic compounds (Brunda, 1995). IL-12-mediated 
inhibition of angiogenesis also has been indicated as an important component of the 
antitumour activity of this cytokine (Trinchieri, 1997). A role in the inhibition of vessel 
formation caused by IL-12 has been suggested for IFN-y and for the antiangiogenic 
protein IP-10, whose production is also stimulated by IL-12 (Sgadari et al., 1996). 
These findings imply that IL-12 may promote an antitumour effect via more than one 
pathway. 
A recent study showed that the systemic administration of a low dose of IL-12 was 
more effective than local administration in curing mice bearing established metastatic 
tumours, due to differences in action kinetics and intensity (Cavallo et al., 1999). 
71 
Systemic treatment of HER-2/neu transgenic mice bearing preneoplastic lesions with 
IL-12 markedly delayed the onset of mammary gland tumours, which normally develop 
in these mice, and reduced tumour multiplicity (Lollini et al., 1999). Interestingly, 
similar inhibition of tumour development was observed in immunocompetent and CD8+ 
T cell-depleted mice, suggesting that IL-12-induced stimulation of nonspecific 
immunity can also prevent tumour formation. 
The encouraging results in animal models have prompted the use of IL-12 in carcinoma 
patients. Recently, clinical trials have been performed in order to analyse IL-12-related 
toxicities and potential methods of their prevention (Golab et al., 1999). 
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1.3.3 ACTIVE IMMUNOTHERAPY ORV ACCINATION 
The classical concept of the vaccine derives from the practice of immunising against 
infectious agents to prevent disease by generating a humoral immunity. In contrast to 
prophylactic vaccines against infectious agents, the major focus in cancer vaccine 
development has been on the generation of antigen-specific T-cell responses. 
Furthermore, in contrast to the limited number of defined antigens for ·viruses and 
bacteria, in the case of most tumours there is an unlimited number of potential antigens 
that can be the target of an immune response. It is also likely that many of these 
antigens arise during or as a result of the tumourigenesis process. 
The most common approach to enhance immunogenicity of an antigen is to mix tumour 
cells or the antigen preparations with non-specific immune adjuvants. Widely used 
adjuvants include alum (aluminum salts), bacterial organisms such as BCG (Bacillus 
Calmette Guerin) or Corynebacterium parvum, components of bacterial cell walls, and 
Freund's adjuvant. Non-specific adjuvants induce local inflammatory infiltration of 
APC, T- and B-cells which produce cytokines and chemokines responsible for local 
microenvironment promoting induction phase of an immune response to the delivered 
antigens. 
Tumour vaccines have not so far been employed to prevent cancer in healthy 
individuals. They are used mostly in experimental studies in patients with established 
malignancies as adjuncts to primary treatment, or in clinical trials in patients with 
advanced disease with high risk of progression into incurable disseminated disease. 
lmmunogenic tumours with known history of spontaneous regression and resistant to 
other available therapies, such as melanoma or renal cell carcinoma, have been most 
extensively treated with tumour vaccines. 
73 
First generation vaccines made of whole cancer or tumour-cell lysates together with non 
specific adjuvants produced about 20% of clinical response and are currently tested in 
prospective clinical trials. Novel second generation vaccines employ tumour cells or 
, antigen presenting cells genetically modified by gene transfer technology (see chapter 
1.4). These vaccines actually are mostly tested in toxicity-exploratory phase I/II trials. 
1.3.3.1 Autologous or allogeneic whole cell or cell lysate vaccines 
Almost all vaccine trials carried out before 1990 involved melanoma patients treated 
with autologous or allogeneic cell line preparations. 
Autologous vaccines consisted of tumour cells isolated from fresh, cryopreserved tissue 
or the cell line established from autologous tissue. Tumour cells contain unique mutated 
antigens, which might be directly presented in the context of the host HLA molecules. 
Autologous vaccines have had many disadvantages: firstly, production of a customised 
vaccine is time-consuming, and dependent on the quantity of available tumour tissue. 
Secondly, naturally evolving tumour cells are generally not immunogenic, display 
defects in expression of HLA and co-stimulatory molecules and may produce 
immunosuppressive factors which limits their ability to induce specific immune 
responses. 
Allogeneic vaccines consisted of in vitro established tumour cell lines. They can be 
partially characterised by expression of known-shared antigens and if mixed they 
display a broad range of antigens, thus diminishing the probability of immune escape. 
Vaccines of cultured established allogeneic cell lines are also much easier to prepare 
and manufacture. 
Allogeneic and autologous cell vaccines have been used in the first large-scale clinical 
trials of tumour vaccines. 
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Five clinical responses were observed in a group of 40 evaluable patients after treatment 
with low-dose of cyclophosphamide, which reduce suppressor cell activity and enhance 
antibody responses, followed by autologous vaccine with BCG as adjuvant (Berd et al., 
1986; Berd et al., 1990). 
In another study, three complete and six partial responses were observed in 40 patients 
vaccinated with three allogeneic melanoma cell lines mixed with BCG (Morton et al., 
1993; Morton et al., 1992). 
Twenty objective responses in 106 melanoma patients treated with allogeneic cell lysate 
~accine mixed were observed. CTL assays and certain HLA phenotypes correlated with 
clinical responses (Mitchell et al., 1988; Mitchell et al., 1993). 
A polyvalent melanoma vaccine prepared from the material shed into culture medium 
by four melanoma lines bound to alum resulted in 50% overall 5-year survival in 94 
treated melanoma patients with stage III disease (Bystryn, 1993; Bystryn, 1995). 
1.3.3.2 Protein- and Peptide-based vaccines 
The aim of protein- and peptide-based vaccine strategies is to administer high doses· of 
antigen peptide that can be loaded onto empty MHC molecules on APCs in vivo. 
Variable results have been observed: whereas vaccination with some tumour-associated 
peptides and proteins has induced systemic antitumour immunity (Mandelboim et al., 
1995), the administration of other peptides has led to the induction of tolerance rather 
activation (Toes et al., 1996). 
Phase I clinical studies of peptide vaccines have been initiated for the treatment of 
melanoma. As for whole-cell vaccines, the only toxicities observed have been grade I/II 
induration and erythema at the vaccine site. 
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One trial of an HLA-Al-restricted MAGE3 peptide reported three partial remissions in 
16 patients with metastatic melanoma at pulmonary and subcutaneous sites (Marchand 
et al., 1995). 
In another study, all three patients with metastatic melanoma demonstrated partial 
remissions that were associated with DTH reactivity at the vaccine sites after 
vaccination with three melanoma-associated HLA-A2-restricted antigenic peptides 
(MART-1/MelanA, tyrosinase and gplOO), given simultaneously with GM-CSF (Jager 
et al., 1996). 
A more recent study evaluated an HLA-A2-restricted gplOO peptide analogue, which 
was modified at one of the MHC anchor residues to improve its binding affinity to 
HLA-A2, in patients with melanoma (Parkhurst et al., 1996). Immunisation with the 
anchor-modified peptide in incomplete Freund's adjuvant induced gplOO- and HLA-A2-
restricted melanoma CTLs in 10 of 11 patients and a clinical response was observed in 
42% of patients who received the vaccine along with systemic IL-2. 
1.3.3.2 (1) Heat Shock protein as a carrier of antigens 
A novel peptide vaccine approach uses heat shock proteins (HSPs ). HSPs, or 
chaperonins, are natural biologic adjuvants found in most cells, which have the capacity 
to bind a wide array of peptides (Lammert et al., 1997). Their ability to elicit anti tumour 
immune responses has been tested in some studies. 
In particular, immunisation with tumour-derived HSP96, an endoplasmic reticulum 
resident, and HSP70, a cytosolic HSP, revealed the stimulation of a tumour-specific 
immunity in mice (Tamura et al., 1997). Furthermore, more recently, vaccination with 
recombinant HSP70 associated to a model peptide antigen was shown to induce 
antigen-specific CD8+ T cell responses (Suzue et al., 1997). The tumour-specific 
immunity appeared to be mediated by specific peptides, which are found bound to HSPs 
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(Blachere et al., 1997). It is postulated that HSPs induce a specific CTL response by 
introducing antigens into the MHC class I and II pathways as well as by binding to 
macrophages, thereby inducing the production of proinflammatory cytokines. 
1.3.3.3 Carbohydrate antigen vaccines 
Carbohydrate antigens aberrantly or overexpressed on tumour cells are further targets 
for immunotherapy. 
Gangliosides GM2, GD2 and GD3, which are cell surface constituents of melanomas 
and other tumours of neuroectodermal origin, have been used as immunogens in 
patients with cancer. 
For example, a trial comparing cyclophosphamide plus BCG versus cyclophosphamide 
plus BCG/GM2 ganglioside was carried out in 122 stage III melanoma patients. 
Vaccine containing GM2 induced lgM responses in 86% patients (Livingston et al., 
1989). A pilot study with GM2 conjugated to keyhole limpet hemocyanin as a carrier 
protein plus an adjuvant produced lgM, lgGl and IgG3 responses in all six immunised 
patients (Helling et al., 1995). Expression of the carbohydrate moiety sialyl Tn (STn) is 
associated with aworse prognosis in colonic (Itzkowitz et al., 1990), gastric (Ma et al., 
1993) and breast cancers (Kinney et al., 1997). Circulating antigen has been detected in 
gastrointestinal and ovarian malignancies and raised levels have been associated with a 
worse prognosis (Kobayashi et al., 1992). A clinical trial using STn conjugated to 
keyhole limpet hemocyanin in patients with breast cancer has recently been reported 
(MacLean et al., 1996). All patients immunised with STn-KLH vaccine generated an 
antibody response to STn, STn-positive mucin and KLH. A therapeutic effect was 
observed in the group of patients pre-treated with cyclophosphamide. 
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1.3.3.4 Anti-idiotypic antibodies vaccines 
Apart from direct therapy of cancer with tumour-specific antibodies, a vaccination 
strategy using antibodies has been proposed. This approach is based on the theory that 
anti-idiotypic antibodies that bear the internal image of tumour antigens may serve as 
immunogens. Anti-idiotypic antibodies recognise idiotopes located on variable region 
of the antibodies, thus they may share conformational or primary structure with the 
corresponding antigen in order to fit the same combining site, just as two keys that fit 
the same keyhole display similar shapes. 
Anti-idiotypic antibodies that bear internal images of tumour antigens have been 
i 
i\ 
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developed for several types of tumours. Clinical trials have been carried out in patients 
with advanced melanoma using anti-idiotypic antibodies that mimicked high-molecular 
weight-melanoma associated antigens (HMW-MAA), GD3 and GM3. In particular, in a 
study carried out in 52 patients treated with anti-idiotypic mAb (HMW-MAA) with 
BCG, a significant increase in survival time was observed in the 18 patients who 
' 
developed anti-HMW-MAA antibodies (Mittelman et al., 1994; Perera, 1990). 
1.3.3.5 Dendritic cell vaccines 
Based on the emerging concept of the central role of APCs. in the initiation of immune 
responses, dendritic cell (DC)-based vaccines are under active investigation. 
Many factors appear to be responsible for the unique potency of DCs in activating T 
cells. Firstly, they express 50-fold higher levels of MHC molecules than macrophages, 
I providing more peptide/MHC ligand for T cell receptor engagement. Furthermore, they 
express extremely high levels of important adhesion molecules, costimulatory 
molecules and DC-specific genes, such as one encoding a T cell specific chemokine 
(Adema et al., 1997b ), critical for T cell activation. 
78 
Either directly isolated or GM-CSP-induced DCs have been used as antigen carriers for 
tumour vaccination. The form of antigen loaded onto DCs was represented by minimal 
MHC class I-restricted peptides (Mayordomo et al., 1995), or by the protein antigen 
(Hsu et al., 1996; Paglia et al., 1996). Moreover, in other cases, the antigen has even 
been presented by fusion of DCs with whole tumour cells (Gong et al., 1997). 
Clinical testing using DC vaccines have been performed. In one study, vaccination of B-
cell-lymphoma patients with DCs loaded with idiotypic antibody generated idiotype-
specific immunity with some clinical response (Hsu et al., 1996). A recent vaccine trial 
in melanoma patients using autologous DCs pulsed with either tumour lysate or MHC 
class I-restricted melanoma peptides, together with keyhole limpet hemocyanin as a 
helper antigen, reported induction of delayed type hyper sensitivity and some clinical 
response (Nestle et al., 1998). 
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1.4 CANCER GENE THERAPY 
A promising approach in cancer therapy involves gene therapy, which consists of the 
introduction of genetic material into a patient' tissues with the intent to achieve 
therapeutic benefit. Different strategies have been developed for the treatment of cancer; 
in particular, current efforts focus on: 
immuno-gene therapy, which involves the introduction of genes m order to 
modulate the patient's immune response capacity; 
chemo-gene therapy, which is the introduction of genes that confer susceptibility to 
chemotherapeutics; 
correction of genetic defects in tumour cells, su~h as the introduction of tumour 
suppressor genes; 
manipulation of tumour growth and invasiveness by introd:uction of genes that 
inhibit the angiogenesis process. 
In the last years, a number of these approach have entered initial clinical testing. 
In the context of this thesis, particular attention will be focused on gene transfer as an 
immunotherapy approach, followed by a less extensive treatment of the other 
approaches. Of crucial importance for all these areas still is the development of efficient 
gene targeting and delivery system. 
1.4.1 GENE TRANSFER STRATEGIES 
Cancer gene therapy strategies can be classified broadly according to the physical 
location where genetic modification of target cells takes place (Miller, 1992a). 
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In an ex-vivo approach, target cells are removed from the patient, established in culture, 
transduced with an appropriate vector, and returned to the patient. 
This strategy relies on the ability to harvest the relevant target cells efficiently, to 
manipulate them in culture without inducing significant alterations of their biologic 
properties, and to transplant them in such a fashion that they perform their intended 
function in vivo. 
An alternate approach, designated in-vivo approach, requires the transduction of 
sufficient numbers of relevant target cells in situ. This scheme offers a number of 
potential advantages over the ex-vivo approach, including the need for fewer 
manipulations of target cell, the simpler administration of therapy and cost reductions. 
1.4.2 METHODS OF GENE TRANSFER 
An ideal delivery system should be· characterised by the following features: protection 
and delivery of DNA into cells efficiently, preferable to a specific cell type; be non-
toxic and nonimmunogenic; be easily produced in large quantities. No existing system 
meets all the requirements and no single vector has emerged as being optimal for all 
gene therapy applications. 
Current systems differ in their suitability for ex-vivo versus in-vivo strategies, their 
capability for persistent gene expression and possible toxicities. 
Gene delivery systems currently employed may be divided into two major groups: non 
viral and viral methods. 
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1.4.2.1 Non- viral methods of gene transfer 
1.4.2.1 (1) Naked DNA 
In non-viral systems the therapeutic gene is placed into a DNA plasmid and delivered to 
the cell of interest. Plasmid DNA transfects both dividing and non-dividing cells; it 
does not integrate with the genome of the target cell and results in transient gene 
expression. No limits in the size of therapeutic DNA, low immunogenicity and safety 
are the most important advantages of this system (Wolff et al., 1990). 
Naked DNA encoding cytokines most commonly is injected directly into the tumour or, 
in the case of genes encoding tumour antigens, into muscles, in which the translated 
proteins appear to be processed efficiently by host professional antigen-presenting cells 
and then presented to T-lymphocytes (Doe et al., 1996; Ulmer et al., 1993). 
Measures to improve naked DNA transfer efficiency include complexing the DNA with 
various compounds. 
1.4.2.1 (2) Liposome complexes 
DNA can be admixed with various formulations of cationic liposomes to form a lipid-
DNA complex with a net positive charge, thus favouring fusion with the cell surface 
membrane (Gao et al., 1995). 
DNA-liposome complexes have been used successfully for in vivo gene transfer to 
tumours in animal models and also in clinical trials (Nabel et al., 1993; Plautz et al., 
1993). Liposomes may also be used for systemic delivery of therapeutic genes to 
disseminated lesions. An intravenous injection of DNA-liposomes resulted in 
expression of a reporter gene in various organs which was detectable for several months 
(Zhu et al., 1993; Liu et al., 1995; Thierry et al., 1995) and intravenous administration 
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of liposome-complexed DNA encoding GM-CSF achieved therapeutic levels of the 
cytokine in the circulation (Liu et al., 1995). 
1.4.2.1 (3) Conjugate vectors 
Complexes that consist of DNA conjugated with a cell-specific carrier molecule have 
the advantage of direct gene transfer to defined cell populations by receptor-mediate 
endocytosis. A cationic molecule such as polylysine is used to bind DNA by ionic 
interaction. The polylysine molecule is also linked to a ligand, for example transferrin, 
able to bind to a cell surface receptor, resulting in endocytosis of the DNA-polylysin-
ligand complex. 
In order to enhance gene transfer efficiency, DNA endocytosed in this way may be 
protected from degradation in lysosomes by linking the complexes to adenovirus 
particles. Capsid proteins of adenoviruses are able to mediate disruption of endosomes, 
thus allowing the DNA to escape degradation (Curiel et al., 1991; Wagner et al., 1992). 
Although strategies employing DNA-polylysine-ligand complexes have proved to be 
extremely efficient in vitro, probably the large size of these particles may impede the 
widespread dispersion of DNA complexes in vivo, making this approach less effective 
for systemic gene delivery (Ledley, 1995). 
1.4.2.1 (4) Particle bombardment 
DNA coated on microparticles may be projected into cells using a "gene gun". DNA is 
first coated onto the surface of 1-3 micron diameter gold or tungsten beads. These 
particles are accelerated by an electric discharge device, or gas pulse, and fired at the 
tissue. Such an approach has been used to transfer various cytokine genes to tumour 
cells in vivo, resulting in inhibition of tumour growth and even complete eradication of 
tumours in some animals (Sun et al., 1995; Rakhmilevich et al., 1996). Furthermore, 
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delivery of DNA encoding tumour antigens by gene gun has been shown to successfully 
elicit protection against tumour (Irvine et al., 1996). Although these positive results 
prove this strategy useful for superficial lesions, the depth of penetration is limited .. 
Thus, it is unlikely that such an approach would be suitable for widespread systemic 
delivery of therapeutic genes. 
1.4.2.2 Viral vectors 
The natural ability of viruses. to infect eukaryotic cells and to introduce their genomes, 
as part of their life cycle into the host cell's genome, is utilised to transfer genetic 
material into target cells. 
Limitations of this system are represented by the size of therapeutic gene (usually, 5-10 
kb depending on the vector used), time consuming and expensive preparations. 
Different viral systems have received attention for gene transfer studies. 
1.4.2.2 (1) Retroviruses 
Of the viral-based vectors, retroviruses have been the most widely used in experimental 
studies. Retroviral vectors are also being employed in some clinical trials. They are 
extraordinarily efficient gene delivery vehicles; in the nucleus the retroviral nucleic acid 
becomes integrated into chromosomal DNA, ensuring its long-term persistence and 
stable transmission to all future progeny of the transduced cell. 
Retroviruses are divided into three subfamilies, based primarily on pathogenicity: 
oncoviruses, lentiviruses and spumaviruses. The oncoviruses are further subclassified 
into 5 groups, A to D, largely on the basis of their morphology and method of release 
from cells. The group which has been used most extensively to derive retroviral vectors 
are the murine C-type oncoviruses. 
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Murine C-type viruses have been classified into the following groups, based on the host 
range of the virus, interference patterns and serotype of the envelope antigen (Weiss et 
al., 1995): 
ecotropic, which infect mouse and rat cells, 
amphotropic, which infect mouse and other cells 
xenotropic, which do not infect mouse cells but are able to infect other cells 
dual-tropic/polytropic, which infects mouse and mink cells. 
i) Structure 
A mature retrovirus comprises an inner core enclosed in a phospholipid envelope. The 
core consists of an icosahedral protein shell, the capsid, separated from the envelope by 
matrix protein, which houses the retroviral genome. The genome consists in two copies 
of a positive sense RNA, carrying a cap at its 5'end and a poly(A) structures at its 3'. 
The core also contains virally-encoded protease, reverse transcriptase and integrase 
enzymes. The envelope is a roughly spherical phospholipid bilayer derived from the 
plasma membrane of the virus-producing cell and is covered with closely packed 
oligomeric membrane spike glycoproteins, which appear as surface projections on 
electron microscopy (Fig. 1.11 ). 
ii) Life cycle 
The retroviral life cycle has been studied extensively (Varmus, 1988) (Fig. 1.12). 
The viral envelope glycoprotein ( env) attaches the virus to its cell surface receptor and 
catalyses a membrane fusion event which releases the viral core into the cytoplasm of 
the target cell. 
Several of the cell surface receptors which are used by retroviruses have been identified, 
some of which are transporter molecules which serve normal cellular functions. 
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Fig. 1.11: Schematic view of a retroviral particle 
Two identical single strands of viral RNA and viral enzymes (reverse transcriptase, 
integrase and protease) are drawn within an icosahedral viral core and the core is 
surrounded by an envelope that is derived from host membranes enriched with viral 
glycoprotein. Interaction of envelope glycoprotein with a host-encoded cell surface 
receptor is shown at the bottom (modified from Varmus, 1988). 
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Fig. 1.12: The retroviral life cycle 
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A virus particle entering a cell, uncoating to form a nucleoprotein complex in which 
viral Ri~A is transcribed into DNA by reverse transcriptase. After migration to the 
nucleus, the complex mediates integration into a host cell chromosome. Synthesis of 
viral RNA and proteins leads to assembly of particles that exit the cell by budding 
through the plasma membrane (modified from Vile et al. , 1995). 
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For example, the Murine Leukaemia Viruses (ML Vs) ecotropic receptor has been 
identified as a cationic amino acid protein (Albritton et al., 1993) and the ML V 
amphotropic receptor is an inorganic phosphate transporter, Ram-1 (Miller et al., 1994). 
Cells infected with one virus or expressing the viral envelope glycoprotein of that virus 
impede superinfection with another virus bearing a similar envelope by competitive 
blocking of receptors. This phenomen is known as receptor interference (Sommerfelt et 
al., 1990). 
The RNA genome is reverse transcribed by a complex mechanism to double-stranded 
(proviral) DNA by reverse transcriptase, which is contained in the core of the virus (Fig. 
1.13). A cellular tRNA is packaged with in the virus; this tRNA acts as a primer for 
synthesis of the minus strand DNA by annealing to the primer binding site (pbs). 
Elongation of the minus strand proceeds through the U5 and R region. The RNA 
template is then removed by the RNAse activity of reverse transcriptase (RNAse H), 
thus allowing the exposed DNA to bind to the complementary R region at the 3'end of 
the genome. Synthesis of the minus strand DNA then continues. Synthesis of the plus 
strand DNA requires RNAse H to cleave the RNA at a specific site (ppt), thus allowing 
the nicked RNA to act as a primer. The plus strand is synthesised through the U3, Rand 
U5 regions, using the minus strand DNA as a template, and continues into a portion of 
the primer tRNA. The plus strand DNA then transfers to the pbs site at the 3' end of the 
minus strand DNA and synthesis of both strands is then completed, forming a double-
stranded copy with long terminal repeats (LTR) consisting of U3-R-U5 at both ends. 
The double-stranded DNA is then transported to the cell nucleus and integrates, after 
capsid disassembly, into a random chromosomal site. This process is mediated by the 
viral enzyme integrase. 
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Fig. 1.13: Generation of a DNA copy of retroviral genome 
The Ri~A genome is reverse transcribed by a complex mechanism to double-stranded 
(proviral) DNA by reverse transcriptase. 
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Capsid of C-type retroviruses cannot traverse the intact nuclear membrane and cell 
mitosis therefore is required for successful progression of the viral life cycle. Retroviral 
integration is non-homologous, with some degree of sequence specificity (Shih et al., 
1988) and a preference for transcriptionally active host integration sites (Mooslehner et 
al., 1990). 
After integration of the double stranded DNA prov1rus, regulatory promoter and 
enhancer elements in the U3 region of the proviral long terminal repeat (L TR) drive 
transcription of the viral genome (Fig. L14). The full lenght transcript encodes the gag 
and gag-pol polyproteins, while a smaller, spliced transcript encodes the env proteins. 
Oligomerisation of the gag and gag-pol polyproteins to form budding viral core 
particles is central to the assembly and release of fully infectious viral progeny. Full-
length (unspliced) viral mRNA binds, through its packaging signal sequence (Psi), to 
the gag polyprotein during particle assembly and env glycoproteins, present at the 
plasma membrane, are incorporated into viral progeny, as they bud from the cell 
surface. Newly budded virions are not infectious until the viral protease cleaves the gag 
and gag-pol polyproteins into their component parts. 
iii) Retroviral vectors 
Various retroviruses have been used as vectors (Miller, l 992b ), but those based. on 
Murine Leukaemia Viruses (ML Vs) are the most advanced and have been most widely 
used to date. 
Most human gene therapy applications require replication defective retroviral vectors 
capable of delivering therapeutic genes to individual target cells, without further 
replicative spread. 
The production of replicative-defective retroviral vectors involves two mam 
components: a vector and a packaging cell line (Fig. 1.14). 
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The vector is constructed from a retroviral genome from which the protein coding 
sequences (gag, pol and env) are removed and replaced by heterologous coding 
sequences. The viral functions required for replication are provided in trans by the 
packaging cell line. 
Some elements need to be retained in cis by the vector, to enable it to be packaged, 
reverse transcribed and integrated into the chromosome of the target cell. These 
elements include: 
the packaging signal sequence, which ensures the encapsidation of the vector RNA 
into virions (Psi). More recent vectors retain an extended Psi sequence, which 
incorporates the start of the gag gene (Psi+), with the AUG start codon of the viral 
gene mutated. The presence of this region has been demonstrated to increase the 
efficiency of packaging, resulting in an increase in viral titre (Bender et al., 1987). 
elements necessary to direct the process of reverse transcription, including the 
primer binding site (PBS), which binds the tRNA primer of reverse transcription; 
the terminal repeat (R) sequences, that guide the "jumping" of the reverse 
transcriptase between RNA strands during DNA synthesis and a purine-rich 
sequence in the 5' region of the 3 'L TR that serves as the priming site for synthesis of 
the second (plus) DNA strand. 
Specific sequences near the ends of the L TRs, that are necessary for the integration 
of the vector DNA into the host cell chromosome in the ordered and reproducible 
manner characteristic of retroviruses. 
Up to 8 kilobases of foreign gene sequence can be packaged in a retroviral vector, since 
a too large vector:..derived RNA transcript cannot be packaged efficiently into retroviral 
particles. Adhering to this size constraint, it is possible to insert 1, 2, or even 3 genes 
into the vector genome in forward or reverse orientation, controlled by viral or non-viral 
promoter and enhancer sequences. 
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Fig. 1.14: Generation of retroviral vectors 
Structure, transcription and splicing of Moloney ML V prov1rus: PBS=tRNA primer 
binding site; Psi=packaging signal sequence; PPP=polypurine tract or plus strand primer 
binding site; sd=splice donor; sa=splice acceptor 
A retroviral packaging cell line: the cell line constitutively produces empty retroviral 
particles lacking an Ri""'JA genome; RNA molecules carrying the packaging signal 
sequence (derived from the vector construct) are efficiently packaged (from Vile et al., 
1995). 
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iv) Retroviral packaging cell line 
The purpose of the retroviral packaging cell line is to provide the viral helper functions, 
the gag, pol and env proteins, which have been deleted from the vector genome. These 
helper functions are stably expressed in the packaging cells from one or more plasmids. 
When a vector genome is transfected into such packaging cells, the viral gag proteins 
recognise and package the vector RNA genome, which is provided by the packaging 
signal sequence, into viral particles. These viral particles are then released into the 
culture supernatant. 
It is essential for employment in clinical trials that retroviral vector stocks are not 
contamined with replication competent retrovirus: The helper and vector sequences 
introduced into a packaging cell carry all the viral genes and regulatory sequences 
required to reconstitute a wild type viral genome. The greater the sequence homology 
between helper and vector genomes, the higher is the chance that they will align and 
undergo homologous recombination. 
The earliest first generation packaging cell lines consist of cells containing a retroviral 
genome deleted only in the Psi region (pMOV-Psr) (Mann et al., 1983). These cells 
provide functions needed for viral replication and produce empty viral particles which 
contain reverse transcriptase, but since the transcript produced from the helper construct 
are Psr, they are packaged at very low frequencies. However, the PsrRNA transcripts, 
derived from packaging cell line, were shown to be packaged with Psi+ vector 
transcripts at low frequency (0.1 % ) into budding retroviruses and replication competent 
retrovirus most frequently arose by recombination of the co-packaged transcripts during 
reverse transcription. Examples of first generation packaging lines are \Jf2 (Mann et al., 
1983), \Jf-AM (Cone et al., 1984) and PA12 (Miller et al., 1985). 
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The best way to reduce the risk of replication competent retrovirus is to provide the 
helper functions on more extensively deleted helper plasmids having minimal sequence 
homology with the vector genome, or to split them onto multiple helper plasmids. 
Second and third generation packaging cell lines have been developed according to 
these principles and are considerably safer, due to increased number of helper-vector 
recombination events required to generate a wild type viral genome. 
P A317 (Miller et al., 1986), a second generation packaging cell line which has been 
used to produce retroviral vectors for human clinical trials (Rosenberg et al., 1990), was 
generated using the plasmid pP AM3, which lacks not only the packaging sequence but 
also the 3 'L TR and polypurine tract, which have· been replaced by an SV 40 
polyadenylation signal sequence. Two recombinations between helper and vector 
sequences are therefore necessary to regenerate replication competent retrovirus and this 
double recombination has proven to be a very low frequency event. 
Third generation packaging cells have further reduced the risk of replication competent 
retrovirus, by separating the gag-pol transcription unit from the env transcription unit on 
different plasmids and by using packaging constructs which have minimal areas of 
homology with the vector genome (Miller, 1990). This arrangement excludes the 
possibility that two co-packaged constructs can recombine to generate replication 
competent retrovirus, since the entire viral genome is now split three ways onto the 
vector construct and the two helper constructs. Examples of these cell lines, some of 
which are used in this thesis, are GP+E86 (Markowitz et al., 1988a) and \jJCRE (Danos 
et al., 1988), which produce viruses with ecotropic host range, and GP+envAM12 
(Markowitz et al., 1988b) and \jJCRIP (Danos et al., 1988), which release vectors with 
amphotropic host range. However, it has been shown that even third generation 
packaging cell lines may package and transfer endogenous murine viral genomes 
(Scadden et al., 1990). 
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More recently, different approaches have been used to improve third generation 
packaging cell lines. 
In order to reduce regions of homology, packaging lines have been constructed which 
minimise their content of ML V-derived sequences in the helper constructs. The Propak-
A (Rigg et al., 1996) and ampli-GPE (Takahara et al., 1992) lines employ heterologous 
promoters to drive gag-pol and env, as well as using heterologous sequences for the 
polyadenylation site. In the ampli-GPE line, in order to maximise viral titres, high 
expression levels of the helper functions are maintained by placing gag-pol and env in 
separate bovine papilloma virus-based constructs which can be amplified 20 to 50 fold 
in an episomal state. 
Packaging lines which produce viral particles bearing_ alternative envelopes, such as that 
derived from gibbon ape leukaemia virus (GALV) have been produced (Miller et al., 
1991 ). GAL V pseudotyped viruses were found to be more efficient in infecting human 
lymphocytes compared with amphotropic viruses. This greater efficiency reflects the 
higher expression of Glvr-1 relative to Ram-I in this cell type (Lam et al., 1996; Porter 
et al., 1996). ·Moreover, GAL V-based packaging lines produce vectors with an extended 
species host range, including hamster and bovine cells, which are not well infected by 
amphotropic viruses (Miller et al., 1991 ). 
v) Efficiency of gene delivery and expression 
For maximum efficiency of gene delivery, a retroviral vector should be available at high 
titre and should have unimpeded access to its target cell population. 
Under optimal. conditions, the most widely used retroviral producer cells can generate 
106 -10 7 infectious vector particles/ml of tissue culture supernatant. The manipulation of 
vectors with extra promoters and a large transgene has the disadvantage that it reduces 
viral titres. 
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A disadvantage of retroviral vectors based on murine leukaemia viruses is their poor 
ability in introducing genes to non-dividing cells (Miller 
1 
et al., 1990). This 
characteristic may be useful in cancer therapy, since the vectors will then be targeted 
preferentially to the tumour cells, which proliferate more actively than neighbouring 
normal host cells. Nevertheless, even in fast-growing tumours, only a small proportion 
of cells is actively dividing at any one time, leaving many cells uninfected. 
Cells infected with retroviral vectors and maintained in vitro usually show constant 
levels of gene expression for long periods of time. However, when cells are returned in 
vivo they often lose expression of the foreign gene over a period of a few weeks. This in 
vivo instability may be due to methylation (Richards et al., 1993; Palmer et al., 1991) or 
deletion (Russell et al., 1991) of the proviral DNA. A strategy to obviate this problem 
has been the use of a cellular promoter to drive expression of the exogenous gene, since 
it might be· expected that such promoters would be less likely to be down-regulated 
compared with viral promoters (Rettinger et al., 1994 ). While, in some cases, 
encouraging results using cellular promoters have been observed, in others, problems 
due to interference effects between promoters (Salmons et al., 1993), as well as a 
methylation inducing a shutdown of promoters, . have been obtained (Richards et al., 
1993). 
A major difficulty with the use of retroviral vectors for in vivo gene therapy in humans 
is that ML V-based vectors are inactivated rapidly by human complement (Welsh et al., 
1975). Sera from Old World Primates, including humans, contain an anti-a-galactosyl 
antibody, the target epitope of which is formed by Gal(al-3)Gal terminal carbohydrates 
present on the surface of most mammalian cells. This epitope is not present on human 
cells, because of the lack of a functional (al-3) galactosyltransferase gene in humans 
(Takeuchi et al., 1996). Therefore, retroviruses produced from non-primate cells acquire 
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this epitope on their envelope, are recognised by the antibody and become inactivated. 
In order to produce viral vectors resistant to human serum, packaging lines such as 
FLYA13, FLYRD18 (Cosset et al., 1995) and Propak-A (Rigg et al., 1996) were 
derived from human cell lines. 
vi) Targeting of retroviral gene transfer 
In the interests of safety and efficiency, it is desiderable that retroviral gene delivery 
should be accurate: the therapeutic genes should be delivered exclusively to the target 
cells and should integrate into a selected chromosomal location. Different strategies 
have been evaluated. One approach is represented by the incorporation of tissue-specific 
or tumour-specific elements in the vector to drive the expression of transgene (Vile, 
1994). The tyrosinase gene promoter has been used to target expression to disseminated 
melanoma cells (Vile et al., 1993; Vile et al., 1993), while the prostate-specific antigen 
gene promoter has been used to target expression to prostate carcinoma cells (Pang et 
al., 1995). 
Furthermore, promoters of genes overexpressed in target tumour cells also have been 
used. For example, the a-fetoprotein gene promoter has been used to target expression 
to hepatoma cells (Huber et al., 1991) and the oncogene c-ERBb2 promoter has been 
used to restrict expression to tumour cells overexpressing this oncogene (Harris et al., 
1994). 
As a different approach, attempts to target binding of retroviral vectors to specific cell 
type have been made by modifying the viral envelope (Salmons et al., 1993). For 
example, the ligand for HER-2 has been incorporated into the viral envelope 
glycoproteins to target retroviral particles to breast carcinoma cells, which overexpress 
HER-2 (Han et al., 1995). 
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1.4.2.2 (2) Adenovirus 
The most obvious advantages of adenoviral mediated gene transfer approaches are their 
safety and their ability to infect almost all cell types, dividing as well as quiescent cells, 
in vitro and in vivo, with high efficiency. Furthermore, adenoviral vectors can accept 
large foreign DNA inserts, up to 7-8 kb, and for in vivo gene transfer high titres, of up to 
1011/ml, may be achieved. Adenovirus rarely integrates into the host genome and 
therefore has little chance to activate cellular oncogenes. The adenoviral vector, once 
inside the nucleus, remains as a nonreplicating extrachromosomal entity resulting in a 
transient expression of the transgene. 
Three loosely defined sets of proteins exist in the mature adenovirus: proteins that form 
the outer coat of the capsid, scaffolding proteins that hold the capsid together and DNA 
binding protein. Protruding from the capsid is the fibre protein, which mediates the 
initial attachment of the virus to a target cell. 
Adenoviruses contain double stranded DNA as genetic material, functionally divided 
into 2 major non contiguous overlapping regions, early and late, transcribed before or 
after viral DNA synthesis, respectively. There are 6 distinct early regions, ElA, ElB, 
E2A, E2B, E3 and E4, each with individual promoters, and one late region, which is 
under the control of the major late promoter with 5 well characterised coding units, L 1 
to LS (Horwitz, 1990). 
Replication-deficient adenoviral vectors are constructed by deletion in the ElA region, 
which encodes for a transactivator that upregulate transcription from the other early 
regions. The ElA-deleted viruses are replication-defective and the viruses need to be 
propagated in a cell line which is able to provide the ElA functions in trans, such as the 
293 human embryonic kidney line. 
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Although designed to be replication-deficient, there is the potential for replication in 
vivo, as a consequence of trans-complementation by ElA-like factors due to pre-
existing or acquired adenovirus sequences, or by other viruses and/or host cellular 
transcription factors. For example, low level replication of recombinant adenovirus has 
been observed in Hela cells, at high multiplicity of infection (Jones et al., 1979). 
In addition to El, other sequences may also be deleted. For example, El- and E3-
deleted vectors, which can accomodate a larger exogenous . gene, have been obtained 
(Bett et al., 1994). 
Despite the fact that expression for more than 1 year has also been observed, duration of 
expression normally is short (about 8 weeks) in adult animals. Therefore, repeated 
administration may be necessary. 
A number of hypotheses have been proposed to explain this short-duration expression. 
First of all is that the high immunogenicity of the viral capsid proteins results in the 
elimination of infected cells by the immune system. A disadvantage of this response is 
that neutralising antibodies make re-administration of the vector less effective (Yang et 
al., 1994a; Yang et al., 1996b). Secondly, it is also possible that a slow accumulation of 
toxic viral-encoded-proteins may kill the cell and/or that the duration of expression may 
be reduced by intracellular methylation of the viral promoter (Doerfler, 1993). 
Strategies to improve adenoviral vectors have been applied. An approach is represented 
by the creation of a helper virus system that provides all the gene functions from the 
deleted region. This approach has the potential to delete from the vector all sequences 
except for cis acting elements, that are necessary to package the recombinant 
adenovirus, allowing the insertion of increased size of DNA and improving the safety 
features (Fisher et al., 1996). After propagation in 293 cells, the recombinant vector 
virions and helper viruses may be separated on .the basis of differential sedimentation 
densities in CsCl gradient. 
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Another approach is represented by the inactivation of viral genes enclosed in the vector 
by introduction of temperature-sensitive mutations. For example, a temperature-
sensitive mutation of the E2A gene, encoding a DNA binding protein, was incorporated 
into an El-deleted vector (Engelhardt et al., 1994). The vector may be propagated in 
vitro at a permissive temperature in 293 cells, but in vivo E2A is not functional and, in 
theory, expression of late viral proteins is diminished. This strategy resulted in a more 
prolonged expression of the transgene in vivo. 
1.4.2.2 (3) Adeno-associated virus 
Another virus that has received considerable attention for gene transfer studies is the 
Adena-associated virus (AA V) (Berns KI, 1966). The appeal of this agent derives from 
its abilities to infect nonreplicating target cells and to integrate into host genome, 
allowing it to achieve sustained gene expression. Only minimal viral gene products are 
retained in current vectors, which affords minimal immunologic reactivity. 
The virion has a simple structure, composed of 3 unglycosylated proteins and 
containing a linear single-stranded DNA molecule. For its replication, AA V require 
coinfection with a helper virus. Without an helper virus, AA V integrate into the host 
genome and remains as a provirus. 
The exogenous gene is inserted between the two terminal repeats, which are the only 
cis-acting elements that need to be retained in the vector. Viral vector particles are 
produced from cells by co-transfection of the plasmid vector and a vector bearing the 
complementing viral proteins, together with co-infection of a helper adenovirus. 
1.4.2.2 (4) Other viruses 
Several other viruses have been studied for their utility in gene transfer. These include 
the herpes simplex virus (HSV), which, given its natural tropism, should be suited for 
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central nervous system applications (Marconi et al., 1996; Roizman, 1996). HSV enters 
into a lytic pathway which leads to cell death, or, in nervous system cells, may persist 
indefinitely in a latent state. Attenuated herpes simplex viruses with oncolytic activity 
against gliomas have been constructed and characterised for residual neurovirulence 
(Martuza et al., 1991). 
Vaccinia viruses are an important tool for tumour vaccination strategies. Soon after the 
entry into the host cells, these viruses replicate in the cytoplasm to high numbers and 
are able to produce high levels of transgene expression (Moss, 1996). Presentation of 
relevant epitopes of the antigen may be facilitated, by direct targeting of heterologous 
protein to the compartment in which processing of MHC class I antigens is initiated for 
. presentation to CDS+ CTLs. Indeed, mini-genes encoding peptides of 8 to 10 amino acid 
residues have been attached to sequences that target the peptides for insertion into the 
endoplasmic reticulum, where the peptides can bind to MHC class I molecules (Restifo 
et al., 1995). Another study has recently demonstrated the potency of vaccinia vector 
carrying the Human Papilloma Virus (HPV) gene E7 fused with the LAMPI gene, a 
lysosomal-associated membrane protein, which targets E7 to the MHC class II antigen-
processing pathway for presentation to CD4+ T cells (Wu et al., 1995; Lin et al., 1996). 
A recombinant E6- and E7-expressing vaccinia virus has been tested in eight patients 
with late-stage cervical cancer. No significant side effects were described and an HPV-
specific CTL response was observed in one patient. However, all eight patients mounted 
an anti-vaccinia antibody response (Borysiewicz et al., 1996), which can be the result of 
either previous immunisations with vaccinia viruses or exposure to cross-reactive 
viruses. Moreover, recently clinical studies in cancer patients using recombinant 
vaccinia viruses encoding tumour antigens (Scholl et al., 2000; Marshall et al., 2000) 
have confirmed the safety and validity of such an approach in stimulating an anti-
tumour response. 
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1.4.3 IMMUNO-GENE THERAPY APPROACHES 
1.4.3.1 Genetic modification of tumour cells 
Novel second generation vaccines employ tumour cells genetically modified to improve 
their immunogenicity. 
Different strategies have been applied and evaluated in experimental and clinical 
approaches. 
1.4.3.1 (1) Introduction ofMHC genes 
It has long been known that increased expression of MHC class I proteins on tumour 
cells enhances their ability to be lysed by tumour-specific -cytotoxic T lymphocytes in· 
vitro. Studies in the 1980s demonstrated that enhancing MHC class I expression by 
gene transfection resulted in decreased tumourigenic capacity and/or metastatic capacity 
of murine tumour models (Hui et al., 1984b; Wallich et al., 1985). 
Despite these positive studies, the relationship between levels of MHC expression and 
tumourigenicity is quite inconsistent when multiple tumour models are studied. Indeed, 
in some cases, tumour cells expressing high levels of syngeneic MHC class I molecules, 
by virtue of gene transfer (Mandelboim et al., 1992), appear to be rejected by syngeneic 
hosts, resulting in an immunisation against low levels of a subsequent parental tumour 
challenge. Surprisingly, in other cases, MHC class I expression resulted in a complex 
phenotype, with paradoxical enhancement of metastasis formation, perhaps related to 
decreased recognition of the transduced tumour by natural killer cells (Glas et al., 1992; 
Kawano et al., 1986). 
While most epithelial tumours express MHC class II products constitutively, the vast 
majority are MHC class II negative. The introduction of MHC class II molecules in 
some systems has also resulted in tumour rejection and systemic immunity (Ostrand-
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Rosenberg et al., 1990). It was postulated that the expression of MHC class II molecules 
on tumour cells allowed for the p~esentation of class II-restricted tumour-specific 
antigens to helper T cells, which ultimately could provide enhanced in vivo help for 
activation of cytotoxic T cells. The major problem with this hypothesis is that most 
epithelioid tumour cells do not express co-stimulatory signals, such as the B 7 molecule, 
and, therefore, are not effective antigen-presenting cells. 
However, while the introduction of autologous MHC class I and class II molecules into 
tumour cells may represent an important experimental model, it is important to 
recognise that because of the polymorphisms in the outbred population, as well as the 
number of different loci in an individual that could potentially be critical in the 
presentation of specific tumour antigens, such a genetic approach in humans would 
necessarily be highly individualised and therefore impratical for treating large numbers 
of patients. 
1.4.3.1 (2) Introduction of the B7 gene 
The B 7 family of costimulatory molecules, originally described as an activation antigen 
on B cells, is expressed constitutively by most APCs and is known to be the ligand for 
two receptors expressed on T cells. These are CD28 and the CTL-associated antigen-4 
(Azuma et al., 1993; Freeman et al., 1993b; Freeman et al., 1993a; Linsley et al., 1991; 
Chen et al., 1992). CD28 is a critical receptor for generating the costimulatory signals in 
T-cell activation. Cross-linking of CD28 has been shown to enhance the level of 
lymphokine production by CD4+ T cells subsequent to antigen recognition. In some in 
vitro systems, CD28 engagement not only enhances T-cell activation but is necessary 
for driving T cells toward activation rather than anergy (Harding et al., 1992). 
With this backgroud, the B7 gene was a logical choice for introduction into tumour cells 
as an approach to enhanced immunisation capacity. 
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A number of laboratories have indeed shown that transfection of B 7 .1 into some 
tumours results in rejection of that tumour and generates systemic immunity against 
wild-type tumour challenges (Townsend et al., 1993). In other studies, cotransfection of 
B7.1 with either MHC class II (Baskar et al., 1993), _interleukin IL-4 (Cayeux et al., 
1995), or IL-7 (Cayeµx et al., 1996) has been shown to induce potent systemic 
immunity. 
1.4.3.1 (3) Introduction of the cytokine genes 
Genes that encode cytokines are the most common types of genes that have been 
introduced into tumour cells. The expression of these genes alters the local 
immunologic environment of the tumour cell so as to either enhance presentation of 
tumour-specific antigens by APCs or to enhance the activation of tumour-specific 
lymphocytes. The cytokine is produced at very high concentrations local to the tumour 
and systemic concentrations generally are quite low. This paracrine physiology much 
more closely mimics the natural biology of cytokine action than does the systemic 
administration of recombinant cytokines. 
Many cytokine genes have been introduced into tumour cells with varying effects on 
both tumourigenicity and immunogenicity. Some of these cytokines, when produced by 
tumour, induce a local inflammatory response that results in elimination of the injected 
tumour. This local inflammatory response is most often predominantly dependent on 
leukocytes other than classical T cells. However, in a subset of the studies, the induction 
of a systemic immune response mediated by T cells has been demonstrated against 
challenge with the wild type parental tumour. 
Given the number of studies done to date with cytokine-transduced tumour cells, it- is 
not surprising that variable results have been seen when different tumour systems are 
analysed. Additional variables, such as cell dose, level of cytokine expression and 
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location of immunisation and challenge site, are crucial parameters affecting vaccine 
efficacy for cytokine-gene engineered tumour cells. 
i) IL-2 gene 
One of the most extensively studied approaches to cytokine gene transfer into tumour 
cells is use of the interleukin-2 gene. 
A number of studies were performed by transfection of different murine tumour models. 
They include a Fisher rat cell line, the J558 plasmacytoma, the CT26 colon carcinoma, 
the Bl6 melanoma, the CMS-5 fibrosarcoma, the P815 mastocytoma and the HSNLV 
sarcoma (Bubenik et al., 1988; Bubenik et al., 1990; Fearon et al., 1990; Gansbacher et 
al., 1990a; Gansbacher et al., 1990b; Ley et al., 1990; Ley et al., 1991; Russel et al., 
1991). 
Several of these studies showed a marked regression of IL-2 secreting tumours and· 
establishment of a T cell-mediated protection against a challenge with the parental 
tumour. The inhibitory effect appeared to be dose-dependent, because the degree of 
suppression of growth correlated directly with the amount of IL-2 produced by the 
tumour cells and the maximum cure rate of mice was observed to be achieve with 
intermediate doses ofIL-2 (Schmidt et al., 1995; Sobol et al., 1995). Jn situ IL-2 release 
led to a dense infiltration of the tumour, involving mainly CD4+ and CD8+ T cells and 
natural killer (NK) cells. 
On the other hand, some studies demonstrated that IL-2 secretion could bypass the 
requirement for T helper function in the generation of tumour-specific cytotoxic T 
lymphocytes (CTL). Indeed, in vivo depletion experiments showed that CD4+ T cells 
were not necessarily required for rejection of the tumour, while CD8+ T cells appeared 
to be essential for complete tumour rejection and for long-term protection against the 
parental tumour (Fearon et al., 1990; Cavallo et al., 1992; Hock et al., l 993b ). 
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IL-2 was reported also to protect against tumour growth when secreted by allogeneic 
cells, with respect to· the tumour and the host animal (Roth et al., 1992). In addition, 
Fakhrai et al. (Fakhrai et al., 1995) demonstrated that tumour cells admixed with IL-2 
transfected bystander cells (fibroblasts) are able to elicit a protective anti-tumour 
immune response in naive animals and therapeutic responses in tumour-bearing hosts. 
Transduction of the IL-2 gene into human primary melanoma cell cultures (Patel et al., 
1994), different human tumours cell lines (Arienti et al., 1994; Cignetti et al., 1994) and 
human fibroblasts (y eelken et al., 1996) has also been reported by several groups, using 
retroviral vectors or non-viral-based gene delivery methods. The transduction of IL-2 
gene in these human cell lines was demonstrated to increase their capacity to the in vitro 
activate tumour-specific and unspecific lymphocytes lines (Arienti et al., 1994). 
ii) IL-4 gene 
A number of studies performed in murine tumolir models, such as plasmacytoma, 
adenocarcinoma, melanoma, renal cell carcinoma and sarcoma revealed regression of 
tumours after transfer ofIL-4 transduced tumour cells (Tepper et al., 1989; Blankenstein 
et al., 1990; Golumbek et al., 1991; Li et al., 1990). The anti-tumour activity of IL-4 
was dose-dependent and could be specifically blocked by an anti-IL-4-antibody (Tepper 
et al., 1992). 
The tumour infiltrate showed a massive presence of macrophages and eosinophils, 
while a small number of T lymphocytes, mostly CD8, infiltrate IL-4-transduced tumour 
sites only a few days after the initial injection (Golumbek et al., 1991). IL-4 is known as 
a direct inducer of tumouricidal activity by macrophages (Crawford et al., 1987), while 
the striking eosinophil infiltrate has been attributed to the induction of VCAM 
expression on local vascular endothelial cells by IL-4 (Thornhill et al., 1991). VCAM 
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appears to be the most important ligand for the VLA-4 receptor, expressed at high levels 
on circulating eosinophils (Schleimer et al., 1992). In vivo antibody-mediated depletion 
of eosinophils resulted in continuous growth of the IL-4 transduced tumour 
demonstrating the crucial role of eosinophils in tumour elimination {Tepper et al., 
1992). 
Human tumour-derived stromal cells and fibroblasts have been successfully transfected 
with the IL-4 gene for clinical vaccination protocols. In vitro studies demonstrated that 
IL-4 transduced stromal cells are able to stimulate proliferation of a patient's PBL (Hunt 
et al., 1993; Lotze et al., 1994). 
iii) IL-12 gene 
IL-12, primarily produced by activated macrophages, can promote cytolytic activity, 
stimulate the production of IFNy and cause promotion of Thl-type responses. Its effects 
suggest an important potential in cancer therapy. 
Transduction ofIL-12 in the CT-26 murine colon carcinoma tumour cells led to delayed 
tumour onset and an increased survival time (Martinotti et al., 1995). In vivo depletion 
ofNK cells resulted in a reduced IL-12 effect on latency or survival, while depletion of 
CD8+ or CD4+ T cells revealed an unchanged effect on tumour regression. Moreover, 
while the tumour infiltrate of normal mice showed a minimal T cell contribution, 
tumour infiltrate of CD4+ depleted animals consisted almost completely of CD8+ T cells 
and NK cells. This result suggests that CD4+ T cells could inhibit the tumour 
infiltration by CD8+ T cells (Martinotti et al., 1995). 
In the case of MCA 207 and MCA 102 sarcomas, which are differentially 
immunogenic, IL-12 secretion by tumour cells led to tumour eradication and resistance 
to rechallenge with original tumour cells. IL-12 engineered cells also protected against 
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distant site inoculation with original_tumour cells. NK cells and IFNy were crucial in the 
early phase of the anti-tumour response, and ·both CD4+ and CDS+ T cells were 
involved in the following phase that led to long-term immunity (Tahara et al., 1995). 
Further preclinical studies in mice indicated that establishment of a BL-6 tumour, that is 
a poorly immunogenic melanoma, was delayed significantly when tumour cells were 
admixed with IL-12 transduced fibroblasts. In addition, preimmunisation with IL-12 
secreting fibroblasts together with irradiated BL-6 cells significantly delayed the growth 
of a subsequent BL-6 challenge. Histological examination revealed that the regression 
of BL-6 is associated with peritumoural accumulation of macrophages and decreased 
numbers of CD4+ T lymphocytes in the BL-6 tumour (Tahara et al., 1994). 
iv) IFN-ygene 
Immunisation with high IFN-y-secreting engineered tumour cells of mice carrymg 
established micro-metastases resulted in almost complete cure of mice by inducing 
cytotoxic T lymphocytes (Porgador et al., 1993). 
IFN-y expression in the malignant mouse C1300 neuroblastoma (Watanabe et al., 1989) 
resulted in an augmented class I MHC antigen expression and induced an improved 
specific anti-tumour immunity in the host. Other studies in several types of tumour cell 
lines derived from various mouse strains, like CMS-5 fibrosarcoma (Gansbacher et al., 
1990), SCl 15 mammary carcinoma tumour (Teramura et al., 1993), J558L 
plasmacytoma (Hock et al., 1993b) and LP92-T lung carcinoma (Yanagihara et al., 
1994), also report that IFN-y- locally secreted by engineered tumour cells can lead to 
tumour rejection in T cell competent-, but not nude, mice. By contrast, studies on some 
models, including MCA101 fibrosarcoma (Restifo et al., 1992), B16 melanoma 
(Dranoff et al., 1993) and OVHM13 ovarian tumours (Yanagihara et al., 1994), did not 
reported a suppression of tumour by IFN-y transduced tumour cells. 
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The mechanism of rejection by syngeneic hosts involved a specific CDS+ T cell-
dependent immunity (Gansbacher et al., 1990; Restifo et al., 1992). The redu.ced tumour 
growth theoretically can result from an enhancement of MHC molecule expression, 
induced by IFN-y, on tumour cells and on professional antigen presenting cells (Restifo 
et al., 1992), but it is likely that the activation effect of IFNy on CTLs (Klavinskis et al., 
1989), macrophages and NK cells (Herberman et al., 1982) also contributes to the 
immune reaction. 
Human melanoma cells, transduced with the IFN-y gene by retroviral transfection, have 
been obtained that secret biologically active IFN-y and exhibit enhanced expression of 
MHC class I and class II molecules. In addition, lymphocytes stimulated with IFN-y 
secreting melanoma cells revealed increased lytic activity against the autologous tumour 
(Abdel-Wahab et al., 1994). 
v) Other cytokine genes 
Systemic anti-tumour immune responses have been demonstrated in 1558 plasmacytoma 
cells engineered to secrete IL-7. Immunity was independent of CD8+ T cells, but 
dependent on CD4+ T cells and macrophages (Hock et al., 1991a). Tumour rejection 
was observed only in syngeneic animals, but not in T cell deficient mice, demonstrating 
a complete Tcell dependence (Hock et al., 1991a; McBride et al., 1992). 
An anti-tumour effect by transduction of the IL-7 gene was also reported in a murine 
fibrosarcoma and in a glioblastoina model, in which the effector cells responsible for 
tumour suppression were CD8+ T cells (Aoki et al., 1992; Jicha et al., 1991). The 
variable T cells subsets required for tumour rejection in the different models may reflect 
the particular level of MHC class I or II molecules expressed by the respective tumour 
cells. 
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Introduction of the TNP-a gene into tumour cells was studied in different mouse tumour 
models (Asher et al., 1991; Karp et al., 1993; Budillon et al., 1991). TNP-a-transduced 
tumour cells typically grew more slowly in vitro and were found to regress after an 
initial phase of growth in a dose-dependent manner. This tumour regression was 
abrogated by the depletion of CD4+ and CD8+ subsets in vivo, suggesting that T cells 
are involved in the immune response (Asher et al., 1991). 
In a separate study, macrophages were observed at the sites of a murine plasmacytoma 
that was engineered to secrete TNP-a, suggesting the implication of inflammatory cells 
in the rejection of this tumour (Blankenstein et al., 1991). 
Granulocyte macrophage colony-stimulating factor (GM-CSP) is known to increase the 
number of granulocytes, eosinophils and monocytes in vivo and to be crucial for the 
differentiation and survival of dendritic cells (Steinman, 1991 ). 
In an elegant study, which compared the ability of ten different molecules to enhance 
the immunogenicity of tumour cells in a murine melanoma model, GM-CSP appeared to 
be the most effective in producing potent, long-lasting and specific anti-tumour 
immunity requiring both CD4+ and CD8+ cells (Dranoff et al., 1993). GM-CSP is 
supposed to recruit dendritic cells that pick up and present tumour-specific antigens to T 
cells, thus inducing specific immunity and memory (Huang et al., 1994). 
An interesting study has recently evaluated an approach based on expression of IL-6 
and its receptor in tumour cells. IL-6 exerts its activity through a membrane-bound 
receptor complex consisting of alpha· (gp-80) and beta-subunits (gp-130). IL-6 first 
binds gp-80, the complex attracting two gp-130 molecules which leads to signal 
transduction. The effect of IL-6 may be enhanced by its agonistic soluble alpha-receptor 
subunit (sIL-6R) (Mackiewicz et al., 1992; Mackiewicz et al., 1995). The IL-6/sIL-6R 
complex in vivo may also activate cells lacking the alpha-subunit, but possessing only 
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the beta-subunit of the receptor. Most of the immune cells express beta, but not alpha-
subunit of the IL-6 receptor and sIL-6R genes (Mackiewicz et al., 1995). 
In a mouse model, the immunisation of mice with B78Hl melanoma cells modified 
with IL6/sIL-6R genes stimulated long lasting anti-melanoma immunity, through 
activation of CD8+ T cells and NK cells (Mackiewicz et al., 1995). 
Several clinical studies using either autologous or allogeneic cytokine gene-transduced 
tumour cells or tumour cells plus transfected bystander cells have been initiated. Only 
preliminary results of phase 1/11 clinical trials have been published. They show minimal 
toxicity of immunotherapy with genetically modified tumour cells and the induction of 
a specific immunity against tumour antigens. However, the earliest available results 
show that only about 10% of patients displayed an objective response (Abdel-Wahab et 
al., 1997; Simons et al., 1997; Belli et al., 1997; Parmiani et al., 1996; Roth et al., 
1997). 
1.4.3.2 Genetic modification of APC cells 
Gene transfer techniques also have been employed to improve antigen presenting cells 
activity, by transduction of tumour-specific antigens. 
Genes encoding the specific antigens are transfected in vitro, or in vivo delivery has 
been used to transduce antigen presenting cells by different strategies, including the use 
ofrecombinant viral and bacterial vaccines, or DNA plasmid injection. 
The intrinsic immunogenicity of viruses together with the development of standard 
techniques to engineer recombinant viruses has engendered broad interest in 
recombinant viral vaccines. Two mechanisms underlie the capacity of recombinant viral 
vaccine to initiate immune responses. First, the cellular damage induced by viral 
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infection elicits danger signals that attract and activate bone marrow derived APCs. This 
activation results in presentation of the transduced tumour antigen in the context of 
costimulatory molecules. The second mechanism is based on the ability of some viruses 
to directly infect bone marrow derived APCs. In this way, viral transduced genes 
encoding tumour antigens are endogenously synthesised in the APC cells and efficiently 
processed and presented in the MHC class I pathway. 
The capacity of some viruses to directly infect APCs allows for modification of 
recombinant viral vaccines to enhance the processing and presentation of encoded 
antigens. For example, graft of endosomal/lysosomal sorting signals onto the gene 
encoding antigen, cloned in recombinant poxviruses, has been reported to enhance 
MHC class II processing by antigen presenting cells and CD4+ T cell activation (Lotze 
et al., 1996; Tepper et al., 1994). 
Vaccination with recombinant viral vectors expressing melanoma antigens (Bronte et 
al., 1997; Wang et al., 1995), differentiation antigens CEA (Abrams et al., 1997) or 
MUC-1 (Akagi et al., 1997) have been described. These vaccinations resulted in a 
specific anti-tumour immunity and tumour regression. 
A number of bacterial strains, including Salmonella (Abdel-Wahab et al., 1997; Wolff 
et al., 1990; Condon etal., 1996) and Listeria monocytogenes (Pardall et al., 1995; Doe 
et. al., 1996), infect monocytes and macrophages and can therefore target antigens to 
professional APCs. 
Recombinant Listeria vaccines have been tested in animal models of macroscopic 
cancer with promising results (Corr et al., 1996; McCabe et al., 1995). The peculiar 
two-phase intracellular life cycle of this bacterium (Falkow et al., 1992), which, upon 
infecting monocytes and macrophages, is characterised by the presence of a 
phagolysosomal phase and a cytolytic phase, resulted in delivery of transduced antigens 
to both class I and class II pathways. 
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Some data have demonstrated the efficacy of this strategy in regression of established 
macrometastases (Pan et al., 1995). 
1.4.3.3 Genetic modification of T cells 
Strategies to enhance the therapeutic efficacy of tumour-infiltrated lymphocytes (TILs) 
through genetic modification have been explored. However, limited success was 
obtained, due to the inefficiency of gene transfection and in vivo tumour targeting. 
Moreover, the use of this approach in a clinical setting is limited by the qifficulty of 
generating large numbers of tumour-specific T cells at the single patient level "'.'ithout 
using high amounts of cytokines, which may cause apoptosis or expansion of 
nonspecific T cells. 
In one reported approach, autologous T cells have been transfected with a chimeric T 
cell receptor bearing the tumour-specific binding domain of a monoclonal antibody to 
enhance their recognition and killing of tumour cells (Gross et al., 1992). Gene 
modification of effector cells with these chimeric receptors offers the advantages of a 
permanent association between receptor and effector cell and the retention of chimeric 
receptor expression in daughter cells following cell proliferation. 
For example, it has been shown recently that nude mice xenotransplanted with ovarian 
cancer cells can be cured by injection of autologous T cells. bearing a chimeric receptor 
with the ScFv of an antifolate receptor highly expressed by ovarian cancer cells (Hwu et 
al., 1995). 
In another approach, tumour infiltrating lymphocytes have been transduced with genes 
encoding T-cell stimulatory cytokines to activate or enhance their anti-tumour activity. 
For example, TIL retrovirally transduced with the TNFa gene have been generated in 
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an attempt to deliver high concentrations of TNF to tumour sites without inducing 
systemic toxicity (Rosenberg, 1992). 
1.4.4 OTHERS GENE THERAPY APPROACHES 
1.4.4.1 Chemo-gene therapy 
The introduction into tumour cells of suicide genes encoding enzymes that convert 
nontoxic substances (prodmgs) into toxic metabolities is an attempt to avoid the 
systemic side-effects of conventional chemotherapy. The main task is to target the genes 
specifically to the tumour cells and to reach as many tumour cells as possible. Recent 
reports provide increasing evidence for the so-called "bystander effect", the cytolysis of 
nontransduced tumour cells, involving both cell-to-cell transfer of the active metabolites 
and stimulation of immune-mediated responses against the tumour cells (Freeman et al., 
1995). 
Moolten (Moolten, 1986) initially reported that tumour cells could be rendered 
ganciclovir-sensitive by herpes simplex vims-thymidine kinase (HSV-tk) gene transfer 
and that mice injected with transfected tumour cells could be cured with systemic 
ganciclovir treatment. HSV-tk phosphorylates ganciclovir approximately 1000-fold 
more efficiently than mammalian thymidine kinase. The resulting ganciclovir 
monophosphate is further phosphorylated by the mammalian enzyme to ganciclovir 
diphosphate and triphosphate, which are cytotoxic because they inhibit DNA 
polymerase (Davidson et al., 1981; Elion et al., 1977). Culver (Culver et al., 1992) 
pioneered the use of HSV-tk gene therapy for cancer showing complete macroscopic 
and microscopic regression of gliomas in ganciclovir-treated rats which were injected 
intratumourally with murine fibroblasts transduced with an HSV-tk retroviral vector. 
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After these preliminary results, a number of studies have been developed using different 
approaches. 
For example, a combination of HSV-tk-IL-2 gene therapy was evaluated in mice 
injected with the MCA26 colon cancer, using two adenoviral vectors containing HSV-tk 
and murine interleukin-2 genes (Chen et al., 1995). Following ganciclovir treatment, a 
massive tumour necrosis surrounded by inflammatory cells, was present and a 
significantly enhanced anti-tumour reactivity was observed in animals treated with a 
combination of the two vectors. The use of FLC lines expressing both HSV-tk and 
interferon-a followed by ganciclovir treatment resulted in cure of 70% to 100% of 
mice, which were also resistant to a subsequent challenge of wild type parental tumour 
cells (Santodonato et al., 1996). 
In another approach, a targeting of the suicide gene expression specifically in murine 
melanocytes and melanoma cells was obtained using the murine tyrosinase promoter to 
express the HSV-tk gene. Mice intravenously injected with retroviral supernatant 
transducing the gene showed a dramatic reduction in the number of B 16 melanoma lung 
metastases after ganciclovir treatment (Vile et al., 1994). Promoters for the human 
alpha-fetoprotein gene and carcinoembryonic antigen gene have also been used to direct 
HSV-tk expression to hepatoma (Ido et al., 1995) or gastric cancer cells (Tanaka et al., 
1996), respectively. 
Cytosine deaminase (CD) has also been used as a suicide-gene. The product of this gene 
acts by converting nontoxic 5-fluorocytosine to toxic 5-fluorouracil by deamination. 5-
fluorocytosine is converted to 5-fluorouracil monophosphate and to 5-fluorouracil 
triphosphate, which block thymidylate synthetase and mRNA transcription, 
respectively. 
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The transfection of a weakly immunogenic colon cancer and C57BL/6 mice-derived 
fibrosarcoma cell lines with the cytosine deaminase gene has been reported (Mullen et 
al., 1994). A significant tumour inhibition was observed after treatment with systemic 5-
fluorocytosine, when these cells were subcutaneously injected into syngeneic mice. A 
significant reduction in the number of secondary tumours was also detected upon 
rechallenge with syngeneic wild-type tumours. 
1.4.4.2 Introduction of tumour suppressor genes 
The transfer of tumour suppressor genes, including p53, p21 and the retinoblastoma 
gene (Rb), into tumour cells has been studied as a method to overcome the loss of cell 
cycle control and to block tumour cell growth. Multiple human and murine tumour cell 
lines have been exploited for in vitro studies, as well as in vivo murine tumour models. 
These studies demonstrated reduced tumour cell proliferation and suppression of 
tumour formation in mice. 
The p53 gene is central to both the cell cycle and differentiation and plays a pivotal role 
in apoptosis. Upon DNA damage, the level of p53 is increased, ultimately leading to 
cell-cycle arrest in G 1 to allow damage repair. P53 acts as a transcription factor to 
activate or repress transcription by binding to p53 target motifs in various promoters. 
In a p53-deficient human prostatic tumour cell line, adenovirus-mediated transfer of 
wild type p53 gene has been reported to produce high levels of wild-type p53 protein, 
which lead to apoptosis, and failed to form tumours in nude mice (Yang et al., 1995). 
Replication-deficient adenovirus transfer of wild type p53 gene has also been used in 
squamous cell carcinoma of the head and neck (Clayman et al., 1995), primary and 
metastatic murine bladder tumour cells (Werthman et al., 1996), murine and human 
melanoma cell lines (Cirielli et al., 1995), the ovarian cancer cell line 2774 (Santoso et 
al., 1995), human T987G glioma cells and H23 small-cell lung carcinoma (Gjerset et 
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al., 1995) and the 9L glioma cell line (Badie et al., 1995), with in vitro or in vivo growth 
suppression of infected cells via p53-mediated apoptosis. 
A retrovirus-mediated wild type p53 gene transfer into MDAM 231 breast cancer cells, 
that contain endogenous mutant p53, resulted in suppression of tumour formation in 
nude mice (Runnebaum et al., 1995). Furthermore, transduced human medulloblastoma 
cells, which endogenously express mutant p53, with a herpes simplex virus vector 
expressing wild type p53 resulted in cell-cycle arrest (Rosenfeld et al., 1995). 
A method to achieve systemic therapy with wild type p53 was evaluated using a 
liposome-p53 complex, that resulted in significant tumour regression, injected into nude 
mice inoculated with breast carcinoma cells (Lesoon-Wood et al., 1995). 
The product of the p21 gene binds proliferating cell nuclear antigen to prevent DNA 
replication; it also acts as a cyclin-dependent kinase inhibitor, preventing cdk-mediated 
phosphorylation of Rb. Overexpression of p21 is known to lead to cell cycle arrest at 
the G 1/S boundary, making it an excellent candidate for cancer gene therapy. Eastham 
(Eastham et al., 1995) transferred the p21 gene under the control of the cytomegalovirus 
promoter into p53-deficient mouse prostate cancer cells via an adenoviral vector. The 
infected cells showed overexpression of p21 protein and downregulation of the cell-
cycle-dependent kinase activity. 
The retinoblastoma gene was the first tumour-suppressor gene identified and has been 
shown to play a role in suppression of tumour invasiveness (Zhou et al., 1994), 
atitiangiogenesis (Richardson et al., 1995) and immunogenicity of tumour (Lu et al., 
1994; Li et al., 1994). Unphosphorylated retinoblastoma is able to sequester 
transcription factors that regulate cell proliferation, keeping the cell in a quiescent state. 
A constitutively active N-terminal truncated retinoblastoma protein (94 kDa) was 
constructed and has been characterised as possessing slower turnover and less 
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phosphorylation than the wild type retinoblastoma protein (I I 0 kDa). Replication-
deficient adenoviral-mediated gene transfer of the truncated retinoblastoma gene into 
nude mice bearing either human non-small-cell lung carcinoma or bladder carcinoma 
rendered more potent tumour suppression than transfer of the wild-type retinoblastoma 
gene (Xu et al., I 996). 
1.4.4.3 Inhibition of angiogenesis 
Angiogenesis is a crucial requirement for tumour growth and its inhibition appears to be 
a promising strategy for cancer treatment. Anti-angiogenesis gene-therapy has been 
evaluated by the use of different approaches (Kong et al., I 998). 
Gene therapy can be used to antagonise stimulators and to enhance inhibitory factors. 
Tumour-derived vascular endothelial growth factor (VEGF) has been shown to be a 
major inducer of tumour vascularization. VEGF is an endothelial-specific mitogen, 
which acts by specific interaction with two transmembrane tyrosine kinase receptors, 
VEGF receptor-I (VEGFR-I) and VEGF receptor-2 (VEGFR-2). 
Transfection with antisense constructs to VEGF appeared to reduce tumourigenicity of 
glioma cells in nude mice (Saleh et al., I996). A retroviral vector was used to infect 
endothelial cells with a dominant negative mutant gene encoding the VEGF receptor- I 
(VEGFR-I). This mutant receptor appeared to dimerize with native VEGFR-I and to 
prevent signal transduction and endothelial cell activation with VEGF (Millauer et al., 
I996). Furthermore, retroviruses encoding a truncated VEGF receptor 2 (VEGF-2) have 
been reported to suppress tumour angiogenesis and prolong survival time of rats bearing 
syngeneic intracerebral glioma tumours. A dual mode of function of truncated VEGFR-
2, consisting in a dominant-negative inhibition of wild-type VEGFR-2 function and 
VEGF depletion by receptor binding, was proposed as mechanism involved in 
angiogenesis inhibition (Machein et al., I 999). 
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The use of trans gene products that specifically target tumour endothelial cells is another 
approach. Jn vitro studies have evaluated the use of promoter sequences from genes that 
are expressed preferentially on endothelial cells, such as VEGFR-2 and E-selectin, to 
express the transgene. These promoter sequences may allow selective expression of 
endothelial inhibitors or toxins to cause vascular destruction (Ebeling et al., 1993 ). 
119 
1.5 BACTERIA AND CANCER 
There is considerable historical evidence concerning the antagonisms between acute 
bacterial infections, or their toxins, and cancer. 
Beginning from the 18th century, remarkable cases of cancer which had recovered 
following an acute bacterial infection have been reported. These cases were often called 
"spontaneous regression" and some of these occurred following acute inflammation or 
fever (Nauts, 1980). 
In the 1890s, William Coley, the first tumour immunologist, began to treat cancer 
patients with preparations derived from streptococcal cultures (Coley's toxins) to 
activate general systemic immunity, a portion of which might be directed against the 
tumour (Nauts, 1989). Studies at that time also pointed to a lower frequency of cancer in 
patients with tuberculosis. 
Beginning from 1970 mycobacteria, m particular Mycobacterium bovis (bacillus 
Calmette Guerin), have been used in experimental model systems and in humans as an 
approach to activate a specific and/or non-specific anti-cancer immunity though this has 
been with variable results. 
1.5.1 IMMUNITY TO MYCOBACTERIA 
Mycobacteria were the first bacterial pathogens of man to be described and they are 
responsible for more mortality than any other. pathogen, particularly in developing 
countries. 
They are slow-growing, aerobic, facultative intracellular bacilli. The two common 
human pathogens in this class of bacteria are M tuberculosis and M leprae; in addition, 
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atypical mycobacteria such as M avium cause opportunistic infections in 
immunodeficient hosts, in. particular AIDS patients. M bovis infects cattle and may 
infect humans; bacillus Calmette Guerin (BCG) is an attenuated, nonvirulent strain of 
M bovis that is used as a vaccine against tuberculosis. 
Mycobacterium tuberculosis causes a respiratory infection, which may be asymptomatic 
in some individuals or may produce damaging pulmonary lesions with severe 
debilitation in others. If the infection is not restricted by immune responses it can 
disseminate to the major organs of the body, most frequently in a fatal form. 
Given the seriousness of the disease, research involving immunity to M tuberculosis is 
most prominent among this class of intracellular bacterial parasites. Current efforts are 
focused on the development of effective vaccines and much of the work is directed 
towards elucidation of the mechanism of protective immunity. 
1.5.1.1 Mechanisms involved in protective immunity 
Classical studies have demonstrated that immunity to Mycobacterium tuberculosis is 
mediated by cells, whereas humoral responses were found not to be of importance 
(Andersen, 1997). 
Much of the work performed in the mouse model has, collectively, tended to support the 
hypothesis that cells mediating specific resistance to mycobacterial infection fall into 
the category of T helper type I (Thl) CD4+ cells, based upon their pattern of cytokine 
secretion. Indeed, kinetic studies performed in mice revealed the emergence of CD4+ 
cells, and to a lesser extent CD8+ cells, in response to intravenous infection with live, 
virulent M tuberculosis that secreted IFN-y (Orme et al., 1992a). The emergence of 
these cell populations coincided with the initial containment of the progressively 
growing bacterial infection and was then followed, a few weeks later, by the emergence 
of a second population of CD4+ cells that had strong cytolytic activity. Similarly, in two 
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· studies usmg bacillus Calmette Guerin (BCG), the secretion of IFN-y correlated 
strongly with the expression of protective immunity (Kawamura et al., 1992; Huygen et 
al., 1992). Interleukin-12 is of crucial importance for murine Thl cell development 
(Hsieh et al., 1993); the main source of IL-12 during infection is the macrophages 
which are stimulated by the phagocytic event (Fulton et al., 1996). 
In a study in humans (Barnes et al., 1993), a slightly different picture has emerged: the 
majority of T cell clones generated from patients with M tuberculosis infection tended 
to make a broad spectrum of cytokines, including IFN-y, tumour necrosis factor (TNF)-
a, and interleukin (IL)-10. 
In addition to a response involving a.p T-cells, some studies have shown that both in 
vivo and in vitro M tuberculosis stimulates the minor subsets of T cells expressing the 
y8 form of the antigen receptor, which are CD4-, CD8- and CD3+. 
y8 T cells accumulate in relatively large numbers in mice infected with M tuberculosis 
(Griffin et al., 1991) and evidence for strong recognition in vivo of a 16 amino acid 
peptide sequence within the mycobacterial heat shock protein (HSP) 60 was obtained 
(Fu et al., 1993). It is postulated that the response of y8 T cells to heat shock proteins is 
a primitive defence mechanism against some microbes, which are involved as a first line 
of defence. 
With regard to y8 T cells obtained from human patients, however, the HSP 60 molecule 
does not appear to be a primary target of immunity (Boom et al., 1992). Also in 
humans, such cells respond strongly to live tuberculosis infection and the degree of 
accumulation/expansion of y8 T cells in infectious lesions seems to relate. directly to the 
degree of protection that subsequently ensues (Barnes et al., 1992). The biological· role 
of lymphocytes bearing y8 T cells is still unclear. Some data support the idea that y8 T 
cells may represent a profuse source of cytokines, since IFN-y and IL-2 are secreted by 
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y8 T cells in vitro after activation with bacteria (Barnes et al., 1992; Follows et al., 
1992). 
A third immune population appeared to be involved in response to mycobacteria. This 
population, represented in very low percentages, is CD4-, CDS- but ap TCR+ T cells. It 
has been demonstrated that this cell type recognises mycolic acid from M tuberculosis, 
presented by the non-MHC encoded CDl molecule (Beckman et al., 1994). Indeed, 
CD 1 proteins have been proposed as antigen-presenting molecules that have evolved the 
ability to present nonpeptide lipid antigens to T cells. 
CD I-restricted T cells have been derived from the tissue lesions and blood of patients 
with mycobacterial infections. This cell population has been proposed to contribute to 
host defence by mediating the lysis of infected macrophages by two different 
mechanisms. First, a direct killing of infected macrophages, supported by in vitro 
experiments which shows a high degree of cytolytic activity against antigen-pulsed 
CDl+ mononuclear phagocytes (Stenger et al., 1997; Moody et al., 1999) and 
recognition and lysis of CD 1 + targets infected with live virulent M tuberculosis bacilli 
(Stenger et al., 1997; Jackman et al., 1998). Second, an indirect effect based on the 
recruitment of freshly macrophages to destroy infected cells, which is suggested by high 
levels of interferon y and low levels of IL-4 (Gong et al., 1998), typical of the Thl 
pattern of cytokines required for activation of macrophage-mediated killing of 
intracellular pathogens (Sieling et al., 1995), released in vitro by mycobacteria-specific 
CDl restricted T cells. 
1.5.1.2 Mycobacterium tuberculosis antigens 
Using a clever fractionation method to separate proteins by molecular size, initial 
progress has been made in defining more precisely the key proteins involved both in 
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protective (Andersen et al., 1991; Andersen et al., 1992) and memory immune 
responses (Andersen et al., 1993 ). 
A consistent number of antigens have been identified and some of these proteins have 
been classified as "immunodominant" on the basis of their ability to induce antibody, or 
proliferative T-cell responses in humans and experimental animals. Generally, the 
immunogenicity of these antigens may be explained on the basis of two different 
properties (Young et al., 1991): 
- several antigens belong to highly conserved stress protein families (Heat Shock 
Protein) (Young et al., 1988). Heat-shock proteins are molecular chaperones, 
mediating the assembly . and folding of other proteins. They are among the most 
immunogenic molecules known (Kaufmann, 1990; Cohen et al., 1991; Young et al., 
1988). The cause of this immunodominance is thought to reside in their universal 
distribution and high degree of sequence conservation, resulting ih continous priming 
of the immune system. 
- Several antigens are secreted or released proteins of M tuberculosis, which may be 
recovered in the culture filtrate (Harboe et al., 1986; Abou-Zeid et al., 1988). It has 
been proposed that proteins which are secreted from intact, viable mycobacteria may 
have a special role in protective immune mechanism, since they are available for 
immune recognition at an early stage of infection. Live dividing mycobacteria are, 
indeed, more effective than killed bacilli in evoking protective immunity (Collins et 
al., 1988; Orme, 1988) and only T cells recognising peptides secreted from live 
bacteria during the early phase of infection provide efficient immune surveillance 
and protection. Therefore, these proteins represent an important target of a strong 
cellular response (Andersen et al., 1991; Andersen et al., 1992; Andersen et al., 
1993). 
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Based on studies of protein release during growth of M tuberculosis, three different 
groups have been defined: excreted proteins, secreted proteins of the outer cell wall and 
cytoplasmic proteins released at late culture timepoints. A short term culture filtrate 
(ST-CF) containing a mixture of shedded outer cell wall proteins, excreted proteins and 
a minimal content of autolytic products, ·released during the first phase of growth, has 
been defined. This filtrate has been evaluated particularly for antigenic properties in 
experimental vaccines against tuberculosis (Andersen, 1994; Andersen et al., 1992; 
Andersen, 1997). Antigens of Mycobacterium tuberculosis contained in this short term 
culture filtrate {ST-CF) have been purified and characterised (Andersen, 1997) (Fig. 
1.15). 
Dna K (70 kDa) and GroES (10 kDa). These molecules are heat shock proteins, which 
function intracellularly as molecular chaperones (Young et al., 1991). They are widely 
conserved and can be found in various procaryotes and eukaryotes. In heat-shocked 
eukaryotic cells, DnaK has been demonstrated on the cell surface as well as in the 
cytoplasm (Rocchi et al., 1993). 
Pro rich complex (45-47 kDa). This antigen initially was identified in M bovis BCG 
culture filtrates as a target for both delayed type hypersensitivity (DTH) and antibody 
responses after immunisation with live, as opposed to dead, bacteria (Romain et al., 
1993; Romain et al., 1993). The corresponding gene from M tuberculosis was 
sequenced and found to encode a 39 amino acid consensus signal peptide (Laqueyrerie 
et al., 1995). The molecule has a predicted molecular mass of 29 kDa, but a high 
percentage of pro line (21. 7%) gives an increased rigidity and changes the mobility of 
the molecule and the apparent molecular mass. 
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Fig. 1.15: Mycobacterium tuberculosis antigens 
Proteins from M. tuberculosis can be divided into three major classes depending of their 
subcellular localization. ST-CF will consist of a mixture of secreted proteins and 
shedded outer cell wall proteins. 
The composition of a defined ST-CF harvested fromalogarithmically growing culture of 
M. tuberculosis: the culture filtrate has been separated in SDS-PAGE and silver stained, 
the localization in ST-CF of previously characterized proteins has been indicated (from 
Andersen et al., 1997). 
126 
L-alanine dehydrogenase (40 kDa). This enzyme catalyses the reversible conversion of 
pyruvate to L-alanine and may be involved in cell wall synthesis, as L-alanine is one of 
the four amino acids constituting the peptide moiety of the peptidoglycan layer (Young 
et al., 1991). 
Phosphate binding protein Ag38 (38 kDa). This molecule is localised mainly in the 
outer cell wall and released to the surroundings in limited amounts. The protein is post-
translationally modified by lipidation and apparently is anchored in the cell membrane 
by its lipid moiety (Young et al., 1991 ). The function of the 3 8 kDa protein is to bind 
and make phosphate available to· the bacteria and the synthesis of this protein is highly 
up-regulated during phosphate starvation (Andersen et al., 1990). lrnrnunogold labelling 
of bacteria grown in medium without phosphate demonstrated the antigen mainly in the 
cell wall and on the cell surface (Espitia et al., 1992). A signal sequence was identified 
in the gene encoding this protein (Andersen et al., 1989). 
Several studies have demonstrated that the 3 8 kDa protein is one of the inost important 
antigens of Mycobacterium tuberculosis, able to induce both serological and cell-
mediated reactivity (Kadival et al., 1987; Harboe et al., 1992; Young et al., 1986). Mice 
sensitised against the 38 kDa antigen preferentially appeared to induce a Thi-like 
immune response, revealed by secretion of IL-2 and IFN-y and the preferential 
· production of lgG2a-type antibody (Agrewala et al., 1995). 
AG 85 complex (30-32 kDa). This group of outer cell wall antigens consists of three 
distinct, although markedly cross-reacting, components denoted AG85A, B and C 
(Wiker et al., 1992). All three components demonstrate varying degrees of fibronectin 
binding and these molecules have been suggested to play an important role in 
macrophage uptake of mycobacteria (Abou-Zeid et al., 1991). Some data indicate that 
AG85 holds mycolyl-transferase activity indicating that outer cell wall synthesis may be 
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the primary function of this molecule (Belisle, 1995). The three components are 
encoded by three separate genes (Wiker et al., 1990; Content et al., 1991 ). Signal 
sequences have been identified. 
The Ag85 complex has been demonstrated to induce strong T-cell proliferation, 
interferon-y production and cytotoxic T lymphocyte (CTL) activity in most healthy 
individuals infected with M tuberculosis (Launois et al., 1994). Furthermore, 
immunisation of mice with plasmid DNA constructs encoding the antigen 85 induced 
substantial humoral and cell-mediated immune responses and conferred significant 
protection against challenge with live M tuberculosis (Huygen et al., 1996). 
MPT51 (27 kDa) and MPT64 (26 kDa). Both proteins are major components of short 
term culture filtrate (ST-CF). MPT51 and the AG85 complex contain cross-reactive B 
cell epitopes, and sequence homology between the AG85 components and MPT64 has 
been demonstrated (Wiker et al., 1992). These findings suggest the existence of secreted 
antigens with common structural features. No information about the possible functional 
relevance of these molecules presently is available. MPT64 is so far the only secreted 
antigen with no intermediate position in the cell wall (Andersen et al., 1991 ). 
Superoxide dismutase (23 kDa). This molecule exists as a tetramer in its native form 
and has an estimated molecular mass of 88 kDa and an apparent subunit molecular mass 
of 23 kDa (Andersen et al., 1991; Kusunose et al., 1976). The protein is found among 
the proteins appearing very early in culture filtrates (Andersen et al., 1991). The 
molecule may play an important role in protecting bacteria from the toxic effect of 
superoxide radicals generated during the oxidative burst in the macrophage and can 
therefore be regarded as a virulence factor. 
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19 kDa lipoprotein. This molecule is secreted across the cell membrane and is anchored 
in the outer cell wall by a lipid moiety. The molecule appears to be post-translationally 
glycosylated (Fifis et al., 1991; Garbe et al., 1993) and the gene encodes a consensus 
signal peptide (Ashbridge et al., 1989). 
Alpha-crystalin (12116 kDa). This M tuberculosis homologue of the alpha-crystalin 
family of low molecular mass heat shock proteins possesses sequence identity with 
members of the family of small heat shock proteins which includes the 18 kDa antigen 
from M leprae (Verbon et al., 1992). The molecule exists predominantly as a 12 kDa 
molecule in culture filtrates whereas the form present in mycobacterial extracts has an 
apparent molecular mass of about 16 kDa. 
ESAT-6 (6 kDa). A low mass secreted protein, identified due to its high reactivity with 
T cells isolated from memory immune mice (Andersen et al., 1995). Importantly, the 
gene encoding ESAT-6 is lacking in all strains of BCG tested whereas it is found in 
virulent M bovis (Harboe et al., 1996). In agreement with this finding ESA T-6 recently 
was identified in a segment deleted in all BCG substrains believed to be the original 
mutation leading to attenuation of M bovis (Mahairas et al., 1996). 
1.5.1.3 Pathogenesis of tuberculosis 
Tuberculosis is an example of infection with an intracellular bacterium in which 
protective immunity and pathologic hypersensitivity co-exist, and the lesions are caused 
mainly by the host response. 
Mycobacterium tuberculosis is inhaled as droplet nuclei, each containing one to three 
bacteria. These small particles are carried via the airstream and distributed to all regions 
of the lung (Wiegeshaus et al., 1989). The mycobacteria are taken up by alveolar 
macrophages; the bacteria may either be destroyed or start to multiply after a lag period 
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of a few days. Pro-inflammatory cytokines and chemokines secreted from infected 
macrophages lead to the recruitment of monocytes and lymphocytes from the blood and 
the development of the inflammatory process (Davatelis et al., 1988; Taub et al., 1993; 
Taub et al., 1993; Murphy et al., 1996). After about 2 weeks of infection (Orme, 1987; 
Andersen et al., 1992) the first signs of specific immunity emerge and involve the 
triggering of cytokine release from specific T lymphocytes (Andersen et al., 1992; Orme 
et al., 1993b; Andersen et al., 1995). The cytokines activate the bacteriostatic activity of 
macrophages and accelerate the lymphocyte recruitment. As the process progresses, 
chronic antigenic stimulation leads to maturation of monocytes into epithelioid cells and 
multi-nucleated giant cells surrounded by T lymphocytes, resulting in the formation of 
granulomas surrounding the microbes (Turk et al., 1982). The outcome of disease is 
determined by a dynamic balance between host and parasite factors. In the resistant 
individual a high level activity may be reached rapidly and the disease consequently is 
controlled in the asymptomatic stage. In the susceptible host, by contrast, the process of 
bacterial multiplication and cellular recruitment continues, the primary lesion enlarges 
and some bacteria are transported to the regional lymph nodes, giving rise to a 
granulomatous reaction. As the disease continues, the amplified immune reaction leads 
to intense inflammation, tissue destruction, caseous necrosis and the formation of 
cavitary lesions (Dannenberg, 1991). 
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1.5.2 USE OF BCG IN CANCER IMMUNOTHERAPY 
The first published use of BCG as a cancer vaccine was in 1935 by Holmgren in 
Sweden but it was not until the late 1950s and 1960s that experimental and clinical 
studies generated enthusiasm for its use against various cancers, including leukaemia, 
colon cancer, lung cancer and melanoma. In particular, the most influential report was 
that of Mathe in 1969 for the treatment of lymphoblastoid leukaemia (Mathe et al., 
1969). However, failure of later controlled studies to confirm these results, plus the 
advent of modem chemotherapy and radiotherapy, led to gradual abandonment of the 
use of BCG for most cancers. 
However, BCG immunotherapy has been demonstrated to be effective specifically in 
bladder cancer treatment. Studies on the use of BCG in bladder cancer revealed that the 
bladder was capable of mounting a strong immune response and that close contact 
between BCG and the cancer was required for maximum effect in animal models 
(Crispen, 1989; van der Meijden et al., 1989). In 1976, Morales described the successful 
treatment, with intravesical instillation of BCG, of a small group of bladder cancer 
patients (Morales et al., 1976). Wide acceptance of BCG immunotherapy for bladder 
cancer, however, began after a controlled study in 1980 that showed the unequivocal 
benefits in terms of decreased recurrence rate and increased median time to recurrence 
in patients given BCG immunoprophylaxis after local surgery (Lamm et al., 1980). 
At present, mostly patients with superficial bladder cancer are treated successfully with 
intravesical instillation of BCG and this treatment has been compared in several trials 
with all other forms of intravesical chemotherapy. BCG in general has proved more 
effective than chemotherapy, especially when trials have been weighted towards more 
aggressive high-grade disease and where re-induction and maintenance therapy has been 
given (Lamm et al., 1995; van der Meijden et al., 1989; Herr, 1992). In addition to its 
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role as an immunoprophylactic agent, BCG has also shown a 50-60% effectiveness 
against small residual tumours and a 70-75% complete response rate for carcinoma-in-
situ. BCG is not effective for muscle-invasive disease, or for tumours that lie out of 
direct contact with BCG, such as those deep within the prostate or in the upper urinary 
tract. 
The use of BCG for bladder cancer does not come without drawbacks. First, the 
response to BCG is unpredictable (Herr, 1992). There are currently no reliable 
prognostic factors that accurately predict treatment success or failure. 
Second, BCG has side-effects (Lamm et al., 1989). Most patients experience local 
symptoms of cystitis including frequency, urgency, dysuria and occasional haematuria. 
Mild systemic symptoms of high temperature, malaise and a transient influenza-like 
illness are also common. Severe side-effects occur in 5% of patients, roughly 10% of 
which involve frank BCG sepsis. Seven deaths due to BCG sepsis from bladder 
instillations have been documented. 
Whether the anti-cancer response is specific is probably one of the most debated 
questions in relation to BCG immunotherapy of bladder cancer. The simplest 
explanation is that the intravesical instillation of BCG results in non-specific cystitis, 
which is accompained by the local production of cytokines and accumulation of 
inflammatory cells that in the medium term have a more damaging effects on malignant 
rather than normal epithelium. Although such non-specific effect may contribute 
towards the efficacy of BCG, other mechanisms might be postulated to contribute to 
antineoplastic effect. Interestingly, BCG treatment has been reported to induce on 
tumour cells the expression of the tumour-associated MAGE antigens (Patard et al., 
1995) and cross-reactive antigens, such as heat-shock proteins (Zlotta et al., 1997). To 
date the development of specific cytotoxic T cells to these antigens remains to be 
established. 
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In the light of existing knowledge on Thl-Th2 responses, it would be plausible that the 
success of BCG treatment in bladder cancer might be due to the preferential induction 
of Thl responses. Indeed, cytokines classically associated with Thl response, such as 
IL-2 and IFN-y, have been detected in the urine of patients after intravesical 
administration of BCG, whereas IL-4 has proved difficult to detect. In addition the 
induction of interleukin-2 mRNA in peripheral'-blood mononuclear cells of patients 
during therapy strongly correlated with clinical response (Kaempfer et al., 1996). 
Furthermore, in a mouse model of BCG therapy of bladder cancer. treatment, success of 
the treatment appeared to be associated with a switch from a Th2 response to a Th 1 
response (McA veney et al., 1994 ). 
Recently the results of a clinical trial of active specific immunotherapy usmg an 
autologous tumour cells-BCG vaccine reported in patients with colon cancer have been 
published (Vermorken et al., 1999). Two hundred and fifty-four patients with colon 
cancer were assigned randomly to postoperative active specific immunotherapy or no 
adjuvant treatment. Active specific immunotherapy was intradermal vaccination with 
irradiated autologous tumour cells with bacillus Calmette Guerin as an adjuvant. The 
5.3 year median follow-up showed 44% risk reduction for recurrence in the recurrence-
free period in all patients receiving active specific immunotherapy. The major clinical 
benefit was observed in patients with stage II disease, with a significantly longer 
recurrence-free period and 61 % risk reduction for recurrences. 
There is some evidence of a mechanistic relationship between the variable efficacy of 
BCG in prophylaxis against tuberculosis and its variable efficacy in tumour prevention 
and therapy (Grange et al., 1995). Several independent studies in different countries 
have shown that neonatal BCG vaccination affords some degree of protection against 
leukaemia and other childhood cancers, but only where it also protects against 
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tuberculosis. By contrast, among young adults to whom BCG afforded little protection 
against tuberculosis, it seemed to cause a slight increase in the frequency of cancer 
(Comstock, 1991), and it had a slightly negative effect when used as adjunct therapy for 
breast cancer (Early Breast Cancer Trialists' Collaborative Group, 1992). 
Variation in the efficacy of BCG vaccination may be attributable to previous imprinting 
of the immune system by contact with environmental mycobacteria, leading to either a 
Thl response, which is protective, or a mixed Thl/Th2 population of responsive T cells, 
which appears not to be effective and results in a phenomenon of indiscriminate tissue 
necrosis (Bretscher, 1992). It has been postulated that using other mycobacterial 
preparations it might be possible to suppress the indiscriminate necrosis and enhance 
Thl-regulated selective destruction of tumour cells (Grange et al., 1995). 
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1.5.3 IMMUNITY TO BACTERIAL DNA: CpG MOTIFS 
Vertebrates have evolved innate immune defence mechanisms that recognise and 
respond to structural patterns that are specific to microbial molecules. Recently an 
increasing body of literature has examined one such pattern recognition system based 
on unmethylated CpG dinucleotides (Wagner, 1999). 
Unmethylated CpG dinucleotides are common in bacterial DNA, but are under-
represented and methylated in vertebrate DNA. Thus, this difference in the context of 
unmethylated CpG dinucleotides between vertebrate and microbial DNA provides a 
structural characteristic through which vertebrate leukocytes may detect and respond to 
infection. 
In particular, it has been observed that ~ptimal immune activation by microbial DNA is 
a consensus DNA motif in which an unmethylated CpG dinucleotide is flanked by two 
5'purines and two 3'pyrimidines (CpG motifs) (Krieg et al., 1995). 
1.5.3.1 CpG DNA effects on immune system 
Several molecular, cellular and in vivo studies have been performed to evaluate the 
specific effects of CpG DNA on the cells of the immune system (Fig. 1.16). These 
studies have been performed using synthetic oligonucleotides containing CpG motifs or 
using bacterial DNA. 
From these studies it appeared that DNA containing CpG motifs triggers humoral 
immunity by inducing B cell activation and IL-6 and IgM secretion. Furthermore, the 
strong activation effect of CpG oligonucleotides toward B cells also affected B cell 
apoptosis. A mechanism to maintain B cell tolerance is based on elimination of self-
reactive B cells by apoptosis in response to surface lgM (slg) cross-linking. Activation 
of mature B cells by antigens may thus require a signal that inhibits slg-mediated 
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apoptosis. Signals to abrogate slg-mediated apoptosis have been demonstrated to be 
generated by an appropriate costimulation, such as CD40 ligation, or stimulation with 
mitogens, such as LPS (Tsubata et al., 1993). Similar to CD40L and LPS, CpG 
oligonucleotides protected cells of the WEHI-231 B cell line from anti-IgM-mediated 
apoptosis (Yi et al., 1996a). This protection appeared to be associated with a reversion 
in anti-IgM-induced down-regulation of c-myc expression and up-regulation of myn, 
bcl-2 and bcl-xt mRNA expression. 
Apart from mitogenic effects on B cells, CpG DNA specifically activates antigen-
presenting cells, the sentinels bridging innate and adaptive immunity (Bendelac et al., 
1997). Indeed, CpG DNA directly activates monocytes and macrophages to express a 
full complement of costimulatory molecules, including CD40, CD80 and CD86 and to 
secrete cytokines, especially IL-12 and TNF-a at a level similar to those provoked by 
LPS (Ballas et al., 1996; Cowdery et al., 1996; Hallas et al., 1999; Stacey et al., 1996). 
It has been demonstrated that the CpG-driven secretion of high level TNF-a may cause 
harmful side-effects by promoting toxic shock, while the CpG-driven induction ofIL-12 
appear to be beneficial by promoting Th-1 polarised T cell responses (Lipford et al., 
1997; Lipford et al., 1997). Interestingly, studies of sequence modifications of CpG 
oligonucleotides have permitted the creation of a CpG motif that effectively induced IL-
12 but not TNF-a in macrophages, both in vitro and in vivo (Lipford et al., 1997; 
Lipford et al., 1997), avoiding TNF-a mediated harmful side effects. 
In contrast to B cells and APCs, bacterial DNA and CpG oligonucleotides did not 
directly activate T cells, even if CpG oligonucleotides are able to costimulate antigen-
reactive T cells that had received a stimulus. Indeed, it has been reported that, on cross-
linking of T cell receptors (TCRs) via plastic-bound anti-CD3 mAb, CpG 
oligonucleotides costimulated T cells to produce IL-2, to express IL-2 receptors and to 
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proliferate and differentiate into CTLs (Chen et al., 1999). Interestingly, neither 
cytosine methylation, CG inversion to GC, nor flanking canonical CpG motifs with 
poly(G)stretches affected T cell costimulation, while all of these modifications 
abrogated direct activation of APCs. These data imply that T cell costimulation is 
mediated by signal pathways distinct from those characterising CpG oligonucleotides-
mediated signaling via the chloroquine-sensitive endosomal pathway (see below). 
However, an indirect activation of T cells by CpG DNA is mediated, as described 
above, by Th-1 type cytokines released by APCs. Indeed, the Thl polarisation of T cells 
induced in vivo after treatment of mice with bacterial chromosomal DNA or CpG 
oligonucleotides was reported to promote resistance to infection with Listeria 
monocytogenes (Krieg et al., 1998; Elkins et al., 1999) or with Leishmania major in 
susceptible BALB/c mice (Zimmermann et al., 1998). 
CpG oligonucleotides have been reported to rapidly induce lytic activity and IFN-y 
secretion by NK cells in vivo (Shimada et al., 1986; Tokunaga et al., 1984; Cowdery et 
al., 1996). In vitro experiments demonstrated that the activation, CpG-mediated, of NK 
cells required the costimulation by cytokines, such as IL-12 and TNF-a, released from 
CpG -activated APCs (Hallas et al., 1999). Indeed, while CpG oligonucleotides alone 
failed to trigger IFN-y production by NK cells, the presence of low concentrations of IL-
12 seems to synergize with CpG DNA inducing secretion of high levels of IFN-y 
(Chace et al., 1997). 
In conclusion, these .studies indicated that CpG DNA induces a predominantly Thl 
pattern of immune activation. These potent and rapid immune-stimulating effects 
indicate that CpG DNA may be a "danger signal" able to activates innate immune 
defense (Krieg, 1996). 
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Fig. 1.16: CpG DNA effects on immune system 
CpG DNA directly activates dendritic cells, monocytes and macrophages to express 
increased levels of costimulatory molecules and to increase antigen presentation and 
cross-prirning. High levels of cytokines, especially Thl-like cytokines such as 
interleukin 12 (IL-12), interferon a (IFN-a) and tumour necrosis factor a (TNF-a), are 
expressed within a few hours, and monocytes and macrophages have increased 
antibody-dependent cellular cytotoxicity (ADCC) activity. NK cells are induced to 
express IFN-y by these cytokines acting in concert with CpG and have increased lytic 
activity. B cells rapidly produce IL-6 and IL-10 and express increased level of 
costimulatory molecules. B cells rapidly enter the cell cycle and become resistant to 
some fom1s of activation-induced cell death. T cells are not directly activated by CpG, 
but because of the T helper 1 (Thl)-like cytokine environment and the increased antigen 
presenting cell (APC) activity, antigen-specific Thl cells and cytotoxic T lymphocytes 
(CTL) are generated (from Krieg et al., 2000). 
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1.5.3.2 CpG DNA-mediated signaling 
Even though it is not completely understood how CpG DNA sequences mediate cell-
activation, some rate-limiting steps in signaling have been unraveled in APCs (Hacker 
et al., 1998) and in B cells (Yi et al., 1998b ). 
The rate-limiting step include cellular binding of CpG oligonucleotides, translocation 
into early endosomes, sensitivity to lysosomotropic compounds, and activation of the 
mitogen-activated protein kinase (MAPK) pathways, known to control transcriptional 
activities of AP-1 and of NFkB molecules. 
Lysosomotropic compounds known to inhibit endosomal maturation, such as 
chloroquine, bafilomycin A, or monensin (Yoshimori 'et al., 1991; Fox, 1993 ), 
completely inhibited CpG DNA-driven antiapoptotic effects in WEHI-231 B cells 
(Macfarlane et al., 1998; Macfarlane et al., 1997) as well as CpG DNA-driven 
activation of APCs (Hacker et al., 1998). The lysosomotropic compounds did not affect 
cellular uptake of CpG oligonucleotides (Hacker et al., 1998), but completely destroyed 
CpG-driven downstream events, such as activation of stress kinases and of transcription 
factors such as AP-1 (Hacker et al., 1998). 
Activation of APCs (Hacker et al., 1998) or B cells (Yi et al., 1998b) was mediated, at 
least in part, by rapid induction of mitogen-activated protein kinases of the "stress 
pathway" (Karin, 1995; Kyriakis et al., 1994) CpG-DNA triggered the kinase activity of 
JNK (Hibi et al., 1993) and of p38 (Han et al., 1994), a MAPK originally identified as a 
kinase activated by LPS. JNK activation and p38 activation were associated with 
subsequent phosphorylation of c-Jun and ATF2, components of the transcription factor 
AP-1 (Ray et al., 1989). 
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1.5.4 USE OF CpG DNA AS ADJUV ANT FOR ANTITUMOUR RESPONSE 
Conceptually, attempts to augment antitumour responses may benefit from the ability of 
bacterial DNA and CpG oligonucleotides to activate B cells, NK cells, macrophages 
and dendritic cells and the adjuvanticity of CpG oligonucleotides for CTL induction 
toward proteinaceous antigens. Furthermore, CpG oligonucleotides acted as adjuvant 
for Thl polarisation of cellular responses. 
In a study to identify the fraction of bacillus Calmette-Guerin (BCG) responsible for its 
antitumour activity, Tokunaga (Tokunaga et al., 1984) implicated the DNA component. 
Injection of a fraction, designated MY-1, purified from BCG containing 98% nucleic 
acid (70% DNA and 28% RNA) caused the IMC carcinoma of CDFl mice and line 10 
tumour of strain 2 guinea pigs to regress and prevented metastasis very effectively. MY-
1 after digestion with RNAse was more effective than undigested MY-1 against 
tumours, while MY-1 digested with DNAse had reduced activity, suggesting that the 
DNA from BCG possessed strong antitumour activity under certain conditions. 
Although studies using CpG oligonucleotides to augment antitumour responses are still 
in their infancy, initial reports appear promising. 
Passive therapy with. monoclonal antibodies (mAbs) can have antitumour effects in 
patients. NK cells and monocytes/macrophages participate in antibody-dependent 
cellular cytotoxicity (ADCC), which played a role in the response to antibody therapy. 
CpG oligonucleotides were assayed for enhancing antitumour effects of mAbs in a 
murine lymphoma model system. In vivo, there was a synergy between CpG 
oligonucleotides and the protective effects of antitumour mAbs. In vitro, CpG 
oligonucleotides increased ADCC (Wooldridge et al., 1997). 
Using the secreted antibody from the 38C13 murine lymphoma to immunize against a 
protein tumour antigen, CpG oligonucleotides were assessed for their adjuvant activity 
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(Weiner et al., 1997). Adjuvancity of CpG oligonucleotides was as effective as that of 
complete Freund'adjuvant in promoting protection against tumour challenge. 
Treatment with oligonucleotides containing a CpG immunostimulatory sequence was 
used recently to cure established neuroblastoma in syngeneic mice (Carpentier et al., 
1999). Whereas none of the control animals survived the tumour challenge, 50% of 
mice treated with daily peritumoural injections of CpG oligonucleotides for 15 days 
were cured, and all of the animals treated with CpG oligonucleotides had reduced 
tumour growth. Intraperitoneally injection of CpG oligonucleotides was less efficient 
than peritumoural injection, suggesting that CpG oligonucleotides exert their effects 
locally and must reach a sufficient concentration at the tumour site. 
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1.6 AIM OF THE THESIS 
The discovery of tumour antigens provided new opportunities for the development of 
therapeutic strategies against cancer. These approaches aim at increasing the 
physiologic recognition of tumour and at stimulating the effector components of the 
immune system which potentially contribute to the eradication of tumour cells. Most 
investigations in the field of cancer immuno-gene therapy have been related to the 
antitumour effect of cancer vaccines with· transfected cytokine genes, major 
histocompatibility antigens and co-stimulatory· molecules or to in vivo delivery of 
specific tumour antigens to antigen presenting cells. 
The work presented in this thesis evaluated, as an approach to stimulating an immune 
response against tumours, the transduction of tumour cells with a bacterial gene, which 
represents a "danger signal". 
Indeed, in less than a decade, the archetypal view that the immune system exists 
primarily to distinguish "self' from "non-self' has been replaced by the paradigm that 
the immune system functions primarily to distinguish dangerous from non-dangerous 
antigens. Presumably the immune system has evolved over millions of years to respond 
to structural patterns, that are specific to microbial molecules with a rapid activation of 
defenses best suited to fight microbial infection. 
Mycobacterium tuberculosis is a major target in this fight and studies on complete 
Freund's adjuvant (CFA) indicate that the mycobacterium contains a number of 
substances that stimulate the immune response and promote Thl differentiation. 
In the light of the pivotal role of M tuberculosis genes and their encoded proteins in 
linking innate and cell mediated adaptive immunity, these bacterial substances are 
promising candidates to be used as adjuvants for the development of effective 
therap'eutic or prophylactic tumour vaccines. The immune response they elicit might 
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facilitate the activation of the immune system against tumour antigens and the eventual 
selective destruction of tumour cells through a specific immune response. 
The Ag38 gene of Mycobacterium tuberculosis, encoding a 38 kDa antigen, has been 
used in this work; on the basis of serologic and immunogenic studies this antigen has 
been defined to be one of the most potent immunogen among mycobacterial antigens. 
Indeed, this molecule, which is cell-wall associated and secreted from bacteria, may 
have a special role in protective immune· mechanisms, since it is available for immune 
recognition at an early stage of mycobacterial infection, and may represent a strategy for 
the host to control the initial bacterial replication. 
Using a retroviral vector, modified to express the leader and transmembrane sequences 
of the Nerve Growth Factor Receptor, the Ag38 gene has been stably transduced into 
tumour cells and expressed as a protein bound to the cell surface. 
The adjuvant effects of Ag38 gene transduction in the response against poorly 
immunogenic tumours have been studied, using two different experimental models: one . 
consisting of a tumour transplant model and one other consisting of a spontaneous 
tumour model. 
In the first model, subcutaneously growing tumours and pulmonary metastases were 
induced in C57BL/6 mice by inoculation of murine melanoma cells. This tumour, as do 
many human tumours, expresses low levels of MHC class I antigens and different 
tissue-specific differentiation antigens, which, in melanoma patients, have been reported 
to represent potential targets for an immune response. This system, therefore, represents 
a suitable model for evaluating immunotherapeutic approaches to break tolerance to 
endogenous antigens. 
In the second model, N202 transgenic mice carrying the proto-oncogene HER2/neu 
under the transcriptional control of the mouse mammary tumour virus promoter 
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(MMTV) have been used. The expression of proto-neu in the mammary tissue of these 
mice results in the development of spontaneous focal mammary tumours in all females. 
These tumours express the transformant. oncoprotein, but are poorly immunogenic. This 
system was chosen as a realistic model to evaluate an immunotherapeutic strategy for 
cancer vaccination in individuals at risk for tumour development, with defined gene 
mutations. 
The efficacy of the cancer vaccine,· obtained by transduction of tumour cells with the 
Ag38 gene, has been determined for its protection against the parental tumour. 
The immunological responses induced by vaccination against tumour have been 
analysed and the involvement of both cellular and humoral immune effectors in tumour 
protection investigated in the two different models. 
The recognition of endogenous tumour antigens stimulated by vaccination with 
transduced cells has been evaluated in particular in melanoma model, where a strong· 
humoral response against specific antigens was observed. 
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CHAPTER TWO 
MATERIALS AND METHODS 
2.1 MOLECULAR BIOLOGY 
2.1.1 General procedures 
All solutions employed for the preparation and manipulation of nucleic acids were made 
up using distilled water. All solutions were autoclaved before use or, in the case of 
thermolabile substances, filter-sterilised using a 0.22µm filter and stored in a sterile 
container. To reduce the chances of RNA degradation by contaminating RNAses, 
solutions used for RNA work were treated overnight with diethylpyrocarbonate (DEPC) 
as a 0.1 % v /v solution and then autoclaved. Unless stated otherwise, all chemical 
reagents were supplied by Sigma (St. Louis, MO) or Merck (Darmstadt, Germany) and 
all enzymes used were purchased from New England BioLabs (Hitchin, Hertfordshire, 
UK) or Boehringer (Mannheim, Germany) 
2.1.2 Concentration of nucleic acids 
Nucleic acids were precipitated by adding 2.5 volumes of ethanol and chilled at -70°C 
for 30 minutes followed by centrifugation at 13,000 rpm for 15 minutes (Sepatech 
Biofuge, Heraeus Instruments). The pelleted nucleic acid was then washed with 70% 
v/v ethanol and then air dried before resuspension in distilled water or Tris-EDTA 
buffer (TE buffer: lOmM Tris-HCl pH 8.0, lmM EDTA pH 8.0). 
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2.1.3 Determination of nucleic acid concentrations 
The absorbance of an aqueous solution of the nucleic acid was measured at 260 run 
(Ultrospec 3000, Pharmacia Biotech). The convention used was that an absorbance of 
one unit is equivalent to a double stranded DNA concentration of 50 µg/ml and an 
RNA concentration of 40 µg/ml. 
2.1.4 Preparation of competent E. coli for transformation 
A single colony of J_MlOl E.coli was used to inoculate 2 ml of L-broth (1 % w /v bacto-
tryptone, 0.5% w /v yeast extract, 1 % w /v NaCl) which was then incubated overnight at 
37°C. From this 0.5 ml of the overnight culture was used to inoculate 50 ml of L-broth 
and this was incubated for several hours until an optical density of between 0.2 to 0.4 at 
600 run was achieved. The culture was cooled on ice for 10 minutes and the bacteria 
were then pelleted by centrifugation at 4000 rpm for 10 minutes at 4 °C (Megafuge, 
Heraeus Instruments). The bacterial pellets were resuspended in 10 ml of O.lM CaCh 
and cooled.on ice for 30 minutes. After recentrifugation, the bacteria were resuspended 
in 2 ml ofO.lM CaCh. 
2.1.5 Transformation of bacteria 
The plasmid DNA was added to 200 µl of competent E. coli. The suspension was 
cooled in ice for 45 minutes, warmed at 42°C for 2 minutes and then returned to ice for 
2 minutes. 800 µl of L-broth was then added to the samples followed by incubation in a 
shaking incubator at 3 7°C for 1 hr to permit expression of the antibiotic resistance gene 
on the plasmid. The bacteria were then plated out onto 90mm petri dishes (Falcon) 
containing L-agar (L-broth with 1.5% w/v agar) with ampicillin (final concentration of 
100 µg/ml). The plates were incubated overnight at 3 7°C. 
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2.1.6 Storage of bacteria 
500 µl of a suspension of bacteria in the log phase of growth was diluted with 100 µl of 
80% glycerol and stored in cryotubes (Nalgene) at -70°C. To resurrect bacteria from a 
frozen stock, a scraping was obtained using a sterile pipette tip and used to inoculate 10 
ml of L-broth containing ampicillin. The bacteria were grown overnight in a shaking 
incubator at 37°C. 
2.1. 7 Small scale preparation of plasmid DNA ("miniprep") 
Plasmid DNA was prepared from small cultures of bacteria using a Wizard Minipreps 
System (Promega, Madison, WI), following the protocol supplied by the manufacturer. 
This procedure was based on the alkaline lysis method for rapid extraction of plasmid 
DNA from bacterial cells (Birnboim et al., 1979) followed by the adsorption of DNA 
onto silica in the presence of high salt (V ogelstein et al., 1979). 
Single bacterial colonies were inoculated into 10 ml of L-broth containing ampicilliri 
and incubated overnight in a shaking incubator at 3 7°C. 1.5 ml of the overnight cultures 
were centrifuged at 13,000 rpm for 5 minutes and the bacteria were then resuspended in 
200 µl of cell resuspension solution (50mM Tris-HCI pH 7.5, lOmM EDTA 100 µg/ml 
Rnase A). 200 µl of cell lysis solution (200mM NaOH, 1 % SDS) was then added and 
mixed gently, followed by adding 200 µl of neutralisation solution (1.32M Potassium 
Acetate pH 4.8) which adjusts the sample to high salt binding conditions and causes 
precipitation of denatured proteins, SDS, cellular debris and chromosomal DNA. The 
samples were then centrifuged at 13,000 rpm for 10 minutes and the supernatants were 
then mixed to 1 ml with Wizard Minipreps DNA Purification Resin. The Resin/DNA 
mix was then transferred to a Wizard Minicolumn and vacuum suction was applied to 
cause flow through the minicolumn. After washing with 2 ml of column wash solution, 
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to remove salts, the DNA was eluted by applying 100 µl of distilled water to the 
Mini column. 
2.1.8 Large scale preparation of plasmid DNA ("maxiprep") 
Qiagen Plasmid Maxi kit (Qiagen, Hilden, Germany) was used which is based on the 
modified alkaline procedures (Birnboim et al., 1979) followed by binding of plasmid 
DNA to an anion-exchange resin. A single bacterial colony was used to inoculate a 2 ml 
volume of L-broth containing ampicillin which was incubated for 8 hr in a shaking 
incubator at 37°C. Then 1 ml of this culture was used to inoculate 500 ml of L-broth 
containing ampicillin which was then incubated overnight. The bacteria were pelleted 
by centrifugation at 6,000 rpm for 20 minutes (Sorvall, DuPont) and resuspended in 10 
ml of resuspension buff er P 1. 10 ml of lysis buffer P2 was then added and left at room 
temperature for 5 minutes. 10 ml of neutralisation buffer P3 (pre-chilled. to 4 °C) was 
added and the lysate incubated on ice for 20 minutes. The cell lysate was centrifuged for 
30 minutes at 15,000 rpm and the supernatant was then filtered onto a QIAGEN-tip 
which had been pre-equilibrated with 10 ml buffer QBT (750mM NaCl, 50mM MOPS 
pH 7.0, 15% ethanol, 0.15% Triton X-100) and allowed to enter the anion-exchange 
resin by gravity flow. Under these conditions, the plasmid DNA binds to the anion-
exchange resin. The resin was then washed with 60 ml of medium salt buffer QC (IM 
NaCl, 50mM MOPS, pH 7.0, 15% ethanol) to remove RNA, proteins and low 
molecular weight impurities. The DNA was eluted with 15 ml of high salt buffer QF 
(l.25M NaCl, 50mM Tris-HCl pH 8.5, 15% ethanol), and was then desalted by 
precipitation with 10.5 ml isopropanol. The DNA was pelleted by centrifugation at 9500 
rpm for 30 minutes at 4°C, washed with 70% v/v ethanol, air dried and then dissolved 
in TE buffer. 
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2.1.9 Preparation of total RNA from cultured eukaryotic cells 
RNA was obtained from adherent cell lines by employing the Rneasy Total RNA 
Purification Kit (Qiagen), which used a modification of the acid guanidinium 
thiocyanate-phenol-chloroform extraction method (Chomczynski et al., 1987) and a 
silica gel-based membrane. Approximately 2x106 cells were trypsinized, pelleted and 
then lysed in 350 µl of Lysis Buffer RL T (containing guanidinium thiocyanate and 
phenol). The lysate was centrifuged for 5 minutes at 13,000 rpm and the supernatant 
mixed vigorously with 1 vol 70% Ethanol. The mixture was then transferred to an 
Rneasy spin column and centrifuged at 10,000 rpm. After washing with Wash Buffer to 
remove salt, the RNA was eluted by applying 50 µl of DEPC-treated water to the 
Mini column. 
2.1.10 Agarose gel electrophoresis of DNA 
Gels were prepared by adding agarose (0.7 to 1.8% w /v) to 150 ml lx TAE (Tris-
acetate-EDTA) buffer (diluted from SOX TAE stock solution: 2M.Tris base, 2M glacial 
acetic acid, 50 mM EDTA) and boiled in a microwave cooker for 5 minutes. On cooling 
to below 50°C, 2 µl of ethidium bromide stock solution (IO mg/ml) was added. Gels 
were poured into a gel former with a well-comb in place. After setting, the gel was 
submerged in an electropheresis tank containing lx TAE buffer. Loading buffer (1/6 
volume of 6X stock solution: 0.25% bromophenol blue, 40% w/v sucrose in water) was 
added to the DNA solutions which were then transferred into the wells,· and 
electrophoresis was performed at constant voltage (70 volts) for 2 to 4 h. The gel was 
transilluminated with short wave ultraviolet light and the DNA was visualised using an 
EagleEye II camera, monitor and printer (Stratagene ). DNA fragments were sized by 
reference to a lkb DNA Ladder (Gibco, Life Technology, Garthersburg, MD) which 
was run concurrently. 
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2.1.11 Purification of DNA restriction fragments 
Agarose gels were visualised by UV transillumination and the bands of interest excised 
using a scalpel blade. The DNA was purified from the gel using the Wizard PCR Preps 
DNA Purification System (Promega), following the instructions provided by the 
manufacturer. The method is based on the binding of DNA to silica under high salt 
conditions (Vogelstein et al., 1979). The excised portion of the gel (300 mg) was 
dissolved in 1 ml Resin by heating at 65°C for 5 minutes. The Resin/DNA mix was then 
transferred onto a Minicolumn and after washing with 2 ml of 80% isopropanol, the 
DNA was eluted by applying 50 µl of water or TE buffer to the Minicolumn. 1 µl of the 
eluate was run on an agarose gel to confirm successful purification of the DNA 
fragment. 
2.1.12 Digestion of DNA with restriction enzymes 
Plasmid DNA was digested in volumes of 20 µl using 3 units of enzyme per µg of DNA 
for 60 minutes at 37°C. Appropriate buffers supplied by the manufacturer were-used. 
2.1.13 Removal of 5' terminal phosphate groups 
To reduce re-ligation of the vector DNA in cases where cohesive ends were present, 
·treatment with calf intestinal alkaline phosphatase (CIP) to remove the 5' phosphate 
groups of linear double stranded DNA was performed. At the end of a restriction 
enzyme digestion, 2 units of CIP were added to the reaction sample and incubated for a 
further 60 minutes at 3 7°C. The sample ·was then run on an agarose gel and the 
appropriate fragment was purified as described above. 
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2.1.14 Preparation of complementary DNA for analysis with PCR 
First strand cDNA was generated from an RNA template using a GeneAmp RNA PCR 
Kit (Perkin Elmer, Norwalk, CT). An aqueous solution containing 1 µg of RNA in a 
volume of 20 µl was heated at 65°C for 10 minutes and then chilled on ice. The 
following were added to the RNA sample and incubated at 42°C for 15 minutes: 5mM 
MgCh, lx PCR Buffer II, lmM dGTP, lmM dATP, lmM dTTP, lmM dCTP, lU 
Rnase Inhibitor, 2.5U Reverse Transcriptase, 2.5µM oligo d(T)t6· For analysis with the 
polymerase chain reaction (rtPCR), 10 µl of the reaction mixture was used in each PCR 
sample. 
2.1.15 Amplification of DNA sequences by the polymerase chain reaction 
Polymerase chain reaction (PCR) was performed by cycling samples containing 
teJ?.1.plate DNA mixed with sequence-specific oligonucleotide primers through three 
temperature incubations in the presence of Thermus aquaticus {Taq) DNA polymerase 
(Perkin Elmer). These cycles were: 
1. Denaturation of double stranded DNA 
2. Annealing of primers to DNA 
3. Extension of target sequences by Taq DNA polymerase. 
The incubations were performed in aDNA Thermal Cycler (Perkin Elmer). The optimal 
cycle number and exact annealing and extension conditions were as described for each 
individual reaction (see Results). Primers were synthesised by PRIMM. Each reaction 
sample consisted of: template DNA (50 ng of plasmid DNA), 200µM dNTPs, lx PCR 
buffer, 25 pmol of 5' primer, 25 pmol of 3' primer, 1 U Taq DNA polymerase and 
distilled water added to a total volume of 50 µI. The reaction was then heated to 95°C 
for 5 minutes and then allowed to proceed through 30 to 35 cycles of denaturation, 
annealing and extension to produce the required degree of amplification. The amplified 
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PCR products were evaluated by mixing I 0 µl of the reaction mixture with 2 µl of 6x 
loading buffer stock solution and were then run on an agarose gel. 
2.1.16 Ligation of PCR products 
For ligation of Ag38 DNA into the pLTMSN vector, the ligation reaction was 
performed in a volume of 15 µl using 1 unit ofT4 DNA ligase and ligase buffer (50mM 
Tris-HCl pH 7.8, lOmM MgCh lOmM DTT, lmM ATP, 25 µg/ml BSA). The molar 
ratio of vector to insert was in the range of 1 :4 to 1: 10. The reaction mixture was 
incubated overnight at 16°C and was then transformed into competent E. coli JMIOI. 
For ligation of TRP2 DNA into the PCR3.1 Uni vector, the TA cloning Kit (lnvitrogen, 
San Diego, CA) was used. This system takes advantage of the nontemplate-dependent 
activity of Taq polymerase which adds a single deoxyadenosine to the 3' termini of the 
double stranded molecules. The linearised vectors which are supplied possess single 
overhanging deoxythymidine residues at the 3' termini, thus allowing the PCR product 
to ligate efficiently with the vector. The ligation reaction was perfomed according to the 
manufacturer's instructions in 10 µI volumes consisting of : lµl of lOx ligation buffer 
(60mM Tris-HCl pH 7.5, 60mM MgCb 150mM NaCl, 1 mg/ml BSA, 70mM P-ME, 
lmM ATP, 20mM DTT, lOmM spermidine), 1 µI T4 DNA ligase, 2 µI linearised vector 
(60 ng), 1 µI PCR reaction mixture and 5 µI distilled water. The reaction mixture was 
incubated overnight at 16°C and was then transformed into competent E. coli (TOPIOF' 
strain) and plated onto L-agar containing ampicillin. 
2.1.17 Agarose gel electrophoresis of RNA for "Northern" transfer 
Separation of RNA was performed in formaldehyde denaturing gels. Agarose was 
dissolved in DEPC-treated water by boiling to 100°C. On cooling to 60°C, lOx MEN 
solution (200mM MOPS, lOmM EDTA, 50mM sodium acetate, pH 7.0) and 
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formaldehyde solution were added to give a final concentration of 1.4% w/v agarose, Ix 
MEN and 2.2M formaldehyde. Gels were cast as described earlier and were submerged 
in Ix MEN running buffer. RNA samples were prepared for electrophoresis by 
precipitation and resuspension in Ix MEN buffer followed by addition of formaldehyde 
and formamide to final concentrations of 2.2M and 50% v /v, respectively, such that 
each sample had a total volume of 12.5 µI. 15 µg of RNA markers (Gibco) were also 
precipitated and treated as for the RNA samples. The RNA samples were heated to 
70°C for 5 minutes and cooled immediately on ice. 0,5 µI of ethidium bromide stock 
solution and 1/10 volume RNA loading buffer (50% glycerol, lmM EDTA, 0.25% w/v 
bromophenol blue, 0.25% xylene cyanol) was added before loading into the wells. 
Electrophoresis was performed at 20V until the dye front had travelled 3/4 of the length 
of the gel. 
2.1.18 Capillary transfer of RNA from agarose gels 
RNA fragments separated by agarose gel electrophoresis were transferred to Hybond-
N+ membranes (Amersham, Buckinghamshire, UK) prior to hybridisation with 
radiolabelled DNA probes (Alwine et al., 1977). Following visualisation of the RNA 
under UV transillumination the gel was placed in denaturing solution of 0.05M NaOH 
for 30 minutes and then soaked in 20x SSC (saline-sodium citrate) solution (3M NaCl, 
0.3M sodium citrate, pH adjusted to 7.0 with NaOH) for 30 minutes. The gel was then 
placed on a raised platform covered with two sheets of Whatman 3MM filter paper pre-
soaked in 20x SSC were the ends of the filter paper extending below the platform into a 
reservoir of 20x SSC. A sheet of Hybond-N+ membrane was then placed in direct 
contact with the gel. Five sheets of filter paper, pre-soaked in 20x SSC, was then placed 
on top of the membrane followed by a box of paper towels compressed with a 1 kg 
weight. The assembly was left overnight to allow transfer of RNA. Completion of 
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transfer of RNA from the gel was checked by UV transillumination of the filter. The 
filter was then exposed to UV irradiation (UV Stratalinker 1800, Stratagene) to enable 
cross-linking of the RNA onto the filter. 
2.1.19 Labelling of DNA probes with radio-isotopes 
Double-stranded fragments for probing RNA blots were labelled usmg mixed 
hexadeoxyribonucleotide primers of random sequence (Feinberg et al., 1983), 
employing reagents supplied in a kit (Boehringer). An aqueous solution containing 50 
ng of DNA was boiled at 100°C for 3 minutes and then mixed in a buffered solution 
containing dATP, dGTP, dTTP and random hexadeoxyribonucleotides in a total volume 
of 50 µ1. Labelling was performed at 37°C for 1 hr with 1.85 MBq of [a-32p]dCTP 
using 10 units of Kienow subunit of DNA polymerase. The labelling mix was then 
passed down a G-50 Sephadex column to remove unincorporated nucleotides. The 
labelled product was then boiled for 5 minutes with 200 µI of salmon sperm DNA (10 
mg/ml) before being added to the hybridisation solution. 
2.1.20 Hybridisation of RNA immobilised on filters 
Blotted filters were wetted in 2x SSC and then transferred to rotating glass bottles. 20 
ml of prehybridisation buffer was then added to the bottle and incubated at 42°C in a 
rotating Techne oven for at least 6 h. Denatured radiolabelled probe was then added and 
incubated overnight at 42°C. Following hybridisation, the blots were washed once in 5x 
SSC for 15 minutes and then twice in O.lx SSC/0.1 % w/v SDS for 15 minutes each. 
After the final wash the filters were wrapped in plastic sheets and exposed to Kodak X-
Omat films with intensifying screens at -70°C. 
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2.1.21 Automated sequencing of DNA by the chain termination method 
Sequencing reactions were performed using an ABIPRISM Dye Terminator Cycle 
Sequencing Reaction kit (Perkin Elmer), according to the protocol provided by the 
manufacturers which is outlined below. Enzymatic extension reaction was performed in 
an asymmetric PCR using a single primer, dye-labeled terminators and the AmpliTaq 
DNA polymerase FS, a mutant form of Taq DNA polymerase which has essentially no 
5 '4 3' nuclease activity and a drastically reduced discrimination for 
dideoxynucleotides. 
Each reaction sample consisted of: template DNA (0.5 µg of DNA plasmid), 3.2 pmol 
Primer, 6 µl Terminator Ready Reaction Mix, which contains AmpliTaq DNA 
Polymerase FS, A-Dye, C-Dye, G-Dye and T-Dye labeled terminators, dITP, dATP, 
dCTP, dTTP, Tris-HCl pH 9, MgCh, thermal stable pyrophosphatase and H20 to 20 µl 
volume. 
Extension reaction was performed in a DNA Thermal Cycler with a denaturation step at 
96°C for 4 min and 25 cycles at 96°C for 30 sec, 50°C for 20 sec, 60°C for 4 min 
followed by a single cycle at 60°C for 3 min. After precipitation of DNA, samples were 
loaded onto a polyacryilamide gel and the samples were analyzed on an ABI PRISM 
377 DNA Sequencer (Perkin Elmer) which was operated by the Sequencing Service of 
Istituto Nazionale Tumori, Milan. 
2.1.22 In vitro-coupled transcription-translation 
. In vitro transcription-translation was performed in a single step using a TnT T7-coupled 
reticulocyte lysate system (Promega), according to the protocol provided by the 
manufacturers which is outlined below. 
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The DNA template (1 µg DNA plasmid) was incubated for 120 minutes at 30°C in a 50 
µl reaction mixture containing 25 µl rabbit reticulocyte lysate, 1 µl T7 TnT RNA 
polymerase, 1 µl amino acids mixture lmM minus methionine, 40 U Rnasin, 2 µl TnT 
reaction buffer and 4 µl translation-grade 358-methionine (1000 Ci/mmol; 10 mCi/ml; 
Amersham). A Sephadex G-25 column (Amersham) was used to purify the translated 
product and the percentage incorporation of 358-methionine was determined by TCA 
precipitation. The reaction was stored at -20°C until needed. 
2.2 CELL BIOLOGY 
2.2.1 Eukaryotic cell culture - General procedures 
All manipulations involving cell culture were carried out in a sterile environment 
provided by a laminar flow hood. All tissue culture reagents were filter sterilised by 
passage through a 0.22µm filter and stored in sterile autoclaved containers. All cell 
culture media were purchased from Sigma. 
The cell lines used in this work are listed in Table 2.1. Adherent cell lines were grown 
as monolayers in plastic tissue culture flasks or dishes (Falcon) in DMEM 
supplemented with 10% v/v fetal calf serum (Gibco) (previously heat-inactivated by 
incubating at 56°C for 30 minutes) and incubated at 37°C in 8% C02. Cells were grown 
until just subconfluent (approximately 2 to 4 days) and were subcultured 1: 10, using 
trypsin (0.05% w/v)/5mM EDTA to detach the cells. Cells grown in suspension were 
cultured in RPMI+l0%FCS and were subcultured 1: 10 every 3 days. All cell lines were 
tested routinely for Mycoplasma infection (performed by technical personnel) and only 
cell lines in which 'infection was undetectable were used for experiments. 
Cell counts were performed using a Burker' s chamber and an inverted microscope. 
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2.2.2 Storage and recovery of cells stored in liquid nitrogen 
Cells were trypsinised, pelleted and resuspended at approximately 10 7 cells/ml in fetal 
calf serum containing 10% v /v dimethylsulphoxide (DMSO), the presence of which 
prevented the formation of damaging ice crystals. 1 ml aliquots were transferred to 1.5 
ml Nalgene cryotubes which were then placed in a -70°C freezer overnight. Frozen cells 
were then transferred to liquid nitrogen tanks (-196°C) the following day. 
Recovery of cells from liquid nitrogen storage was performed by rapid thawing in a 
3 7°C water bath. Thawed cells were washed in 10 ml of medium, harvested by 
centrifugation (1200 rpm for 5 minutes) and were then transferred to 25cm2 flasks 
containing fresh culture medium. 
2.3 GENE TRANSFER INTO EUKARYOTIC CELLS 
2.3.1 Growth selection in Geneticin (G418 sulphate) 
Geneticin is an aminoglycoside antibiotic related to Gentamicin and is toxic to both 
prokaryotic and eukaryotic cells. Introduction of the neomycin phosphotransferase gene 
into eukaryotic cells can confer resistance to Geneticin added to normal medium. 
Geneticin (Gibco) was added to. DMEM to a concentration of 1 mg/ml for selective 
growth of B16 and Bl6.B78 cells, 0.5 mg/ml for N202.1A cells and 0.8 mg/ml for 
CHO-Kl and NIH-3T3 cells, these being the concentrations previously determined to 
be optimal for selective inhibition of growth of these cells. 
2.3.2 Calcium phosphate/DNA co-precipitation 
This method involves mixing DNA with CaCh and a phosphate buffer to form a fine 
precipitate which is deposited onto the cultured cells (Graham et al., 1973). Twenty-four 
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hours prior to transfection, 5xl05 cells were plated out in a 25cm2 flask. 10 µg of the 
plasmid DNA to be .transfected were made up to 300 µI using sterile distilled water 
followed by the addition of 100 µI of 2.5M CaCh and 600 µI of sterile distilled water. 1 
ml HEPES-P04 was then added dropwise to the mixture, during which time a fine 
precipitate became visible. The sample was incubated at room temperature for 3 0 
minutes and then added dropwise to the medium in the cell culture flask. On the 
following day the medium was removed and replaced with fresh medium. 
2.3.3 · Liposome/DNA complexes 
Lipofectin reagent (Gibco) was used to form lipid-DNA complexes which were able to 
fuse with cells resulting in efficient uptake of the exogenous DNA (Feigner et al., 
1987). Lipofectin is a l:l(w/w) formulation of the cationic lipid N-[1-(2,3-
dioleyloxy)propyl]-n,n,n-trimethylammonium chloride (DOTMA) and dioleoyl 
phosphotidylethanolamine (DOPE) in water. Twenty-four hours prior to transfection,. 
approximately 5xl05 cells were plated out in a 25cm2 flask to produce. a culture which 
was approximately 40-60% confluent. 5 µg of the plasmid DNA to be transfected were 
made up to 100 µI in serum-free DMEM. In a separate tube, 20 µI of Lipofectin was 
combined with 80 µI of serum-free DMEM. The DNA solution and the diluted 
Lipofectin were then combined and incubated at room temperature for 15 minutes. 
During this time, the growth medium was removed from the cell culture flask and the 
cells washed twice with 5 ml of serum-free DMEM. After incubation, the 
DNA/Lipofectin mixture was mixed with 1.8 ml of serum-free medium and then added 
to the cells and incubated at 37°C for 24h. The DNA-containing medium was then 
replaced with fresh normal growth medium. In order to obtain stable transfectants, the 
cells were split into selection medium after another 48 hr . 
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2.3.4 Retroviral-mediated gene transfer 
2.3.4 (1) Generation of producer cell lines 
Since to make stable lines it is important to infect rather than transfect the packaging 
cells (Miller et al., 1989), producer cell lines have been generated by infection with the 
supernatant obtained after transient transfection of a different packaging line. 
Amphotropic packaging cells, GP+envAM12 (Markowitz et al., 1988b), were 
transfected with 10 µg of vector plasmid DNA using the calcium phosphate/DNA co-
precipitation method. 48 hr after transfection the supernatant from AM 12 cells was used 
to infect the ecotropic packaging cells GP+E86 (Markowitz et al., 1988a) in the 
presence of polybrene (at a final concentration of 8 µg/ml) to enhance virus-ce 11 surface 
interaction. The cells were split into selection medium 72 hr after infection. After 14 
days, individual colonies and the bulk culture which survived selection were recovered 
and expanded. 
2.3.4 (2) Harvest of retroviral stocks 
Virus was harvested from producer cells by exposing 8 ml of fresh medium to 5x106 
cells in a 75cm2 flask and harvesting the medium 16 hr later. The medium was filtered 
(0.45µm) to remove cell debris and was either used for infection of target cells 
immediately or was stored frozen at -70°C. 
2.3.4 (3) Infection of target cells by retroviral stocks 
Tumour cells to be infected ("target ce 1 ls") were plated out in a 25cm2 flask to produce 
a culture which was approximately 40-60% confluent the following day. The medium 
was removed and replaced with 2 ml of viral supernatant which contained polybrene (at 
a final concentration of 8 µg/ml) to enhance virus-cell surface interaction. After 2 hr at 
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3 7°C, 5 ml of media was added and cells incubated 16 hr at 3 7°C. The viral supernatant 
was then removed and replaced with fresh normal growth medium. The cells were 
grown for another 48 hr and then split into selection medium. Resistant surviving 
colonies were visible after about 14 days and these were lifted using trypsin- transferred 
to individual wells of a 24-well plate, followed by expansion into larger cell culture 
flasks. 
2.3.4 (4) Determination of viral titre 
Supernatant from individual G418-resistant colonies and from the bulk culture of 
producer cells was tested for the viral titre as the capacity to provide G418 resistance to 
NIH3T3 fibroblasts. Fibroblasts were plated out in a 25cm2 flask to produce a culture 
which was approximately 40-60% confluent the following day. The medium was 
removed and replaced with 2 ml of viral stocks dilutions (10-3, 104 , 10-5) in the presence 
of polybrene, as above. After 2 hr at 3 7°C, 5 ml of media was added and 24 hr later the 
cells were transferred in media containing 800 µg/ml G418. G418-resistant clones were 
counted 14-18 days later. 
2.4 ASSAYS 
2.4.1 Flow cytometry 
Flow cytometry was used to detect the expression of cell surface or intra-cellular 
molecules on tumour cells. Adherent tumour cells were trypsinised and washed twice in 
ice-cold PBS and then resuspended in PBS-0.03% BSA at a concentration of 5xl06 
cells/ml. For detection of cell surface molecules 100 µl of the cell suspension was 
incubated at 4°C for 45 minutes with the primary monoclonal antibody (at the optimal 
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pre-determined concentration) or with polyclonal antiserum, as specified in Results. As 
a negative control, PBS-0.03% BSA was added in place of the primary antibody. After 
washing and spinning down (1200 rpm for 5 minutes) the cells twice with PBS, cells 
were resuspended in PBS-0.03% BSA and an appropriate FITC-conjugated secondary 
antibody (used at dilutions indicated in Table 2.3) were added to the cells and incubated 
at 4°C for 30 minutes. After two washes with PBS, the cell pellet was resuspended in 
300 µl of PBS and the cells were then analysed using a F ACScan or a F ACScaliber 
flow cytometers (Becton Dickinson, Mountain View, CA). For intracellular staining, 
permeabilisation was obtained by treatment with 50% methanol solution for 30 min at 
4°C or with 3% paraformaldehyde (10 min at room temperature) and PBS-Digitonin (50 
µg/ml) (10 min at room temperature). 
Multiparameter analysis was used to detect expression of cell surface markers and 
cytokine production by murine splenocytes. Splenocytes were cultured for 21 hr with 
immobilised anti-CD3 mAb (10 µg/ml) and 1 µM monensin added for the last 12 hr 
(Sigma). Cells were washed twice in PBS and then fixed with 4 % paraformaldehyde 
for 5 min at room temperature and permeabilised with PBS-0.2% saponin for 15 min at 
room temperature. Cells were triple-stained with Cy-Chrome-labeled, FITC-labelled 
and PE-labelled monoclonal antibodies. Isotype-matched FITC-, PE- and Cy-Chrome-
conjugated mAbs were used for background determination. All mAbs were purchased 
from Pharmingen (San Diego, CA) and diluted as indicated in the supplier's sheet. 
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2.4.2 Detection of cytokines using the enzyme-linked immunosorbent assay 
(ELISA) 
ELISA was performed usmg optimised ELISA kit purchased from Genzyme 
(Cambridge, MA), Euroclone (Paignton, Devon, UK) and Pharmingen, using the 
protocol and reagent's dilutions recommended by the manufacturers as outlined below. 
Kits purchased from Genzyme or Euroclone supplied also plates pre-coated with the 
appropriate antibody, ready to use. When working with the kit from Pharmingen, the 
coating was performed by adding 100 µl aliquots of purified antibody diluted in coating 
buffer to wells of a protein binding 96-well plate (Nunc Maxisorp) and by incubation 
overnight at 4 °C. In all experiments plates were then washed twice by immersion in 
PBS/Tween (0.05% v /v Tween-20 in PBS) and each well was then filled with 200 µl 
PBS/10%FCS and left at room temperature for 2 h. After two washes with PBS/Tween, 
100 µl of each test sample were placed in duplicate in individual wells and incubated at 
room temperature for 2 hr. For standards, a range of diluted recombinant cytokine was 
used. The plates were then washed four times in PBS/Tween followed by addition of 
100 µl of biotinylated antibody, diluted in PBS/10%FCS, to each well. After incubation 
at room temperature for 1 hr, the plate was washed six times with PBS/Tween. Each 
well was then filled with 100 µl of HRP-conjugated streptavidin. After incubation at 
room temperature for 30 minutes the plate was washed eight times with PBS/Tween 
followed by addition of 100 µl of the TMB substrate (Sigma) to each well. The plates 
were read at OD 450 nm using a Microplate reader 550 (Biorad). 
2.4.3 Assay for cytotoxic lymphocyte activity (CTL assay) 
This assay of cytotoxicity was performed 5 days after in vitro or in vivo restimulation 
with irradiated tumour cells. 
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2.4.3 (1) Preparation of splenocytes 
Fresh splenocytes were harvested from mice and spleens removed usmg aseptic 
technique. The spleens were gently teased apart in 10 ml of RPMI in a petri dish to 
obtain a cell suspension. The cells were pelleted by centrifugation (1500 rpm for 5 min) 
and then resuspended in 3 ml aqueous ammonium chloride 0.17M for 10 min to lyse red 
blood cells. The suspension was then restored to isotonicity by adding 20 ml of RPMI. 
After centrifugation (1500 rpm for 5 min), the cells were suspended in RPMI. 
2.4.3 (2) Restimulation in vitro 
Splenocytes were resuspended to a concentration of 5x106 cells/ml in RPMI medium 
containing 2-J3-mercaptoethanol (final concentration of 5x 10-5M) and recombinant IL-2 
(final concentration of 25 units/ml). 1 ml of the cell suspension was then placed in each 
well of a 24-well plate. 
Adherent tumour cells were trypsinised, washed in growth medium and resuspended in 
10 ml of PBS. The suspension of cells in PBS was then irradiated (20,000 rad) and, after 
centrifugation, resuspended in RPMI at a concentration of 5x104 c.ells/ml. 1 ml aliquots 
were added to each of the wells in the 24-well plate and the cell mixture was incubated 
at 3 7°C for 5 days. 
2.4.3 (3) Labelling and lysis of target cells 
Approximately 2x 106 adherent cells were trypsinised, washed in medium and 
resuspended in 300 µl of medium. 100 µl of sodium [51 Cr]-chromate (3.4 MBq) was 
added to the cells and incubated for 45 minutes at 37 °C, and then the cells were washed 
three times in 10 ml of serum-free medium followed by resuspension in RPMI at a 
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concentration of 5x 104 cells/ml. 100 µl of the labelled-cell suspension was then added 
to each well of a round-bottomed 96-well plate. 
Splenocytes were centrifuged (1500 rpm for 5 min) and resuspended at concentrations 
of 5x106, 2.5x106 and 1.25x106 cells/ml and 100 µl of each of these dilutions were 
added to the target cells to give effector:target ratios of 100, 50 and 25: 1. The samples 
for each effector:target ratio were tested in replicates of three to four. Also included in 
the assay were samples to which no lymphocytes had been added, to indicate the level 
of spontaneous lysis. In addition, samples to which 100 µl of 2% Triton were added 
were used to indicate maximum lysis. After incubation at 37 °C for 4 hr, the plate was 
centrifuged at 1500 rpm for 5 min. 100 µl of supernatant was then carefully aspirated 
from each well and the radioactivity determined using a beta counter (LS 1801 
Beckman). The percentage of lysis was determined as: 
% Lysis = (T-S) I (M-S) x 100, where 
T is the radioactivity (cpm) released into the supernatant in the presence of effector 
cells, 
S represents spontaneous release in the absence of effector cells, 
M represents maximal lysis. 
2.4.4 Assay for complement-dependent cytotoxicity 
This assay was used to determine the antibody-mediated cytotoxicity in sera from 
vaccinated mice. The target cells were labelled with [51 Cr] as in the CTL assay and 
2x103/well were incubated with mice serum at serial dilutions for 45 min at 37°C. After 
washing, rabbit complement (Cedarlane, Homby, Ontario, Canada) was added, and 
after 2 hr incubations at 3 7°C supematants were harvested for determination of released 
radioactivity. As above, I also included in the assay samples to which no serum had 
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been added, to indicate the level of spontaneous lysis, and samples to which 2% Triton 
was added, to indicate maximum lysis. Percent cytotoxicity was calculated as follows: 
% Lysis = (Ab-S) I (M-S) x 100, where 
Ab is the radioactivity ( cpm) released into the supernatant in the presence of serum, 
S represents spontaneous release in the absence of serum, 
M represents maximal lysis. 
2.4.5 Lymphocyte proliferation assay 
The proliferation assay was used to determine the ability of splenocytes to proliferate in 
the presence of tumour cells. Splenocytes were resuspended·to a concentration of lx106 
cells/ml in RPMI medium containing 2-J3-mercaptoethanol (final concentration of 5x10-
5M), recombinant IL-2 (final concentration of 25 units/ml) and with or without 
irradiated (3000 rads) fresh syngeneic splenocytes at concentration of 2.5x105 
cells/well, as feeder cells. Irradiated (20,000 rad) tumour cells were resuspended in 
RPMI at a concentration of 1x105 cells/ml and 100 µl aliquots were added to each of 
the wells in the 96-well plate as stimulator cells. After 3 days of co-incubation at 37°C, 
cultures were pulsed with 1 µCi [3H]thymidine (Amersham) incubated at 37°C. After 8 
hr, cells were harvested and transferred to a filter (Spot-on filtermat; Pharmacia 
Biotech). Tritiated thymidine uptake was determined by a 1205 betaplate liquid 
scintillation counter (Wallace Inc.). Counts per minute were expressed as means of 
triplicate cultures. 
2.4.6 Tumour cell-proliferation assays 
In vitro inhibition of tumour cell growth was determined usmg an SRB 
(sulphorhodamine B) assay. SRB stains for cellular proteins. Cells were seeded at 
1.5x 103 cells/well in 96-well microplates in 100 µl of culture medium alone. After 24 hr 
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incubation at 3 7°C, the specific treatment diluted in 100 µl of final volume was added in 
each well and cells were incubated as indicated in the Results. Recombinant IFN-y or 
IL-4, added as treatments in some experiments, were purchased from Peprotech 
(London, UK). After removing culture medium, cells were fixed in 50% trichloroacetic 
acid at 4 °C for 1 hr, washed five times with distilled water and stained with 1 % acetic 
acid-0.4 % (w/v) SRB solution at room temperature; after 30 min, plates were washed 
five times with 1 % acetic acid and air-dried. SRB bound to cellular proteins was 
dissolved by addition of 10 mM Tris-HCI, pH 10.5, to each well. Absorbance at 550 
nm, proportional to the number of cells attached to the culture plate, was measured by 
spectrophotometry. Each test was performed in quadruplicate. 
2.5 BIOCHEMICAL STUDIES 
2.5.1 Total cellular protein extraction 
Confluent cultures cells were trypsinised, washed twice in ice-cold PBS and solubilised 
by incubation at 0°C for 1 hr in solubilisation buffer, containing 25 mM Tris-HCl pH 
7.4, NP40 1 %, and protease inhibitors (10 µg/ml Aprotinin, 5 µg/ml leupeptin and 1 
mM PMSF). The lysate was then cleared by centrifugation at 13000 rpm for 5 minutes. 
The samples were stored at -20°C until needed. 
2.5.2 Cell membrane protein extraction 
Membrane protein extract was obtained according to the technique of Landowski et al. 
(Landowski et al., 1995) with minor modifications: 1.5x 108 cells were lysed in ice-cold 
25mM Tris/0.3M sucrose (pH 7.4) buffer, including protease inhibitor, by sonication 
with 5x5-sec bursts on ice, followed by centrifugation at 1000 rpm for 5 min at 4 °C. 
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This step was repeated 3 times and the supernatant was collected. After centrifugation at 
47,000 rpm for 90 min at 4°C (Ultracentrifuge LS-70, Beckman), the pellet was 
resuspended and rotated end-over-end for 12-16 hr at 4°C in 50mM Tris/150mM NaCl, 
pH 7.4, buffer containing 1 % NP40 detergent and protease inhibitor. Insoluble material 
was pelleted by centrifugation at 47,000 rpm for 60 min and the supernatant, 
corresponding to the cytosolic fraction, was discarded. To obtain the membrane 
fraction, the pellet was resuspended and rotated end-over-end for 1 hr at 4°C in 50mM 
Tris/150mM NaCl pH7.4 buffer containing 1 % P-octyl detergent and protease inhibitor. 
Insoluble material was pelleted by centrifugation at 13,000 rpm for 5 min and the 
supernatant was recovered and stored at -20°C. 
2.5.3 Protein determination 
Protein concentrations were determined by the bicinchoninic acid (BCA) test developed 
by Pierce (Rockford, IL). Protein content was extrapolated from a standard curve with 
bovine serum albumin standard solution (lmg/ml). 
2.5.4 Cell surface radiolabelling 
Surface radiolabelling was obtained by membrane lactoperoxidase-catalysed iodination. 
Confluent cultures of cells were trypsinised, washed twice, placed in Dulbecco's PBS 
for 3 hr before labelling. Cells were then incubated for 10 min at room temperature in a 
total volume of 2 ml PBS containing 20 µl 125I (2mCi), 195 µg lactoperoxidase and 25 
µl of 0.03% H202. After 5 min another 25 µl of H202 were added. The reaction was 
stopped by adding 10 ml of cold PBS and the cells were then washed 3 times with the 
same buffer. After extraction of the total cellular proteins, the percentage of labelling 
was determined after TCA precipitation using a gamma-counter (Cristal II Multidetector 
Ria System, Packard). 
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2.5.5 Immunoprecipitation 
The protein extracts were precleared by adding Gamma Bind Plus ~epharose 
(Pharmacia Biotech, Uppsala, Sweden) to the cell extract which then was rotated end-
over-end for 1 hr at 4 °C. The precleared extract was recovered by centrifugation and 
aliquots of;..., 1x10 7 cpm of labelled proteins or 4 mg of unlabelled lysate were incubated 
with sera or antibodies and rotated end-over-end at 4°C. After 2 hr, 50 µl of Gamma 
Bind Plus Sepharose was added and samples were incubated for another 2 hr under the 
same conditions. The Sepharose-conjugates were washed 3 times with solubilisation 
buffer and precipitated molecules were extracted in Laemmli SDS reducing ~ample 
buffer (0.05M Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 5% 2-mercaptoethanol and 
0.001 % bromophenol blue) by heating for 10 min at 95°C and centrifugation. 
Immunodepletion experimen~s were performed by sequentially treating solubilised 
extracts with antibodies as described in Results, using the supernatant from each 
reaction for each subsequent immunoprecipitation. After 3 cycles of such absorptions, 
proteins remaining in the supematants were subjected to a final antibody 
immunoprecipitation. 
2.5.6 Electrophoretic procedures 
Protein samples were analysed by Laemmli SDS gel electrophoresis system (Laemmli, 
1970) using homogenous (15% or 10% or 8% acrylamide) gels or exponential gradient 
(5-15% acrylamide) gels. Gels containing the desired concentration of acrylamide were 
prepared by diluting acrylamide in a buffer containing: 0.375M Tris pH8.8, 0.1 %SDS, 
0.1 %Ammonium persulfate and 0.1 % TEMED in the Resolving gels and 0.125M Tris 
pH6.8, 0.1 %SDS, 0.1 %Ammonium persulfate and 0.1 % TEMED in the Stacking gels. 
After denaturation of the proteins by heating at 95°C for 5 min in Laemmli SDS 
reducing sample buffer, samples were loaded into the wells of vertical gels and run in 
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electrophoresis buffer (25mM Tris, 250mM glycine pH 8.3 and 0.1 % SDS) at a constant 
current of 25 mA. Unlabelled (Biorad) or methylated 14C-labelled (Amersham) standard 
proteins were loaded ·and run concurrently in the same gel to estimate, by comparison 
with their mobilities, the molecular weights of the protein samples. After separation, the 
samples were analysed by autoradiography or Western blot. 
2.5.7 Autoradiography and Western blot 
When labelled proteins were resolved the gels were fixed in 10% trichloroacetic acid, 
dried and autoradiographed at -70°C with intensifying screens. 
Unlabelled proteins were transferred from the gels to nitrocellulose membranes by 
Western blot. After equilibration in transfer buffer (39mM glycine, 48mM Tris base, 
0.037% SDS and 20% methanol), the gels were sandwiched between a sheet of 
nitrocellulose membrane (Hybond-C super, Amersham) and several sheets of blotting 
paper, then assembled into a blotting apparatus and electroeluted in transfer buffer,_ 
applying a current of 0.65 mA/sq. cm of gel for 2 hr. The blots were then blocked by 
gently shaking in PBS-5% non fat dry milk overnight at 4°C ~d proteins detected by 
incubation of the blots with primary antibody or anti-serum diluted at optimal pre-
determined concentration (see Table· 2.2) in PBS-5% non fat dry milk for 2 hr at room 
temperature. After 3 washing with PBS-0.1 % Tween, the blots were incubated with the 
appropriate peroxidase-coupled secondary antibody diluted 1 :3000 in PBS-0.1 % Tween-
5% non fat dry milk for 1 hr at room temperature. After washing proteins were 
visualised using the ECL detection system (Amersham). 
2.5.8 Protein sequencing 
For protein sequencing, samples obtained from immunoprecipitation were 
electrophoresed onto 10% acriylamide and then transferred to polyvinylidene difluoride 
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(PVDF) membranes, strong solid phase supports which bind proteins hydrophobically 
and are inert to most solvents (Matsudaira, 1987). The gels were soaked in transfer 
buffer (lOmM 3-[ cyclohexylamino ]-1-propanesulfonic acid, 10% methanol, pH 11.0) 
for 5 min to reduce the amount of Tris and glycine. During this time a PVDF membrane 
was rinsed with 100% methanol and stored in transfer buffer. The gel, sandwiched 
between a sheet of PVDF membrane and several sheets of blotting paper, was then 
assembled into a blotting apparatus and electroeluted in transfer buffer. The PVDF 
membrane was washed in deionised H20 for 5 min, stained with 0.1 % Coomassie Blue 
R-250 in 50% methanol for 5 min and the band was cut out with a clean razor. 
Sequencing of the protein corresponding to the eluted band was operated using an 
Applied Biosystems model 470 sequenator by the Institute of Veterinary and 
Biochemical Physiology, University of Milan. 
2.6 ANIMAL STUDIES 
2.6.1 Mice 
C57BL/6 mice and Balb/C athymic nude mice, 6 to 8 weeks old, were purchased from 
Charles River (Calco, Italy). FVB-NeuN transgenic mice (Guy et al., 1992) were bred in 
the animal facility of Istituto Nazionale Tumori, Milan. All animals were treated in 
accordance with institutional guidelines. 
2.6.2 Assessment of tumourigenicity 
Tumour cells in log-phase growth were trypsinised, washed twice m saline and 
resuspended in saline at the desired cell concentration (see Results for individual 
experiments). Mice were injected subcutaneously in the flank with 200 µl of the cell 
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suspension. The mice were examined daily until the tumour became palpable, 
whereafter the diameter, in two dimensions, was measured twice weekly using calipers. 
A tumour was considered to be present when a palpable mass > 0.2 cm was noted. Mice 
were killed when the tumour size was approximately 1.0 x 1.0 cm. 
2.6.3 Vaccination of mice using irradiated tumour cells 
Tumour cells suspensions were irradiated (20,000 rads) and resuspended in saline at the 
desired concentration (see Results for individual experiments). Mice were injected 
subcutaneously with 200 µl of the irradiated cell suspension twice with a 4-week 
interval. Mice that received a live tumour cell challenge were injected subcutaneously in 
the opposite flank of vaccination or intravenously 4 weeks after the second 
Immunisation (see Results for individual experiments). 
In some experiments mice received injection intraperitoneally with IL-12 . (kindly 
provided by Dr. L Adorini, Roche Milano Ricerche, Milan. Italy), immediately after 
vaccination with irradiated cells and on days +1, +2 and +3 (150 ng/day diluted in PBS 
containing 100 µg/ml mouse serum albumin). 
2.6.4 Collection and storage of mice sera 
Mouse sera were obtained by bleeding from the retroorbital venous plexus. Blood was 
collected in sterile centrifuge tubes· and allowed to clot at room temperature. After 
centrifugation for 10 min at 1500 rpm, the clots were discarded and the antisera 
transferred to fresh tubes and stored in small aliquots at -20°C. 
2.~.5 Depletion of lymphocyte subsets 
If!- vivo depletion of CDS+ cells was achieved by using an anti-CDS monoclonal 
antibody as listed in Table 2.2 (protocol and antibodies were kindly provided by Dr. 
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Giovarelli, Department of Clinical and Biological Sciences, University of Turin). 
Animals were given 3 intraperitoneal injections of lmg of antibodies over a period of 5 
days. Control mice were injected with an isotype-matched irrelevant antibody. 
In experiments of monitoring the passive transfer of immunity (Winn test), control 
splenocytes from mice in vivo depleted of CD8+ cells were subjected to passage over a 
nylon wool column (Berke et al., 1972; Julius et al., 1973) to obtain cell populations 
enriched in T-lymphocytes and depleted of adherent cells like B-lymphocytes, 
monocytes and macrophages. The cell suspension was slowly injected into a Uni-Sorb 
T&B Column (Nycomed Pharma As, Oslo, Norway) and the column incubated at 37°C 
for 1 hr. After incubation, the non-adherent T cells were eluted by washing through the 
column with three volumes of RPMI medium. 
2.6.6 Cytokine production from popliteal lymph nodes cells. 
In experiments to evaluate the patterns of cytokine release by T cells, mice were 
immunised s.c. into the right hind footpad with 5 x 106 irradiated cells in 50 µl of saline. 
Five days later, mice were sacrificed and popliteal lymph nodes were removed 
aseptically. Pools for each group were made, each containing the nodes of 2 or 3 
animals. Lymphocytes were dissociated mechanically and cultured (2x105 cells per 
well) in 96-well flat-bottom plates precoated, or not, with 1 µg/well of anti-CD3 MAb 
at 37°C for 18 hr. Cytokine-containing supernatant was collected and tested for IFN-y 
and IL-4 production by ELISA. 
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2.6. 7 Statistical analyses 
All statistical analyses were performed using a Graph Pad Prism computer program 
(GraphPad Software, Becton Dickinson). Statistical significance was considered to be p 
<0.05. 
In experiment to evaluate tumour growth, different groups of mice were compared by 
the logrank test, using the 'occurring event' as the time at which a tumour appeared. A 
tumour was considered present when a palpable mass > 0.2 cm was noted. 
In experiment to evaluate the number of metastatic nodules and the cytokine production 
in different groups of mice statistical analysis was performed using the Unpaired t test. 
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Table 2.1 Cell lines used in the thesis 
B 16 murine melanoma (Fidler, 1970) 
B 16.B78 murine melanoma (Silagi et al., 1972) 
NIH 3T3 murine fibroblast (Pulciani et al., 1982) 
GP+envAm12 retroviral packaging cell line (Markowitz et al., 1988b) 
GP+envE86 retroviral packaging cell line (Markowitz et al., 1988a) 
N202.1 A murine mammary carcinoma (Nanni et al., 2000) 
N202.1E murine mammary carcinoma (Nanni et al., 2000) 
TT3 murine mammary carcinoma (Nanni et al., 2000) 
CHO-Kl ATCC 
Table 2.2 Monoclonal antibodies and antisera used in the thesis 
Antibody isotype antigen used 
HBT12 mouse M tuberculosis Ag3 8 IF: 10 µg/ml 
(Singh et al., 1992) WB: lµg/ml 
H-2Ld/H-2Db mouse MouseMHCI IF: 10 µg/ml 
(Clone 28-14-8) (Ld, Db, Dq, L q) 
Litton 
H-2Kb mouse MouseMHCI IF: 10 µg/ml 
(Clone 28.13.3) (Kb) 
Litton 
TIB126 rat Mouse pan MHC I-II IF: 10 µg/ml 
ATCC 
c-neu Ab-4 mouse Rat Neu IF: 2.5µg/ml 
Calbiochem 
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TIB105 rat Mouse CDS In vivo depletion 
(Clone Lyt2) 
ATCC 
AZN-LAM rabbit Mouse gplOO IF: 1 :100 
antiserum WB:1:3000 
(Schreurs et al., 1997) IPPT: 1:100 
aPEP8 rabbit Mouse TRP-2 IF: 1:50 
antiserum WB:l:lOOO 
(Tsukamoto et al., 1992) IPPT: 1:50 
agp70 goat MuLV gp70 IF: 1:100 
antiserum IPPT: 1:100 
(Traversari et al., 19S9) 
atotal virus goat MuL V proteins IF: 1:100 
antiserum IPPT: 1:100 
(Traversari et al., 1989) 
TA99 mouse Human TRP-1 IF: 10 µg/ml 
(Mattes et al., 19S3) WB: 10 µg/ml 
T311 mouse Human Tyrosinase IF: 10 µg/ml 
(Chen et al., 1995) WB: 10 µg/ml 
IPPT: 10-µg/ml 
CD3e Armenian MouseCD3e In vitro stimulation 
(Clone145-2Cl 1) Hamster · ofT cells 
Pharmingen 
IL-12 Rat Mouse IL-12 (p40/p70) In vivo neutralization 
(Clone Cl 7.S) 
(Wysocka et al., 1995) 
Table 2.3 FITC-conjugated antibodies used for immunostaining for flow cytometry 
(all purchased from Pharmingen) 
Antibody Clone Fluorochrome dilution used 
Rat anti-mouse CDS 53-6.7 FITC 1µg/106 cells 
Rat anti-mouse CDS 53-6.7 Cy-Chrome 1µg/106 cells 
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Rat anti-mouse CD4 H129.19 Cy-Chrome 1µg/106 cells 
Rat anti-mouse IFN-y XMGl.2 FITC O.Sµg/10 6 cells 
Rat anti-mouse IL-4 1 lBll PE O.Sµg/10 6 cells 
Mouse anti-mouse NKl.1 PK136 PE 1µg/106 cells 
Table 2.4 FITC-conjugated secondary antibodies used for immunostaining for 
flow cytometry 
FlTC-conjugated antibody dilution used 
goat anti-mouse IgG+IgM 10 µg/ml Jackson ImmunoResearch 
rabbit anti-goat lgG biotinylated 10 µg/ml Amersham 
+ Streptavidin-FITC 20 µg/ml Amersham 
goat anti-rabbit IgG 10 µg/ml Jackson ImmunoResearch 
rat anti-mouse lgG 1 (Clone A85-1) 1µg/106 cells Pharmingen 
rat anti-mouse lgG2a (Clone R19-15) 1µg/106 cells Pharmingen 
rat anti-mouse IgG2b (Clone R12-3) 1µg/106 cells Pharmingen 
rat anti-mouse IgG3 (Clone R40-82) 1µg/106 cells · Pharmingen 
rat anti-mouse IgM (Clone R6-60.2) 1µg/106 cells Pharmingen 
rat anti-mouse lgA (Clone RS-140) 1µg/106 cells Pharmingen 
rat anti-mouse lgE (Clone R35-72) 1µg/106 cells Pharmingen 
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Table 2.5 Horseradish peroxidase-conjugated secondary antibodies used in 
Western blot 
(all purchased from Amersham) 
· Horseradish peroxidase -conjugated antibody 
Sheep anti-mouse immunoglobulins 
Donkey anti-rabbit immunoglobulins 
Sheep anti-rat immunoglobulins biotinylated 
+ Streptavidin-Horseradish peroxidase 
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dilution used 
0.1 µg/ml 
0.1 µg/ml 
2.s µg1m.1 
0.6 µg/ml 
CHAPTER THREE 
GENE TRANSFER AND EXPRESSION OF AG38 GENE IN 
TUMOUR CELL LINES 
3.1 CHOICE OF THE STRATEGY 
Preliminary studies focused on creating an optimised strategy to express in an efficient 
and stable fashion the bacterial antigen in tumour cells. 
The use of a conventional eukaryotic vector to express the entire mycobacterial gene, 
provided with its own signal peptide sequence, under the control of the CMV promoter 
resulted in a low and unstable expression of the bacterial product in tumour cells. 
These studies led to the choice of a retroviral system to transduce the bacterial gene in 
tumour cells and to the use of a retroviral vector (pLXSN), modified to express the 
leader and transmembrane portion of the Nerve Growth Factor Receptor and the stop 
codon region of human IL-3 (pLTMSN). 
As an initial hypothesis for the purposes of cloning using this vector, it was predicted 
that the modification of the vector would provide three advantages: 
the induction of cell surface expression of the bacterial antigen, thus allowing future 
detection and tagging of transduced cells; 
an increase in stability, gained by the presence of eukaryotic leader sequence, 
ensuring correct processing of the bacterial protein; 
the likely combination of peptides derived from the bacterial protein complexing 
with MHC class I molecules during transport through to the cell membrane, 
promoting the bacterial antigen immune recognition. 
178 
3.2 MODIFICATION OF pLXSN VECTOR AND CLONING OF AG38 GENE 
Plasmid pL TMSN, kindly provided by Dr M.P. Colombo (Istituto Nazionale Tumori, 
Milan), was obtained by modification of retroviral vector pLXSN. The modification, 
described below, was performed in the Dr. Colombo laboratory. 
A fragment containing the first 843 bp of the nerve growth factor receptor (NGFR), 
lacking the intracellular domain, was cloned into the shuttle vector pGEM 5Zf+ 
(Promega); the extracellular portion of the NGFR was excised and replaced in-frame 
with a synthetic polynucleotide sequence containing three unique cloning sites (Notl, 
ClaI and EcoRV). The entire insert was designated pLTM. At the 3' -end, the last 28 bp 
of the human IL-3 sequence, containing the stop codon, were joined in-frame by 
replacement of the IL-3-encoding fragment with the pLTM fragment in the pBBG 14 
vector (British Biotechnology; Oxon, UK). The entire construct was excised from the 
plasmid and ligated into the retroviral vector pLXSN, to obtain the vector designated 
pLTMSN. 
When I received .this vector (empty) the DNA encoding residues 24-372 of the 
Mycobacterium tuberculosis Ag38 gene was obtained by polymerase chain reaction 
(PCR) using plasmid pMS9-2 (kindly provided by Dr. Singh, GBF, Braunschweig, 
Germany) (Singh et al., 1992) as template and sense and antisense primers, which 
incorporate NotI and Clal restriction sites, respectively. The sense primer corresponds 
to nucleotides 215-246 of the Ag38 gene, thus excluding the signal peptide region of the 
Ag38 gene; the antisense primer corresponds to nucleotides 1235-1267, thus excluding 
the stop codon region of the Ag38 gene (Fig. 3.1). The amplified fragment was 
subcloned into the pLTMSN retroviral vector, in-frame with the NGFR signal peptide 
and transmembrane sequences, to obtain the pLAg38TMSN vector (Fig. 3.2). 
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Fig. 3.1: Ag38 gene sequence 
Nucleotide sequences of Ag38 gene and the deduced amino acid sequence ofthe protein 
product. Sense and antisense primers used to amplify the encoding region, excluding the 
signal peptide and the stop codon, are indicated by arrows (red). Putative processing site 
is indicated with a vertical bar (green); CpG motifs contained in the gene sequence are 
boxed (blue). 
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SV40 Neo LTR 
5' -GCGGCCGCTGGCTCGAAACCACCGAGCGGTTCGCCTGAA-3' 
5' -GCGGTGGTGAAGTTGTCTGACGCGTTGATCGCATCGATT-3' 
Fig. 3.2: Cloning of Mycobacterium tuberculosis Ag38 gene 
Schematic diagram showing the strategy of cloning. The sequences of the sense and 
antisense primers used to amplify the gene are reported in the box. 
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3.3 GENERATION OF STABLE PRODUCER CELL LINES 
Retroviral particles transducing the pLAg38TMSN vector were obtained by the 
infection technique as described in Materials and Methods, using the ampho-ecotropic 
packaging cell lines gp+AM12 and gp+E86 (Markowitz et al., 1988b; Markowitz et al., 
1988a). G418-resistant individual colonies of producer cells were screened for cell 
surface Ag38 expression by FACScan analysis using anti-Ag38 MAb HBT12 (kindly 
provided by Dr. Singh, GBF, Braunschweig, Germany) (Singh et al., 1992) and 
characterised in terms of viral titre. The clone that showed the best characteristics, either 
as viral titre, or in terms of antigen expression, and the bulk culture were used to 
produce viral supernatant for tumour cells infections (Fig. 3.3). 
3.4 EXPRESSION OF THE AG38 GENE IN MURINE MELANOMA CELL 
LINES 
B16 murme melanoma cell line and its variant B16.B78 were infected with the 
pLAg38TMSN viral supernatant. 
The murine melanoma B 16.B78 is a clone of the C57BL/6 derived tumour B 16, which 
expresses no detectable MHC class I antigen in vitro. On the contrary, low level 
expression of MHC class I molecules is detectable on B 16 cells (Lollini et al., 1990). 
The level of MHC class I expression in the two different sublines was evaluated by 
FACScan analysis (Fig 3.4). 
Infections were performed as reported in Materials and Methods. Five rounds of the 
same infection cycle were performed using the single clone as well as the bulk culture 
derived supernatants, to improve infection efficiency. 
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Fig 3.3: Ag38 expression and viral titre of producer cell line 
Expression of Ag38 protein on cell surface detected by FACScan analysis with HBT12 
antibody and viral titres of the bulk culture and of selected clone 2.4. F AC Scan analysis 
with HBT12 a...ritibody on wild type cells is shown on the top. Open areas indicate cells 
stained with secondary antibody alone. 
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Fig. 3.4: FACscan analysis of MHC class I expression on murine melanoma lines 
MHC class I expression on B16.B78 (top) and B16 (bottom) melanoma cells, detected 
by F ACscan analysis with anti-mouse MHC class I Db and Kb antibodies (kindly 
provided by Dr. M. Rodolfo, Istituto Nazionale Tumori, Milan). Open areas indicate 
cells stained with secondary antibody alone. 
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Individual clones were selected in G418-containing medium and tested for bacterial 
antigen expression. 
RT-PCR was performed to detect the expression of Mycobacterium tuberculosis Ag38 
transcript in transduced cells (Fig 3 .Sa). 
Western blot analysis using MAb HBT12 failed to reveal any reactivity when 
performed on total cellular protein extract, but revealed two specific bands in the cell 
membrane protein extract. The two bands, characterised by a molecular weight of 4 7 
kDa and 42 kDa, were supposed to correspond, respectively, to the unprocessed form, 
which contains both the leader and transmembrane sequences (123 and 117 nucleotides, 
respectively), and to the mature protein after cleavage of the leader sequence (Fig 3.5b). 
The majority of transduced cells were positive for cell surface expression of the 
mycobacterial protein, as revealed by FACS analysis. Clones of B16.B78 and B16 cells 
showing the highest cell surface expression of Ag38 antigen are shown in Figure 3.6; 
Bl6.B78-Ag38 clone 17 and Bl6-Ag38 clone 7 were used in the subsequent 
experiments. 
G418-resistant colonies recovered from B16 and B16-B78 melanoma cells transduced 
with the empty vector were obtained and used as controls (mock cells). Both wild-type 
and melanoma cells transduced with the empty vector showed no detectable 
mycobacterial product by RT-PCR, Western blot or FACScan analysis. 
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Fig. 3.5: Ag38 gene expression in transduced melanoma cells 
Expression of Mycobacterium tuberculosis Ag38 gene in a representative clone of 
B16.B78 transduced cells. 
A: Detection of Ag38 mRNA by RT-PCR of total RNA from: B16-B78 wild-type 
melanoma cells (lane 1 ); B 16-B78 cells transduced with pLTMSN vector (lane 2); B 16-
B78 cells transduced with pLAg38TMSN vector (lane 3). Lane 4, amplification of 
pLAg38TMSN vector; M, molecular weight marker (1 kb ladder); 
B: Detection of Ag38 protein by Western blot analysis of membrane proteins extracted 
from: B16-B78 wild-type melanoma cells (lane 2); B16-B78 cells transduced with 
pLTMSN vector (lane 3); and B 16-B78 cells transduced with pLAg38TMSN vector 
(lane 4 ). Lane 1, bacterial recombinant Ag3 8 protein. 
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Fig. 3.6A: Cell surface expression of Ag38 protein on B16.B78 transduced cells 
Detection of Ag38 protein by FACScan analysis on the surface of B16.B78 cells 
transduced with the pLTMSN vector (mock) or with the pLAg38TMSN vector. Clones 
showing the highest cell surface expression of Ag38 protein are represented. Open areas 
indicate cells stained with secondary antibody alone. 
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Fig. 3.6B: Cell surface expression of Ag38 protein in B16 transduced cells. 
Detection of Ag38 protein by F ACScan analysis on the surface of B 16 cells transduced 
with the pLTMSN vector (mock) or with the pLAg38TMSN vector. Clones showing the 
highest cell surface expression of Ag3 8 protein are represented. Open areas indicate 
cells stained with secondary antibody alone. 
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3.5 EXPRESSION OF THE AG38 GENE IN THE N202.1A MAMMARY 
CARCINOMA CELL LINE 
Tumour cell line N202.1A was derived from a mammary carcinoma spontaneously 
grown in FVB-neuN transgenic mice (Kindly provided by Dr. P. Nanni, Institute for 
Cancer Research, University of Bologna, Italy). This cell line is characterised by 
expression of high levels of the HER2/neu oncogene on the cell membrane, as revealed 
by F AC Scan analysis with the specific antibody (Fig 3. 7). 
Furthermore, a high level of MHC class I molecules expression was detected by 
F AC Scan analysis with the specific antibody (Fig 3. 7). 
Ag38-transduced N202.1A cells were obtained by multiple rounds of infection cycle 
with pLAg38TMSN viral supernatant and selected in G418-containing medium, as 
above described. Individual clones were tested for bacterial antigen gene expression by 
RT-PCR and FACScan analysis. Clones showing the highest cell surface expression of 
Ag38 antigen are shown in Figure 3.8; N202. lA-Ag38 clone 4 was used in the 
subsequent experiments. 
G418-resistant colonies recovered from N202. l A cells transduced with the empty 
vector were used as controls. 
3.6 IN VITRO GROWTH· OF CELLS EXPRESSING AG38 BACTERIAL 
ANTIGEN 
In in vitro culture, cells expressing Ag38 protein had morphological appearances similar 
to the parental cells. No differences in growth between the parental and the Ag38-
expressing cells were observed in the three different lines. Only minimal differences in 
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Fig. 3.7: FACScan analysis of Her2/Neu and MHC class I expression on N202.1A 
cell line 
Characterisation of N202.1A cell line as Her2/Neu oncogene (top) and MHC class I 
(bottom) expression, detected by F ACscan analysis with the specific antibodies ( c-neu-
Ab4 and TIB 126, respectively). Open areas indicate cells stained with secondary 
antibody alone. 
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Fig. 3.8: Expression of Ag38 gene in N202.1A transduced cells. 
B 
A: Detection of Ag38 mRNA by RT-PCR of total RNA from: N202.1A cells transduced 
with pL TMSN vector (lane 1 ); N202.1 A cells transduced with pLAg3 8TMSN vector 
(lane 2); and amplification of pLAg38TMSN vector (lane 3). M, molecular weight 
marker (1 kb ladder). 
B: Detection of Ag38 protein by FACScan analysis on the surface of N202.1A cells 
transduced with the pLTMSN vector (mock) or with the pLAg38TMSN vector. Clones 
showing highest expression are represented. Open areas indicate cells stained with 
secondary antibody alone. 
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size of the cells were detected in the N202.1A cell line, in which Ag38-expressing cells 
appeared slightly larger than parental cells. 
Stable expression of Ag3 8 protein was observed in all tumour cell lines after several in 
vitro passages. No modulation in MHC class I expression was detected in any cell lines 
and no modulation in HER2/neu oncogene expression was revealed by F ACscan 
analysis in N202.1A-Ag38 cells (data not shown). 
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CHAPTER FOUR 
MODULATION OF THE IMMUNE RESPONSE AGAINST 
MELANOMA BY VACCINATION WITH Ag38-TRANSDVCED 
TUMOUR CELLS IN C57BL/6 MICE 
4.1 TUMOURIGENICITY OF AG38-TRANSDVCED MELANOMA CELLS 
As a first approach, the efficacy of a cancer vaccine expressing the Ag3 8 bacterial 
antigen was evaluated using the B16.B78 melanoma cell line. The in vivo growth of 
parental and Ag38-expressing B16.B78 cells was investigated by subcutaneous 
injection of 2.5x105 cells in the right flank. Mice were monitored for the development of 
a tumour, which was considered to be present when a mass measuring greater than 
0.2x0.2 cm was detected. Figure 4.1 shows the results of a representative experiment 
comparing the growth of parental and Ag38-transduced cells in syngeneic 
immunocompetent mice. All 5 mice injected with B 16-B78 cells developed tumours 
within 9 to 21 days (mean 13.8) and had a mean survival time of 36.6 days. Necroscopy 
revealed lung metastases in all of these mice. By contrast, 3 out of 5 mice injected with 
2.5x105 transduced melanoma cells developed tumours and these mice showed a delay 
in appearance of the tumour (mean 30.6 days) that resulted in an increase in survival 
time (mean 52.3 days); no metastases were observed in the lungs, liver, kidneys or 
peritoneal cavity. Two different 3 8-kDa transduced clones also showed no spontaneous 
metastasis (not shown), making it unlikely that the Ag38 gene was inserted into a gene 
involved in metastasis. However the absence of spontaneous metastasis cannot be 
definitively attributed to the expression of Ag38 since B 16 melanoma cell clones are 
reportedly heterogeneous with respect to metastatic potential (Poste et al., 1980). 
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Fig. 4.1: Tumourigenicity of Ag38-transduced B16.B78 cells 
Percentage of tumour free mice after challenge with 2.5x105 parental B16.B78 cells 
(n = 5, solid line) or 2.5x105 Ag38-expressing B16.B78 cells (n = 5, dotted line). 
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4.2 PROTECTIVE IMMUNITY AGAINST PARENTAL CELLS BY 
VACCINATION WITHAG38-TRANSDVCED MELANOMA CELLS 
Analysis into whether vaccination with irradiated Ag38-transduced melanoma cells 
protects mice against a subcutaneous or intravenous challenge with parental cells was 
used to determine the immunogenicity of the transduced clones. 
The same immunisation protocol was used in all experiments. 106 transduced or 
parental irradiated melanoma cells were injected s.c. twice, with a 4-week interval 
between injections, in the left flank of syngeneic mice. Four weeks after the second 
immunisation, the ability of Ag38-expressing melanoma cells to elicit a protective 
systemic immunity was evaluated by two approaches: 
Mice were challenged subcutaneously in the right flank with 2.5x105 viable parental 
cells and then monitored for the development of a tumour. 
Mice were challenged intravenously with 5x 105 viable parental cells and evaluated 
for the number of lung metastases or survival time. 
4.2.1 Protection induced by vaccination with Ag38-transduced cells against 
subcutaneoustuD1our 
Figure 4.2 shows the result of a subcutaneous challenge experiment performed with 
B16.B78 transduced cells. All of 9 naive mice and 8 out of 10 mice immunised with 
wild-type B16.B78 melanoma cells developed tumours, whereas significant protection 
(p<0.01) was observed in mice immunized with the Ag38-transduced B16.B78 
melanoma cells, since only 2 out of 10 mice developed tumours. Moreover, in these 
mice, the onset of tumour development as well as the mortality were delayed m 
comparison with non-immune and wild-type melanoma-immunised animals. 
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Fig 4.2: Protection against subcutaneous tumour by vaccination with Ag38-
transduced melanoma cells 
Percent tumour incidence (A) and overall survival (B) of mice either non-immunized (n 
= 9, dotted line) or immunised with irradiated wild-type B16-B78 (n = 10, dashed line) 
or with irradiated transduced B16-B78 melanoma cells (n = 10, solid line). Mice were 
challenged with 2.5x105 wild-type B16-B78 melanoma cells. 
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Since wild-type melanoma cells are highly tumourigenic and poorly immunogenic, 
these data suggest that the expression of the 38-kDa antigen in transduced cells elicits a 
strong immune response against the tumour. 
Endogenous expression of Ag38 appears to be essential for protection, since C57BL/6 
mice immunised with the purified 3 8-kDa protein developed tumours with no 
significant difference in respect to non-immunised controls, when challenged with wild-
type melanoma cells (see chapter 6). 
4.2.2 Protection induced by vaccination with Ag38-transduced cells against 
experimental lung metastases 
Figure 4.3 shows the result of intravenous challenge experiments using B16.B78 
transduced cells. In a first experiment the number of experimental lung metastases 
induced by i.v. inoculation of parental B16.B78 cells was evaluated in a group of mice 
immunised with irradiated Ag38-transduced B16.B78 cells. Inhibition of experimental 
metastasis development was observed in mice immunised with transduced cells, as 
indicated by the absence, or the low number, of lung metastases at 4 weeks after 
challenge, as compared to control mice (A). 
Two experiments were then performed using the same challenge protocol to evaluate 
the effect of immunisation on survival time. In the first experiment (B), the 6 mice 
immunised with Ag38-transduced cells survived significantly longer than the 6 non-
immunised control mice (p=0.0005), which all developed lung metastases and died 
within 31 days after tumour inoculation. Two out the 6 immunised mice were still alive 
at the end of the observation period (90 days). In the second experiment (C), a 
significant increase in survival time (p=0.0001) was observed in the 8 immunised mice 
versus the 8 control mice, and 2 animals were still alive after 150 days. 
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Fig 4.3A: Protection against experimental lung metastases by vaccination with 
Ag38-transduced melanoma cells: evaluation of metastases number 
Lung metastases from mice immunised with irradiated Ag38-transduced B16.B78 
melanoma cells (top) and from non-immunised mice (bottom), sacrified 4 weeks after 
i.v. challenge with 5x105 wild-type Bl6.B78 melanoma cells. 
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Fig. 4.3B: Protection against experimental lung metastases by vaccination with 
Ag38-transduced melanoma cells: evaluation of survival time 
Two representative experiments showing the overall survival of mice immunised with 
irradiated Ag38-transduced B16-B78 melanoma cells (dotted line) or non-immunised 
mice (solid line) after i.v. challenge with 5x105 wild-type B16-B78 melanoma. n = 6 per 
group in the experiment represented in the top and n = 8 per group in the experiment 
represented in the bottom. 
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These data indicate that vaccination with murine melanoma cells transduced with the 
38-kDa Mycobacterium gene induces a significant inhibition of lung metastases of i.v.-
injected parental tumours, leading to prolonged survival. 
The efficacy of vaccination with B16 melanoma cell line transduced with the Ag38 gene 
was evaluated for its protection against experimental metastases. Unlike the B 16.B78 
cell line, B16 cells express a low level ofMHC class I molecules. 
Results similar to those obtained with the B16.B78 variant were observed. Indeed, after 
i.v. challenge with 5x105 untransduced parental B16 melanoma cells, 4 out of the 6 
mice vaccinated with M tuberculosis Ag38-transduced B16 cells showed an increase in 
survival time (mean 50.8 ± 5.8) as compared to the control group (mean 27.2 ± 0.4). 
The remaining 2 mice survived until the 90th day with no metastases (p<0.01). 
Therefore, irrespective of MHC context, the endogenous expression of Ag38 antigen in 
melanoma cells induces a significant inhibition of lung metastases of i.v.-injected 
parental tumours. 
4.3 THI- AND TH2-TYPE CYTOKINE SUBSETS ACTIVATED BY 
VACCINATION 
Based on increasing evidence that suggests the importance of the Thl-type response in 
the control of tumour growth, the Thl- ·and Th2-types of reactions in mice vaccinated 
with Ag38-transduced cells were evaluated. 
Mice were immunised s.c. into the right hind footpad with i) 5 x 106 irradiated wild-type 
melanoma cells, ii) 5 x 106 irradiated Ag38-transduced cells, and iii) 5 x 106 irradiated 
wild-type melanoma cell plus 3 µg Ag38 purified protein. Five days later, mice were 
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sacrified and popliteal lymph nodes were removed aseptically. Pools for each group 
were made, each containing the nodes of 2 or 3 animals. Lymphocytes were dissociated 
mechanically and cultured in plates precoated, or not, with anti-CD3 MAb at 37°C for 
18 h. The result of a representative experiment is reported in Table 4.1. Analysis of 
cytokine levels in the culture supematants revealed an increase in IFN-y levels in mice 
injected with B16.B78 transduced cells compared to mice injected with irradiated wild-
type melanoma cells and to mice injected with irradiated wild-type melanoma cells plus 
the 3 8-kDa purified antigen. In contrast, secreted IL-4 levels were higher in mice treated 
with wild-type Bl6.B78 plus purified 38-kDa protein than in mice injected with 
transduced cells. 
These data suggest that the endogenous expression of Ag3 8 antigen in tumour cells 
induces a preferential induction of a Thl response. 
A similar trend, which confirms this preferential pattern, was observed using the B 16 
cell line to perform the same experimental protocol. Indeed, lymphocytes obtained from 
popliteal lymph nodes of mice immunised with transduced cells showed a ratio of 
12.5±5.8 of IFN-y:IL-4 production versus a ratio of 4.8±0.6 observed in mice 
immunised with wild type cells. 
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Injected antigen 
816.878 
816.878-Ag38 transduced 
816.878+Ag38 protein 
Cytokine production (pg/ml)* 
IL-4 IFN-y 
5.6 ± 0.7 8.2±1.1 
<5 32.0 ± 7.5 
13.6 ± 2.0 <5 
Table 4.1: Production of IL-4 and IFN-y by popliteal lymph nodes of vaccinated 
mice. 
Data refer to a representative experiment performed in triplicate and are expressed as 
mean±SD obtained by subtracting the cytokine levels in the supernatant of lymphocytes 
cultured in the absence of anti-Cb3 antibody. 
IL-4/IFN-y ratio between: B 16 transduced to B 16 p=O. 0013; B 16 transduced to 
B16+Ag38 p=0.0109 (Unpaired t test). 
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4.4 LYMPHOCYTES SUBSETS INVOLVED IN MEDIATING 
PROTECTIVE IMMUNITY 
Because of the importance of the CDS-mediated response in tumour rejection, the role 
of this subpopulation was investigated in mice depleted of CD8+ T lymphocytes, using 
the specific monoclonal antibody TIB 105. 
Figure 4.4A shows FACS analysis of splenocytes from mice subjected to the depletion 
protocol to remove CD8+ lymphocytes and demonstrates depletion of the appropriate 
subset. 
Depleted mice were vaccinated with Ag38-transduced melanoma cells and i.v. injected 
with parental melanoma ·cells, using the same vaccination-challenge protocol reported 
above. Non-depleted mice immunised with Ag38-transduced cells or non immunised 
mice were injected with parental cells and used as control groups. As shown in Figure 
4.4B, CD8 depletion induced a decrease, although not significant, of survival time with 
respect to non-depleted immunised mice. 
4.5 SUMMARY 
Expression of Mycobacterium tuberculosis Ag3 8 antigen reduced the tumourigenicity 
of murine melanoma cells in immunocompetent mice. 
Vaccination with Ag38-transduced cells induced a significant protection of mice against 
both subcutaneous and intravenous challenge with parental melanoma cells, indicating 
that the presence of mycobacterial protein greatly enhances immunological recognition 
of structures expressed by parental cells. 
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Fig. 4.4: Protection against experimental lung metastases in CDS-depleted mice 
A: FACScan analysis with FITC-anti-CD8 antibody on splenocytes from mice depleted 
of CD8+ T lymphocytes (filled) or non-depleted control mice (overlay). 
B: Overall survival after i.v. challenge with 5x105 wild-type B16.B78 cells of non~ 
depleted control mice (n = 5), non-depleted and immunised with BI6.B78-Ag38 cells 
mice (n = 6) CDS-depleted and immunised with BI6.B78-Ag38 cells mice (n = 6). 
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Comparison of Thl and Th2 responses in immunised mice revealed a preferential Thl 
response when the Ag3 8 protein was endogenously expressed. 
Similar protection and response to vaccination was observed usmg both Ag38-
transduced B 16.B 78 and B 16 cell line variants, suggesting that the mechanism of 
protection is independent from MHC class I expression level in tumour cells. CD8 
depletion experiments revealed that tumour protection was mediated by the involvement 
of different immune cell subsets. 
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CHAPTER FIVE 
RESPONSE AGAINST MELANOMA TUMOUR ANTIGENS 
5.1 HUMORAL RESPONSE 
The immunological effectors involved in the response against parental melanoma cells, 
elicited by Ag38-transduction, were investigated. 
As a first approach, the induction of an humoral response by vaccination with Ag38-
transduced melanoma cells was analysed. The presence of antibodies directed against 
antigens expressed on melanoma cell surface in sera obtained from mice vaccinated 
with irradiated cells was evaluated by flow cytometry analysis. 
As shown in Figure 5.1, sera obtained from mice vaccinated with Ag38-transduced cells 
showed very low titres of antibodies reacting with parental cells. Indeed, no significant 
differences in reactivity against parental cells were observed between sera obtained 
from mice vaccinated with Ag38-transduced cells and sera from non-vaccinated mice or 
mice vaccinated with non-transduced cells. 
Furthermore, as shown in Fig. 5.2, no specific response against Ag38 mycobacterial 
protein was induced by vaccination with transduced cells. 
The low serological response against melanoma cells was m keeping with the 
hypothesis that vaccination with tumour cells that endogenously express the 
mycobacterial protein induced a preferential Thl response. 
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Fig. 5.1: Humoral response against parental melanoma cells after vaccination 
Reactivity against melanoma antigens in some representative serum samples from not 
vaccinated mice (untreated), mice vaccinated with non-transduced cells (B16) and mice 
vaccinated with Ag38-transduced cells (B16-Ag38). FACScan analysis was perfo1med 
on B 16 cells, incubated with serum diluted 1 :50 and stained by an indirect method using 
goat FITC-anti-mouse IgG+IgM. Open areas indicate cells stained with secondary 
antibody alone 
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Fig. 5.2: Humoral response against Ag38-transduced melanoma cells after 
vaccination 
FACScan analysis performed on Ag38-expressing melanoma cells with some 
representative serum samples obtained from not vaccinated mice (untreated), mice 
vaccinated with non-transduced cells (B16) and mice vaccinated with Ag38-transduced 
cells (Bl6-Ag38). Dilution of sera and cell staining were performed as in figure 6.1. 
Open areas indicate cells stained with secondary antibody alone 
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Interestingly, mice vaccinated with Ag38-transduced cells, which resulted partially or 
completely protected from the intravenous challenge with parental melanoma, displayed 
very high titres of antibodies against melanoma cells. A representative serum sample 
from a protected mouse is shown on figure 5 .3. 
Isotype analysis of these antibodies revealed the presence of mainly IgG2a 
immunoglobulins (Fig. 5.4). Since this class represents the main IFN-y-dependent 
isotype in mice, it is likely that the humoral response observed after challenge with 
viable cells is related to the presence of mycobacterial-activated Thi lymphocytes 
against melanoma-associated antigens. 
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Fig. 5.3: Humoral response against parental melanoma cells in mice protected 
from tumour challenge 
F ACS analysis of a representative serum sample obtained from a mouse vaccinated with 
Ag38-transduced cells and protected from tumour challenge. Reactivity against B 16 
cells was evaluated before (upper; blue color) and after (down; red color) tumour 
challenge at three different dilutions. Open areas indicate cells stained with secondary 
antibody alone (goat FITC-anti-mouse IgG+IgM). MFI = mean fluorescence intensity 
(log). 
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Fig. 5.4: Isotype analysis of anti-melanoma cells antibodies 
IgGl 
IgGJ 
Antibody isotype analysis performed on B 16 cells incubated with post-challenge serum 
diluted 1: 100 and stained using rat FITC-anti-mouse IgA, IgE, IgG 1, IgG2a, IgG2b, 
IgG 3, or IgM. 
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5.2 ANTITUMOUR ACTIVITY OF ANTIBODIES 
In view of the increase in antibody titre against parental melanoma cells, which is 
generated in mice vaccinated with Ag38-transduced cells, and the partial or complete 
protection from intravenous challenge with parental cells which this protocol induces, in 
vitro and in vivo assays were performed to determine the antitumour activity of these 
antibodies. 
5.2.1 In vitro complement assay 
Complement-dependent cytotoxicity was tested by incubating sera at different dilutions 
with 51 Cr-labeled melanoma.cells. As reported in figure 5.5, which shows the result of a 
representative experiment, the assay demonstrated the presence in these sera of 
antibodies able to recognise and lyse melanoma cells. Therefore, under the conditions of 
these in vitro experiments, complement fixation appears to be a plausible mechanism by 
which antibodies directed against melanoma cells might mediate tumour rejection. 
5.2.2 In vivo passive immunization 
To evaluate whether a protective immunity could be induced in vivo by the anti-
melanoma specific antibodies, a passive immunisation experiment was performed using 
a pool of immunoreactive sera derived from protected· Ag38-transduced melanoma 
immunised mice. Eight mice were challenged i.v. with lxl05 parental melanoma cells 
and four mice were treated intraperitoneally with a pool of reactive sera at days 0 and + 
2. The other four mice were treated, as a control, with an unrelated hyperimmune serum. 
Four weeks after the challenge, the number of experimental lung metastases was 
evaluated. As reported in Fig. 5.6, comparing to the control group a decrease in the 
number of lung metastases was observed (54 % of inhibition, p>0.05). 
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Fig. 5.5: Complement-dependent cytotoxicity of sera from protected mice 
Complement-dependent cytotoxicity against B 16 melanoma target cells of sera from 
vaccinated and protected mice (A, B, C) and of control serum (D). Values are expressed 
as means± SD and refer to a representative experiment performed in triplicate. 
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Fig. 5.6: In vivo passive immunisation with sera from protected mice 
Mean number of lung metastases in mice i.v. challenged with B 16 melanoma cells and 
intraperitoneally treated with a pool of reactive sera (TREATED) or with an unrelated 
control serum (CONTROL). P value> 0.05 by Unpaired t test. 
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However, due to the low number of mice, this decrease was below the level of 
significance. These data, although obtained in a few numbers of mice, support the 
possible role of antibodies in inhibiting in vivo growth of the melanoma tumour. 
5.3 INITIAL APPROACHES TO IDENTIFY THE ANTIGENS 
RECOGNISED BY THE HUMORAL RESPONSE 
Flow cytometry analyses were performed with immunoreactive sera, obtained from 
mice vaccinated with Ag38-transduced melanoma cells and protected from tumour 
challenge, and these revealed a strong reactivity against antigens expressed on the 
melanoma cell surface. 
In order to identify the target molecules recognised by this humoral immune response, 
melanoma cells were cell-surface radiolabelled, solubilised, subjected to pre~clearing 
and immunoprecipitated with sera derived from protected mice. Subsequent separation 
by SDS-gel electrophoresis revealed a single, and specifically immunoprecipitated, 
band with a molecular weight between 70-85 kDa (fig. 5.7). 
As a first approach to identify the antigen expressed on the melanoma cell surface 
which was recognised by sera from protected mice, an attempt was made to sequence 
the N-terminal residues of the immunoprecipitated molecule (this work was performed 
in collaboration with the Institute of Veterinary and Biochemical Physiology, University 
of Milan). To this aim, proteins immunoprecipitated with reactive sera were 
electroblotted onto a polyvinylidene difluoride membrane (PVDF), which represents a 
solid phase support for protein sequencing, and stained with Coomassie Blue to reveal 
the specific band. The bands, cut from the PVDF membrane, were then subjected to 
automated NH3-terminal Edman degradation. 
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Fig. 5.7: Immunoprecipitation of soluble B16 cells with sera from protected mice 
Immunoprecipitation of solubilised membrane-1251-labeled B16 melanoma cells with a 
control serum (lane 1) or with sera collected from two survived B 16-transduced 
immunised animals (lane 2 and lane 3). 
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Unfortunately, no information about aminoacid sequence was obtained by this 
approach, since the N-terminal ends of the bands appeared to be inaccessible to 
automated degradation. 
As a second approach, the possible correspondence of the specific band 
immunoprecipitated from B 16 cell surface with known murine melanoma antigens 
reported to have a similar molecular weight (between 70 and 85 kDa) was investigated. 
In particular, the following antigens, known to be expressed on murine B 16 cells and to 
represent potential targets for an immune response, were evaluated: 
i) the tyrosinase family, which includes tyrosinase (Jimenez et al., 1991), 
tyrosinase-related protein 1 (TRP-1) (Hara et al., 1995) and tyrosinase-related 
protein 2 (TRP-2) (Bloom et al., 1997), 
ii) the gpl 00 protein (Schreurs et al., 1997), 
iii) products encoded by endogenous retroviruses, known to be expressed on B 16 
melanoma cells (Li et al., 1998; Leong et al., 1988). 
Since it was not known whether all these antigens, corresponding to melanosomal 
proteins or endogenous retroviral products, were expressed also on B 16 cellular 
membranes, a preliminary analysis was performed by flow cytometry. Figure 5.8 shows 
the result of this analysis performed on B 16 cells using the following specific 
antibodies: 
the AZN-LAM antiserum (kindly provided by Dr. M. W. J. Schreurs, University 
Hospital Nijmegen St Radboud, EX Nijmegen, The Netherlands) directed to gplOO 
protein, 
the aPEP antiserum (kindly provided by Dr. V Hearing, National Institutes of 
Health, Bethesda, MD) directed to TRP-2 antigen, 
the anti gp70 antiserum (kindly provided by Dr. M. L. Sensi, Istituto Tumori 
Milano, Italy) directed against MuLV gp70 protein, 
217 
the TA99 monoclonal antibody (kindly provided by Dr. L. J. Old. Sloan-Kettering 
Cancer Center, New York, NY) directed against TRP-1, 
the T311 monoclonal antibody (kindly provided by Dr. L. J. Old, Sloan-Kettering 
Cancer Center, New York, NY) directed against tyrosinase, 
As shown in the figure, TRP-1, TRP-2, gplOO and gp70 proteins were expressed at an 
high level on B 16 cell surface, while a very low reactivity against the tyrosinase was 
observed using the specific antibody. 
Precipitation of TRP-1, TRP-2, gp 100 and gp70 antigens from solubilised cell-surface 
radio labelled B 16 cells was performed therefore using the specific antibodies. 
Figure 5.9 shows the result of the experiments which compares, in the same run-
conditions, the products precipitated by AZN-LAM antiserum (a, lane 2), aPEP 
antiserum (a, lane 3), anti gp70 antiserum (a, lane 4), TA99 monoclonal antibody (b, 
lane 1) and immunoreactive serum from protected mice (a, lane 5 and b, lane 3). 
As illustrated in the figure 5.9, the immunoreactive serum precipitated from B16 cell 
surface proteins a molecule with a weight higher than that immunoprecipitated by anti-
TRP-1 and anti-TRP-2 sera, and similar to that immunoprecipitated by an antiserum 
directed against murine leukaemia virus (MuL V) gp 70 product. No precipitation was 
observed using anti-serum against gplOO. 
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Fig. 5.8: FACScan analysis of melanoma antigens expression on B16 cell surface. 
F ACScan analysis was performed on B 16 cells incubated with T311 antibody, or TA99 
antibody, or aPEP8 antiserum, or AZN-LAM antiserum or agp70 antiserum. Cells were 
stained by an indirect method using FITC anti-mouse IgG+IgM (T311 and TA99), or 
FITC anti-rabbit IgG+IgM (aPEP8 and AZN-LAM) or FITC anti-goat IgG+IgM 
( agp70). Open areas indicate cells stained with secondary antibody alone. 
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Fig. 5.9: Comparison of products immunoprecipitated from solubilised B16 cells 
with reactive sera and with anti-melanoma antigens antibodies 
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Immunoprecipitation of solubilised membrane- I-labelled Bl6 melanoma cells with: 
a) control serum (lane 1), AZN-LAM serum (anti-gplOO) (lane 2), aPEP8 serum (anti-
TRP-2) (lane 3), agp70 serum (anti-viral gp70 env) (lane 4), serum from a survived 
Ag38-transduced immunised animal (lane 5); 
b) TA99 mAb (anti-TRP-1) (lane 1), control serum (lane 2), serum from a survived 
Ag38-transduced immunised animal (lane 3). 
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5.4 DEFINITIVE IDENTIFICATION OF ANTI-RETROVIRAL HUMORAL 
RESPONSE 
In view of the result obtained using the strategy describe above, it was of interest to 
perform further experiments to evaluate the possible correspondence of the molecule 
immunoprecipitated by the reactive serum with an endogenous retroviral product. 
5.4.1 Reactivity against PT cells 
The murine NIH/3T3-transformed pT cell line and its variant pT-N, derived after 
transplantation in vivo into nude mice, were used to perform a F ACScan analysis with 
the reactive serum. As a consequence of one passage into nude mice, known to harbor 
endogenous xenotropic and ecotropic C-type virus, the pT-N variant acquired murine 
type C viruses and therefore expresses retroviral products. 
As shown in Figure 5.10, flow cytometry analysis performed on the two tumour cell 
variants revealed a strong reactivity of the immunoreactive sera only on the viruses-
infected line. This result therefore is consistent with the hypothesis of the presence, in 
reactive serum, of antibodies directed against endogenous retroviral antigens. 
5.4.2 Immunoprecipitation of retroviral products 
Conclusive results were obtained by performing immunodepletion and 
immunoprecipitation experiments from solubilised cell-surface radiolabelled B 16 
melanoma cells. 
In a first experiment, an antiserum directed against total murme leukaemia virus 
products was used to remove viral antigens from solubilised cell-surface radiolabelled 
B 16 melanoma cells. 
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Fig. 5.10: FACScan analysis ofsera reactivity on pT and pT-N tumour cell lines 
F ACS analysis of pT and pT-N tumour cells incubated with immunoreactive serum 
diluted 1: 100 and stained with goat FITC-anti-mouse IgG+IgM. Open areas indicate 
cells stained with secondary antibody alone. 
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Complete immunodepletion of virus products was obtained by three cycles of 
subsequent immunoprecipitations with the antiserum (lane 1, 2 and 3). 
As shown in Fig 5 .11, after immunodepletion of virus products, precipitation was no 
longer observed with the sera from protected mice (lane 4). 
To better define the viral molecule recognised by reactive serum, further experiments 
were performed using an antiserum directed against the virus envelope protein gp70, 
able to recognise both the virus envelope mature protein and its polyprotein precursor of 
85 kDa (Traversari et al., 1989). In this experiment, the radiolabelled cell-surface B 16 
melanoma cells were subsequently immunoprecipitated three times with 
immunoreactive murine serum to remove the target molecule specifically recognised by 
this serum. The depleted supernatant was then subjected to immunoprecipitation with 
anti-gp70 serum. As shown in Figure 5.12, in this condition, only a narrow band with a 
molecular weight of 70 kDa was still immunoprecipitated. Since the anti-gp70 serum 
was able to precipitate from the non-depleted supernatant both the . virus envelope 
protein gp70 and its polyprotein precursor of 85 kDa (not completely resolved in the 
condition of gel running), this result demonstrated that the immunoreactive sera 
specifically recognised the 85-kDa polyprotein precursor of the gp70 virus envelope 
protein. 
In summary, in mice immunised with Ag38-transduced melanoma cells and protected 
from tumour challenge a strong humoral response directed against endogenous 
retroviral antigens was detected. These antibodies had the ability to immunoprecipitate 
their target molecules, expressed on the B 16 cell surface, from solubilised cells. 
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Fig. 5.11: Immunoprecipitation with reactive sera after depletion with an anti-total 
virus serum 
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Immunoprecipitation of solubilised I-labeled B16 melanoma cells with a 
representative serum sample from a protected mouse before (lane 5) or after (lane 4) 
immunodepletion performed by sequential immunoprecipitation of solubilised extracts 
three times with anti-total virus (murine leukemia virus) serum. Proteins conjugated to 
Sepharose in each subsequent passage were recovered and loaded (lanes 1, 2 and 3, 
respectively). After three cycles of absorption, proteins remaining in the supernatant 
were subjected to immunoprecipitation with serum. 
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Fig. 5.12: Immunoprecipitation with anti-gp70 serum after immunodepletion with 
·a reactive serum 
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Immunodepletion of I-labeled and solubilised Bl6 melanoma cells, performed by 
sequential immunoprecipitations as described in Fig. 5.10, with serum from a protected 
transduced Bl6-immunized mouse (lanes 1, 2 and 3, for each subsequent 
immunoprecipitation), followed by immunoprecipitation with anti-gp70 serum (lane 4) 
and immunodepletion with a control serum (lanes 5, 6 and 7), followed by 
immunoprecipitation with anti-gp70 serum (lane 8). 
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5.5 EVALUATION OF THE HUMORAL RESPONSE AGAINST LINEAGE-
SPECIFIC ANTIGENS 
Even though the antibody response was directed mainly against endogenous retroviral 
antigens, immunisation with Ag38-transduced cells may also have induced a lesser 
response against tumour associated antigens. In addition, these antibodies may have not 
been able to immunoprecipitate their target molecules from solubilised B 16 cells under 
the conditions of the above experiments. Therefore, further analyses were performed to 
investigate the presence of antibodies specifically directed to melanocyte lineage-
specific antigens in sera of protected mice. 
This study particularly focused on the evaluation of the presence of anti-TRP-2 
antibodies, since this antigen has been shown to be the main target of an immune 
response against B 16 cells. Indeed, it has been described that CTL clones recognising 
the· TRP-2 antigen can be raised from B 16 immunized-C57BL/6 splenocytes after 
repeated stimulation in vitro with.IL-2 and B7.1 transfected B16 cells (Bloom et al., 
1997). 
5.5.1 Lack of a detectable humoral response against TRP-2 
In order to evaluate the presence of antibodies directed against TRP-2 antigen in sera of 
protected mice, the murine TRP-2 coding region was cloned by RT-PCR into the 
pCR3.1 Uni eukaryotic vector and the protein was produced using an in vitro 
transcription-translation system. 
Total RNA obtained from B16 cells was reverse-transcribed and the cDNA fragment 
corresponding to the open reading frame (ORF) ofmurine TRP-2 was amplified by PCR 
using forward and reverse primers reported in Figure 5 .13. 
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Fig. 5.13: Cloning of murine TRP2 
Schematic diagram describing the cloning of murine TRP-2 in pCR3.1 Uni vector. The 
open reading frame of murine TRP-2 was reverse transcribed and amplified by PCR 
with 3 '-A overhangs at each end. PCR product was then directly ligated in the linearised 
vector which contained 3 '-T overhangs at each end. Nucleotide position and sequences 
of sense and antisense primers used for amplification are reported in the text box. 
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As shown in the picture in the same figure, the reaction product was ligated directly into 
the vector to obtain the pCR3.lmTRP2 construct. 
To verify the integrity of the construct, restriction analysis and automated DNA 
sequencing of the TRP2 insert were performed. 
The TRP-2 cDNA cloned into the pCR3.1Uni vector was in the correct orientation for 
expression of TRP-2 from the T7 promoter. The insert was in vitro transcribed and 
translated by a TnT T7-coupled reticulocyte lysate system to obtain the TRP-2 protein 
labelled with 358-methionine. 
As shown in figure 5.14 A), analysis by 8D8-PAGE and autoradiography of the purified 
labelled molecule revealed a single protein product with a molecular weight in 
agreement with that predicted from the amino acid sequence of the protein. 
In order to evaluate the presence of antibodies directed against the TRP-2 antigen in 
sera from protected mice, the ability of sera to immunoprecipitate the labelled molecule 
was analysed. 
As shown in figure 5.14 B), the level of radioactivity precipitated by sera obtained from 
three different protected mice was very low and similar to the background obtained by 
precipitation with an unrelated hyperimmune serum. However, in the same conditions, 
the 358-TRP-2 molecule was precipitable by the rabbit anti-PE~8 serum, which 
recognises a peptide consisting of the C-terminal 14 amino acids of murine TRP-2 .. 
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Fig. 5.14: Reactivity of sera against in vitro transcribed-translated TRP-2 
A) SDS-PAGE and autoradiography of in vitro transcribed-translated 35S-TRP-2 (lane 
2) and control reaction with empty vector (lane 1 ). 
B) Immunoprecipitation of 35S-TRP-2 with (A) anti-PEP8 serum, (B, C, D) 
hyperimmune sera from three protected mice immunised with transduced B 16 cells and 
(E) an unrelated hyperimmune mouse serum. Precipitated radioactivity is expressed as 
ct/min and represents the mean(± standard deviation) calculated from two independent 
experiments. 
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To exclude the possibility that the glycosylation-free in vitro transcribed-translated 35S-
TRP-2 used was not recognised because of the lack of some epitopes, the murine TRP-2 
cDNA was expressed in a non-melanoma cell line, which does not endogenously 
express this protein. The Chinese Hamster Ovary tumour cell line was chosen for this 
experiment. 
CHO cells were transfected with the pCR3.1-mTRP2 construct by lipofection 
technology and stably transfected clones were selected in G418. 
Northern blot analysis performed using a probe corresponding to the entire ORF of the 
TRP-2 gene revealed the specific expression of TRP-2 transcript in stable transfected 
clones (Fig. 5.15 a). 
Western analysis of total protein extracts obtained from TRP-2-transfected cells using 
the anti-murine TRP2 rabbit aPEP8 serum revealed the expression of TRP-2 protein in 
TRP-2-transfected CHO cells (Fig. 5.15 b). 
The reactivity of sera from protected mice on TRP2-expressing CHO cells was 
evaluated by Western blot analysis and immunofluorescence analysis. Figure 5.15 c 
shows the result of Western blot analysis, performed on total protein extract from 
TRP2-transfected or mock cells with the reactive sera. No specific band, detectable only 
in TRP2-expressing cells, was revealed using this approach. 
Immunofluorescence analysis performed on permeabilized cells also failed to reveal any 
difference in the reactivity of sera detected on mock and on TRP-2-transfected CHO 
cells (Fig.5.16). 
In summary, no reactivity was found in sera from protected mice against TRP2 antigen, 
either obtained by in vitro transcription-translation or stably expressed in a non-
melanoma cell line. 
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Fig. 5.15: TRP-2 gene expression in CHO-transfected cells 
a) Northern blot analysis of the expression of murine TRP-2 mRNA in transfected CHO 
clones: 10 µg of total RNAs from mock cells (lane 1), from two representative clones of 
transfected CHO cells (lanes 2 and 3), and from B16 cells (lane 4) was loaded in each 
lane. Expression of the P-actin gene was included as control. The position of 28S and 
18S RNAs is indicated. 
b) Western blot analysis of the expression of murine TRP-2 in transfected CHO cells: 
100 µg of total soluble extract from B 16 cells (lane 1 ), from one representative clone of 
transfected cells (lane 2), and from mock cells (lane 3) was loaded in each lane and 
reacted with anti-PEP8 serum. 
c) Western blot analysis to evaluate reactivity of sera from protected mice on murine 
TRP-2 transfected CHO cells: total soluble extract from B16 cells (lane 4), from one 
representative clone of transfected cells (lane 5), and from mock cells (lane 6) was 
loaded in each lane as in figure b) and reacted with serum diluted 1 :500 
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Fig. 5.16: FACScan analysis of sera reactivity on TRP2-transfected CHO cells 
Immunofluorescence analysis on permeabilised mock and TRP-2-transfected CHO cells 
after incubation with reactive serum at 1: 100 and staining with goat FITC-anti-mouse 
IgG+IgM. Open areas indicate cells stained with secondary antibody alone. 
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· 5.5.2 Lack of a detectable humoral response against tyrosinase, TRP-1 and gplOO 
antigens 
The presence in sera of protected mice of antibodies directed to other melanocyte 
lineage-specific antigens was then analysed. 
Tyrosinase and gp 100 antigens were immunoprecipitated from total protein extract of 
B 16 cells with the specific antibodies. Each product obtained from the 
immunoprecipitations was loaded in duplicate and separated by SDS-PAGE. Western 
blot analysis was then performed using the specific antibodies, to verify the presence of 
the protein antigens or, using reactive sera from protected mice, to evaluate the 
reactivity against these antigens. 
As shown in figure 5 .17, gp 100 and tyrosinase antigens were detectable by Western blot 
analysis with their specific antibodies AZN-LAM and T311. However, no specific 
bands were detectable in analysis performed under the same conditions using sera from 
protected mice (a). 
Since T A99 antibody was not observed to work in the experimental conditions of 
Western blot, a different approach was used to verify the precipitation of TRP-1 
antigen. 1251-radiolabelled solubilised B 16 cells were immunoprecipitated with T A99 
antibody and the product obtained from precipitation was loaded in duplicate and 
separated by SDS-PAGE. Autoradiography and Western blot analysis were used 
respectively to evaluate the precipitation of the specific protein and the reactivity of 
sera. As shown in figure 5 .17 b ), autoradiography revealed the precipitation of a single 
labelled protein with a.molecular weight in agreement with that of the TRP-1 antigen. 
However, Western blot analysis using sera from protected mice did not reveal the 
presence of antibodies able to recognise this molecule. 
Therefore, no reactivity in the conditions of Western blot analysis was found in sera 
from protected mice against gp 100, tyrosinase and TRP-1 antigens. 
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Fig. 5.17: Evaluation of sera reactivity against tyrosinase, gplOO and TRP-1 
antigens 
a) Immunoprecipitation of gplOO (lane 2) and tyrosinase (lane 4) from solubilised B16 
cells and Western blot analysis with specific antibodies AZN-LAM and T311 (top) or 
with sera from protected mice (bottom). Immunoprecipitations with a normal rabbit 
serum (lane 1) and a normal mouse serum (lane 3) were loaded as negative control. 
b) Immunoprecipitation of TRP-1 (lane 2) with TA99 antibody from 1251-radiolabeled 
solubilised B 16 cells: autoradiography of precipitated labeled TRP-1 (top) and Western 
blot analysis with sera from protected mice (bottom). Immunoprecipitation with a 
normal mouse serum (lane 1) was loaded as control. 
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5.6 CELLULAR RESPONSE 
To evaluate whether vaccination with Ag38-transduced cells also induce the activation 
of a cellular response against melanoma tumour, a standard 4-h 51 Cr release assay was 
performed using fresh splenic lymphocytes obtained from mice vaccinated twice with a 
4-week interval with 106 irradiated transduced-B16 cells and in vivo restimulated 5 days 
before the assay with Ag38-transduced cells. 
No significant T cell cytotoxicity against melanoma cells (less than 4% of cytotoxicity 
at an effector:target ratio of 1: 100) was detected in these conditions. 
5.7 SUMMARY 
Following vaccination with the Ag38-transduced cell vaccine a low serological response 
against melanoma cells was observed, while a high titre of antibodies directed against 
parental B 16 cells, mainly of IgG2a isotype, were found in protected mice after 
·challenge. These antibodies showed a complement-dependent cytotoxicity against 
melanoma cells in vitro whilst, in vivo, passive immunisation induced a decrease in the 
number of experimental B 16 lung metastases. 
Most of these antibodies were directed against endogenous murine leukaemia viruses, 
while no reactivity against melanocyte lineage-specific antigens was observed. In 
particular, no reactivity was found in sera from protected mice against TRP-2, either 
stably expressed in a non-melanoma cell line or obtained by in vitro transcription-
translation, or against tyrosinase, TRP-1 and gp 100 antigens immunoprecipitated from 
B16 cells. 
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No cytotoxic T cell activity against melanoma cells was detected in mice vaccinated 
with Ag38-transduced melanoma cells. 
Thus, in the B 16 murine model, the presence of dominant viral antigens induces a very 
strong humoral response that might be protective and may inhibit or mask the presence 
of minor clonotypes. 
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CHAPTER SIX 
EVALUATION OF DIFFERENT VACCINATION PROTOCOLS 
AGAINST MELANOMA 
6.1 EVALUATION OF DIFFERENT STRATEGIES BASED ON THE USE 
OF MYCOBACTERIAL PRODUCTS 
Different vaccination strategies, based on the use of fractions or materials derived from 
Mycobacterium tuberculosis, were considered and compared to the use of an Ag38-
expressing cellular vaccine. In particular, the administration of purified recombinant 
Ag38 protein, Ag38 encoding DNA plasmid or Bacillus Calmette-Guerin (BCG) as 
vaccines to induce a protective immune response against melanoma were analysed. 
6.1.1 Vaccination with recombinant Ag38 protein 
The ability of recombinant Ag3 8 protein, administered in mice as a vaccine, to induce 
protection against tumour challenge of parental B16 cells was evaluated. To this aim, 
fourteen mice were vaccinated· with 10 micrograms of purified Ag3 8 protein (Kindly 
provided by Dr. M. Singh, GBF, Braunschweig, Germany) administered subcutaneously 
in incomplete Freund's adjuvant (eight mice) or in the presence of 106 irradiated 
parental melanoma cells (six mice). The same treatment was repeated twice at.4-week 
intervals. Four weeks after the third vaccination, all mice were challenged intravenously 
with 5x 105 viable parental cells. 
The result of the experiment, represented as survival time, is reported in Figure 6.1. A 
low protection was observed in mice vaccinated with the protein administered in 
incomplete Freund's adjuvant or in the presence of irradiated parental cells. 
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Fig. 6.1: Protection against experimental lung metastases by vaccination with Ag38 
protein 
Overall survival of mice either non-immunised (n = 8) ( .... )or immunised with purified 
Ag38 protein, administered in incomplete Freund' s adjuvant (n = 8) (-)or in presence 
of irradiated melanoma cells (n = 6) (-•-).Mice were i.v. challenged with 5x105 viable 
melanoma cells. 
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Thus, compared to vaccination with Ag38-expressing tumour cells, the level of 
protection against tumour evoked by the exogenous administration of the purified Ag3 8 
protein, also in the presence of tumour cells, consistently was less effective. 
6.1.2 Vaccination withAg38-encoding DNA 
In vivo vaccination with DNA plasmid encoding the Ag3 8 antigen as an alternative 
strategy to in vitro transduction was also evaluated. 
To measure Ag38 DNA vaccine efficacy, sixteen mice were injected intra-muscularly 
three times (at 3-week intervals) in both quadriceps with 60 micrograms, of an Ag38-
encoding DNA construct and, one month after the third injection, intravenously 
challenged with 5x105 viable parental cells. A group of eight mice received only tumour 
challenge and was used as control. 
As shown in Figure 6.2, a very low protection was obser\red after intramuscular 
immunisations with the Ag3 8 coding plasmid. 
6.1.3 Vaccination with Bacillus Calmette-Guerin (BCG) 
Application of Mycobacterium or its derivatives has a long history in tumour therapy 
approaches, including administration of BCG as a general immunostimulant or as an 
adjuvant administered together with tumour cells. The ability of whole live Bacillus 
Calmette-Guerin to stimulate an immune response able to protect against tumour 
challenge was therefore investigated. 
Sixteen mice were injected subcutaneously with 106 live M bovis BCG (Pasteur 
Merieux Connaught, Italy) and one month later intravenously challenged with 5x 105 
viable parental cells. A group of eight mice received only tumour challenge and was 
used as control. As shown in Figure 6.3, as compared to control mice, immunisation 
with BCG generated a protective immunity, which resulted in a delay in tumour growth. 
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Fig. 6.2: Protection against experimental lung metastases by vaccination with 
Ag38-encoding DNA 
Overall survival of non-immunised (n = 8) ( ... )or Ag38 DNA-immunised (n = 8) (-) 
mice after i.v. challenge with 5x105 viable melanoma cells. 
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Fig. 6.3: Protection against experimental lung metastases by vaccination with BCG 
Overall survival of non-immunised (n = 8) ( ... ) or BCG-immunised (n = 8) (-)mice 
after i.v. challenge with 5xl 05 viable melanoma cells. 
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However, this level of protection was less than that evoked by vaccination with Ag38-
expressing tumour cells. 
6.2 EVALUATION OF A RECALL WITH AG38-TRANSDUCED CELLS 
AFTER TUMOUR INOCULATION 
To optimise the use of Ag38-transduced cells to enhance antitumour immune responses, 
studies were performed on vaccination schedules. In particular the effect of re-
administration (recall) of irradiated transduced cells after tumour challenge was 
investigated. 
A group of sixteen mice were vaccinated subcutaneously twice at a 4-week interval with 
106 transduced irradiated melanoma cells and, four weeks after the second vaccination, 
challenged intravenously with 5x 105 viable parental cells. Another group of eight mice 
received only tumour challenge and was used as control. 
On days + 1, +8 and + 15 from tumour challenge eight of sixteen mice pre-vaccinated 
with transduced cells received s.c. a recall-treatment with 106 transduced, irradiated 
melanoma cells. The three groups of mice were evaluated for survival time. 
As shown in Figure 6.4, in mice vaccinated with Ag38-transduced cells, the re-
administration of transduced cells after tumour challenge resulted in a reduction of 
tumour protection induced by vaccination. 
This result suggests that the recall treatment might stimulate a suppressive response able 
to abrogate the efficacy of vaccination. 
In agreement with this hypothesis, it has been reported that vaccination with 
Mycobacterium proteins can induce an immunosuppressive response depending on dose· 
and schedule by inducing secretion of immunosuppressive cytokines (Fine et al., 1990). 
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Fig. 6.4: Recall with Ag38-transduced cells after tumour inoculation 
Evaluation of a recall with Ag38-transduced cells after tumour challenge with 5x 105 
viable melanoma cells: overall survival of non-immunised mice (n = 8) ( ... ),or of mice 
immunised with irradiated Ag38-transduced cells (n = 8) (-), or of mice immunised 
and re-called, after the tumour challenge, with irradiated Ag38-transduced cells (n = 8) 
(-•-). 
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6.3 EVALUATION OF A THERAPEUTIC PROTOCOL WITH AG38-
TRANSDUCED CELLS 
Experiments were performed to determine whether administration of Ag38-transduced 
cells might have a therapeutic effect on existing tumour. 
Sixteen mice were intravenously challenged with 5x 105 viable parental cells. On days 
+ 1, +8 and + 15 from tumour challenge, eight of sixteen mice were subcutaneously 
injected with 106 Ag38-transduced irradiated melanoma cells. The remaining group of 
eight mice challenged with tumour was untreated and used as control. 
As shown in Figure 6.5, no therapeutic effect was observed in mice with existing 
tumours since no differences in survival time between mice receiving only tumour 
challenge and mice treated with transduced cells after tumour challenge were detectable. 
However, as with other cancer vaccines, the limited efficacy in curing existing tumours 
is thought to be due mainly to the rapid growth of the tumour, leading to the death of 
mice before the activation of an efficient immune response. Furthermore, an inadequate 
penetration into the tumour site by immune cells and the escape from this immune 
response by tumour cells might represent additional limiting causes. 
6.4 SUMMARY 
Different vaccination strategies based on the use of mycobacterial products were 
compared to vaccination with Ag38-transduced tumour cells. Administration of purified 
Ag38 mycobacterial protein, DNA vaccination using the Ag38 encoding plasmid, or 
administration of BCG were evaluated. A very low protection was obtained using 
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Fig. 6.5: Therapeutic protocol with Ag38-transduced cells 
Evaluation of a therapeutic protocol with Ag38-transduced cells: overall survival of 
untreated mice (n = 8) ( ... ), or of mice injected with irradiated Ag38-transduced 
melanoma cells (n = 8) (-) after i.v. challenged with 5xl 05 viable melanoma cells. 
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immunisation schedules which employ the purified Ag3 8 protein or Ag3 8 coding 
plasmid; only a mild protection was observed by immunisation with BCG. 
In experiments to determine whether mycobacterium-transduced cells have a 
therapeutic effect, no differences were observed between mice receiving only tumour 
challenge and mice treated with transduced cells after tumour challenge. 
Moreover, in experiments to optimise the use of Ag38-expressing cells as tumour 
vaccine, the re-administration of transduced cells (recall) after tumour challenge 
unexpectedly resulted in a reduction of the tumour protection induced by vaccination. 
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CHAPTER SEVEN 
MODULATION OF THE IMMUNE RESPONSE AGAINST 
SPONTANEOUS MAMMARY CARCINOMA BY VACCINATION 
WITH Ag38-TRANSDUCED CELLS IN FVB-NeuN MICE 
7.1 THE FVB-NeuN TRANSGENIC MODEL 
It was decided to evaluate the efficacy of vaccination with Ag38-transduced tumour 
cells in a model of spontaneous tumour development. 
To this aim, an animal model that mimics the human breast carcinoma pathology was 
chosen. This model consists of mice transgenic for the rat HER2/neu protooncogene 
placed under the control of a specific promoter for mammary tissue, the mouse 
mammary tumour virus (MMTV) promoter. 
In this strain, the transgene expression starts at about 2 months of age and at 4-5 months 
the mammary glands show hyperplasia and microfoci of in situ carcinomas. At about 6 
months, female transgenic mice start to develop invasive carcinomas and by 12 months 
the tumour incidence reaches 100% (Guy et al., 1992; Boggio et al., 1998). 
Transgenic mice, which expressed the transgene physiologically, were found to be 
rather tolerant to the transgene. Indeed, immunisation with transgenic tumour cells 
overexpressing HER2/neu did not induce immunity against tumour development. 
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7.2 PROTECTIVE IMMUNITY AGAINST SPONTANEOUS ARISING 
MAMMARY CARCINOMA BY VACCINATION WITH AG38-
TRANSDUCED CELLS 
Protection induced by vaccination with Ag38-transduced tumour cells against 
spontaneous tumour development was evaluated. The N202.1A tumour cell line, 
derived from a mammary carcinoma spontaneously grown in FVB-NeuN transgenic 
mice, was used to create the Ag38-expressing syngenic cell vaccine, as described above 
(see chapter 3.5). 
In each experiment, proto-neu-transgenic virgin female mice were divided randomly 
into groups. The groups were always extremely homogeneous with respect to birth 
dates, thus avoiding the variability in the time of tumour appearance seen in our 
experiments, which may be associated to different seasonal development periods. In 
each experiment, vaccination was performed by two subcutaneous injections, at a 4-
week interval, with 106 irradiated non-transduced tumour cells or 106 irradiated Ag38-
transduced tumour cells. Mammary glands were inspected weekly and two 
perpendicular diameters of tumour masses were recorded. Differences between groups 
were analysed using the log rank test. 
Figure 7 .1 shows the result of a preliminary experiment performed using a small 
number of animals ( 5 for each group), which received the first vaccination treatment at 
the age of four months (i.e. 2 months before spontaneous tumour formation). All mice 
vaccinated with parental cells developed spontaneous tumours, whilst a partial 
protection was observed in the group of mice vaccinated with transduced cells. Indeed, 
in this group, a delay in tumour development in 1 out 5 mice and a complete protection 
at the end of the observation period (700 days) in 1 out of 5 mice was observed (p = 
0.366). 
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Fig. 7.1: Protection against spontaneous mammary tumour by vaccination with 
Ag38-transduced N202.1A cells in a preliminary experiment 
Spontaneous mammary tumour development in proto-neu transgenic female mice 
vaccinated with non-transduced N202.1A cells (n = 5) and Ag38-transduced N202.1A 
cells (n = 5). P = 0.36, determined by log-rank test. 
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A second experiment was performed using a larger group of animals (11 for each group 
of vaccinations) and administering the first vaccination treatment at the age of two 
months. A third group of 8 mice was left untreated and used as a control to evaluate 
spontaneous tumour incidence. 
The result of the experiment is represented in figure 7.2. In mice vaccinated with Ag38-
transduced cells the onset of the first spontaneous mammary tumour was significantly 
delayed as compared with the control group (p = 0.033) (b ), whereas no difference in 
tumour onset was observed between mice vaccinated with non-transduced N202.1A 
cells and controls (p = 0.689) (a). Moreover, the number of mammary glands with a 
palpable tumour was reduced in mice vaccinated with irradiated Ag38-transduced 
tumour cells as compared to mice vaccinated with non-transduced tumour cells: at 300 
days, the mean number of tumours per mouse was 2.1 in this group as compared with 
3 .1 in mice vaccinated with non-transduced tumour cells. 
These data indicate that the expression of Ag3 8 protein in tumour vaccine induces a 
protective immunity, which results in a delay in tumour appearance. Protection was 
achieved in this model, as it was in the melanoma model, against a tumour challenge, by 
using irradiated cells and after only two vaccinations. 
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Fig. 7.2: Protection against spontaneous mammary tumour by vaccination with 
Ag38-transduced N202.1A cells 
Spontaneous mammary tumour development in proto-neu transgenic female mice 
vaccinated with non-transduced N202.1A cells (n = 11 ) (a) and Ag38-transduced 
N202.1A cells (n = 11) (b). Control group n = 8. P values were determined by log-rank 
test. 
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7.3 SYNERGISTIC EFFECT OF IL-12 
Bacterial DNA has been reported to induce macrophages to secrete IL-12 and, indeed, 
serum of mice maintained under specific pathogen-free conditions revealed a detectable 
levels of IL-12 after injection of bacterial DNA (Krieg et al., 1998). The protection 
observed with Ag38-transduced tumour cell vaccine could be related to a released of IL-
12 induced by the presence of M tuberculosis DNA in transduced cells. Therefore, it 
was investigated if a systemic co-administration of recombinant IL-12 (rIL12) together 
with the non-transduced tumour cells could induce the same anti-tumour response 
observed using transduced-tumour cell vaccine. 
At the same time the anti-tumour immunity induced by Ag38-transduced cancer vaccine 
plus systemic co-administration of rIL-12 was evaluated. Indeed systemic 
administration of rIL-12 was recently reported to potentiate the effects of cancer 
vaccines engineered to secrete different cytokines (Vagliani et al., 1996; Taniguchi et 
al., 1998; Kurzawa et al., 1998). 
Thirty six female transgenic mice were divided randomly into three groups (12 
mice/group). Two groups were vaccinated at the age of 2 months with non-transduced 
or transduced cells as above, and systemically infused with rIL-12 immediately after 
vaccination with irradiated cells and on days+ 1, +2 and +3 (150 ng over 4 days). The 
third untreated group was used as control. 
The result of the experiment is reported in figure 7.3. All mice vaccinated with non-
transduced cells plus rIL-12 developed tumours with a slight delay in tumour onset as 
compared with the control group (p=0.056) (a), whereas spontaneous tumour 
development was significantly delayed in mice vaccinated with Ag38-transduced cells 
plus rIL-12, (p=0.001 versus control group) with 2 tumour-free mice at the end of the 
400-day observation period (Fig. b ). 
252 
a 
100 / / : 
------- -------·····-·---
-~ 0 
-
----- - N202 .t.1?\+IL-12 
Q) 
.~ - control 
E 
Q) 
Q) 50 
.... 
.... 
.... 
:J 
0 p = 0.056 
E 
:J 
.... 
0 
0 100 200 300 400 
Age (days) 
b 
100 II 
-~ 0 
-
------ N202.1A-Ag38+ IL-12 
Q) 
.~ - control 
E 
Q) 
Q) 
50 .... .... 
.... 
:J 
0 
p = 0.001 
E 
:J 
.... 
0 
0 100 200 300 400 
Age (days) 
Fig. 7 .3 Protection against spontaneous mammary tumour by vaccination with 
Ag38-transduced N202.1A cells plus IL-12 
Spontaneous mammary tumour development in proto-neu transgenic female mice 
vaccinated with non-transduced N202.1A cells plus rIL-12 (n = 12) (a) and Ag38-
transduced N202.1A cells plus IL-12 (n = 12) (b). Control group n = 12. P values were . 
determined by log-rank test. 
253 
Moreover, the number of mammary glands with a palpable tumour was reduced in mice 
vaccinated with irradiated Ag38-transduced tumour cells: at 300 days, the mean number 
of tumours per mouse was 0.91 in this group as compared with 1.5 in mice vaccinated 
with non-transduced tumour cells plus rIL-12 and 2.08 in the control group. 
Therefore, only a slight delay in tumour appearance was observed in mice systemically 
administered with non-transduced cells plus a low dose of recombinant IL-12 (rIL12). 
On the contrary, systemic co-administration of low dose rIL 12 enhanced efficacy of 
Ag38-transduced cell vaccine, suggesting a synergy in the adjuvant potency of these 
reagents. 
7.4 THl- AND TH2-TYPE CYTOKINE SUBSETS INDUCED BY 
VACCINATION 
The Thl- and Th2- responses, represented respectively by IFN-y and IL-4 production, 
induced by the different vaccination treatments was evaluated. 
Mice were vaccinated subcutaneously into the right hind footpad with 5x106 non-
transduced or transduced irradiated cells alone or in the presence of rIL-12 injected 
intraperitoneally (150 ng/day on days 0, + 1, +2, +3). Six days later, mice were 
sacrificed and popliteal lymph nodes were removed aseptically and pooled from 2 mice 
in each group. Lymphocytes were mechanically dissociated and cultured in plates 
precoated with 1 µg/well anti-CD3 MAb at 37°C for 18 h. Supernatant was then 
collected and tested for IFN-y and IL-4 production. 
Figure 7.4 shows the result of a representative experiment. 
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Fig. 7.4: Production ofIFN-y and IL-4 by popliteal lymph nodes of vaccinated mice 
IFN-y and IL-4 production by lymphocytes from popliteal lymph nodes of mice 
vaccinated with non-transduced N202.1A or Ag38-transduced N202.1A cells, without 
(a) or with rIL-12 (b), and stimulated with immobilised anti-CD3 mAb. Values were 
obtained by subtracting the cytokine levels in the supernatant of lymphocytes cultured 
in the absence of anti-CD3 antibody. P values were determined by two-tailed unpaired t 
test. 
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Lymphocytes obtained from popliteal lymph nodes of mice footpad-injected with Ag38-
transduced N202.1 A tumour cells alone or in the presence of rIL-12 produced 
significantly higher levels of IFN-y, as compared respectively to lymphocytes obtained 
from mice vaccinated with non-transduced cells alone or in the presence of rIL-12. A 
greater than additive effect, between Ag38-transduced vaccine and rIL-12, was indicated 
by the greater level of IFN-y secreted by draining lymph node cells from mice injected 
with the two reagents together. No production ofIL-4 was observed in any group. 
The induction of a preferential Thi response by an endogenously expressed 
mycobacterial antigen is consistent with previous data obtained in the melanoma model. 
7.5 ROLE OF IL-12 ON CYTOKINE PRODUCTION 
Bacterial DNA has rapid immunostimulatory effects both in vivo and in vitro, mediated 
by the recognition of unmethylated CpG dinucleotides within specific flanking bases. 
CpG dinucleotides, referred to as CpG motifs, are under-represented and selectively 
methylated in vertebrate DNA, but are present at higher frequency and unmethylated in 
bacterial DNA. These motifs may have evolved as an ancestral mechanism used by the 
innate immune system to detect DNA of pathogens, such as bacteria and viruses 
(Hartmann et al., 2000). DNA containing these motifs has been reported to directly 
activate macrophages to secrete IL-12 (Halpern et al., 1996). 
The role of IL-12 in mediating the vaccination efficacy of Ag38-tranduced cells was 
evaluated. The purpose of this study was to analyse whether the vaccination efficacy of 
Ag38 transduction in tumour cells was mediated through the production of IL-12, as the 
analysis of Ag38 gene sequence revealed the presence of 11 such CpG motifs, or is 
independent of IL-12. It was of interest to analyse this issue since it could demonstrate 
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if the cooperativity observed between Ag38 and IL-12 was due to an increased IL-12 
production or due to additional factors related to Ag38 expression that cooperate with 
IL-12 in inducing greater levels of IFN-y. 
It was, therefore, investigated if a neutralising antibody against IL-12 affected the 
dominant Thl response to vaccination with Ag38-transduced cells. To this aim, mice 
were intraperitoneally treated for 4 days with 1 mg of purified rat anti-murine IL-12 p40 
antibody (kindly provided by Dr. Trinchieri, The Wistar Institute of Anatomy and 
Biology, Philadelphia, PA), or, as control, with the same dose of an unrelated isotype 
antibody. Six hours after the first treatment with the antibody, mice were vaccinated s.c. 
into the right hind footpad with 5x106 transduced cells alone or with 5x106 non-
transduced cells in the presence of rIL-12, injected i.p. (150 ng/day for 4 days). The 
experiment was then carried on as described above to evaluate IFN-y production by 
draining lymph node cells. 
Figure 7.5 shows the result of the experiment. In mice footpad-injected with Ag38-
transduced cells, the administration of an anti-IL-12 antibody did not significantly 
change IFN-y-prod~ction, as compared to control group (17% inhibition, p=0.603). On 
the contrary, in mice footpad injected with non-transduced cells and systemically 
infused with rIL-12, the antibody administration induced, as expected, a significant 
reduction in IFN-y production (87% inhibition, p=0.0013). Therefore, IFN-y release 
induced by vaccination with Ag38-transduced cells does not seem to be mainly 
mediated through the production of IL-12. This result suggests that the cooperativity 
observed on vaccination between Ag38 and IL-12 is probably attributable to additional 
Ag38-induced factors that cooperate with IL-12 in inducing greater levels ofIFN-y. 
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Fig. 7.5: Production of IFN-y in response to vaccination in mice treated with anti-
IL-12 antibody 
IFN-y production by lymphocytes from popliteal lymph nodes of mice i.p. treated with 
anti-murine IL-12 p40 antibody and vaccinated withAg38-transduced N202.1A cells (a) 
or with N202.1A cells plus rIL-12 (b). Control mice not treated with the anti-IL-12 
antibody received an i.p. injection with an unrelated antibody. Values were obtained by 
subtracting the cytokine levels in the supernatant of lymphocytes cultured in the 
absence of anti-CD3 antibody. P values were determined by two-tailed unpaired t test. 
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7.6 LYMPHOCYTE SUBSETS ACTIVATED BY VACCINATION 
The type of T cell subset activated by vaccination and responsive to the tumour was 
then investigated. 
To this aim, spleen cells of mice vaccinated with 106 irradiated Ag38-transduced tumour 
cells, or 106 irradiated non-transduced cells plus rIL-12 (150 ng/day on day 0, +1, +2, 
+ 3) or 106 irradiated non-transduced cells alone, were removed 7 days after vaccination 
and cultured in vitro with weekly restimulation with irradiated N202.1A tumour cells 
and low-dose IL-2 (25 U/ml). Syngeneic irradiated splenocytes were added to each well 
as feeder cells . 
. Only spleen cells of mice vaccinated with transduced tumour cells were able to survive 
to prolonged culture in vitro and to proliferate in the presence of tumour cells. After 
four in vitro stimulations, the presence of activated CD4+ or CDS+ lymphocytes and 
their cytokine production were determined by F ACScan analysis of cells triple-stained 
with Cy-Chrome-labelled anti-CDS or anti-CD4, FITC-anti-IFN-y and PE-anti-IL-4 
mAbs. As shown in figure 7.6, these cells were shown to be mainly CD3+ CDS+ and to 
produce IFN-y. 
7.7 RECOGNITION OF MAMMARY CARCINOMA CELL LINES BY 
ACTIVATED LYMPHOCYTES 
The production of IFN-y in response to the specific recognition of tumour antigens was 
then evaluated. 
In a first experiment, the recognition of N202.1A parental cells was investigated. CD3+ 
CDS+ lymphocyte population obtained from mice immunised with Ag38-transduced 
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Fig. 7.6: Analysis of lymphocytes subset(s) activated by vaccination 
Characterisation of splenocytes obtained from mice vaccinated with Ag38-transduced 
N202.1A cells and restimulated in vitro with N202.1A tumor cells and IL-2. Flow 
cytometry analysis of cells stimulated with immobilised anti-CD3 mAb, in the presence 
of monensin, and triple-stained with Cy-Chrome-anti-CDS or Cy-Chrome anti-CD-4, 
PE-anti-IL-4 and FITC-anti-IFN-y mAbs. Analysis of cytokine production was 
performed setting a gate on CD4- (top) or CD8- (bottom) positive cells. 
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cells was in vitro stimulated with irradiated N202.1A cells, or cultured alone, in the 
presence of IL-2 (25 U/ml). After 24 h of incubation, supernatant was recovered and 
IFN-y levels were determined. As reported in figure 7.7, IFN-y production was 
detectable only in the presence ofN202.1A tumour cells (a). 
Since the N202.1A cell line is characterised by the overexpression of the neu oncogene, 
it was of interest to investigate whether the production of IFN-y was restricted to the 
specific recognition of the oncogene. Indeed, it was presumed that immunisation with 
tumour cells overexpressing HER2/neu oncoprotein transduced with Ag38 gene might 
have induced the break of the tolerance to the trans gene. 
Therefore, the production of IFN-y was evaluated after stimulation with the N202.1E 
line, an independent FVB-NeuN derived spontaneous tumour cell line characterised by 
the lack of expression of HER2/N eu oncoprotein. 
As reported in figure 7. 7, IFN-y production was detectable also in the presence of 
N202.1E tumour cells (b). 
In summary, vaccination with Ag38-transduced N202.1A tumour cells induced the 
activation of a prevalent type 1 CD8+ T cell population producing IFN-y. The 
production of this cytokine was observed in response to stimulation with non-
transduced tumour cells and this response was not specifically restricted to stimulation 
with HER2/neu-positive tumour. 
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Fig. 7.7: Production of IFN-y by activated lymphocytes in response to stimulation 
with tumour cells 
IFN-y production by splenocytes obtained from mice vaccinated with Ag38-transduced 
cells, measured in supernatant of lymphocytes cultured alone or in the presence of 
N202.1A (a) or N202.1E (b) tumour cells. 
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7.8 INHIBITION OF TUMOUR PROLIFERATION BY IFN-y 
A direct role for some cytokines in inhibition of tumour proliferation has been reported 
in a number of normal and malignant cells (Burke et al., 1999; Gooch et al., 1998). 
To assess whether IFN-y produced by vaccination treatments might have a direct growth 
inibitory effect on spontaneous mammary tumour in FVB-NeuN mice, the sensitivity of 
different transgenic tumour cell lines to IFN-y was evaluated in vitro. 
Cultures of the three different tumour cell lines N202.1A, N202.1E and TT3, each 
derived from a mammary carcinoma spontaneously grown in FVB-neuN transgenic 
mice, were incubated with a range of concentrations of the cytokine. In vitro 
proliferation of cells was determined using .an SRB (sulforhodamine B) assay. 
As shown in figure 7.8, after 5 days of incubation with IFN-y, even at the very low dose, 
a strong decrease of the proliferation index of cells was observed in all the different cell 
lines. 
The strong inhibitory effect of this cytokine on the three different transgenic tumour 
cells suggest that induction of this cytostatic cytokine at the tumour site might represent 
at least one mechanism of action of the vaccine. 
7.9 SUMMARY 
The efficacy of vaccine obtained· by transduction of a mammary tumour cell line with 
the M tuberculosis Ag38 gene, was investigated in female mice transgenically 
expressing the rat HER-2/neu protooncogene. These mice spontaneously develop 
stochastic mammary tumours after a long latency period. 
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Fig. 7.8: Direct effect of IFN-y on proliferation of transgenic mice-derived tumour 
cell lines 
Effect of IFN-y on proliferation of N202.1A, N202.1E and TT3 tumour cells. 
Proliferation index is expressed as a percentage of absorbance in the absence of IFN-y. 
Data are mean± S.D. of quadruplicate determinations. 
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The onset of spontaneous mammary tumours w~s significantly delayed in mice 
vaccinated with Ag38-transduced cells, but not in mice vaccinated with non-transduced 
cells as compared with untreated mice. Protection from spontaneous tumour 
development was increased when mice were vaccinated with the mycobacterium-gene-
transduced vaccine plus a systemic administration of IL-12 at a low dose. Mice 
vaccinated with non-transduced cells plus IL-12 developed tumours, with only a slight 
delay in tumour appearance as compared with the control group. 
Lymphocytes obtained from lymph nodes of mice vaccinated with transduced cells 
secreted high levels of IFN-y. This secretion was not mainly dependent from a IL-12-
mediated stimulation. 
An activated CD3+ CD8+ T cell population was evoked in mice vaccinated with 
transduced cells. This population responded to tumour cells with IFN-y production, 
which was not specifically restricted to HER2/Neu oncoprotein expression. 
These data indicate the efficacy of a short-term protocol of vaccinations exploiting the 
adjuvant potency of a M tuberculosis gene and low doses of IL-12 in a model of 
stochastic development of mammary tumours. 
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CHAPTER EIGHT 
CHARACTERIZATION OF IMMUNE RESPONSE IN MICE 
PROTECTED FROM SPONTANEOUS MAMMARY CARCINOMA. 
Further analyses were performed to investigate the immunological effectors activated in 
protected mice. These studies were performed in two mice completely protected from 
spontaneous tumour development, gained as a result of the administration of Ag38-cell 
vaccine plus IL-12 as the most effective protocol. 
8.1 SEROLOGICAL RESPONSE 
Based on the results obtained in the melanoma model, it was of interest at first to 
evaluate whether an humoral response against tumour was induced in mice protected 
from spontaneous tumour development. 
All serum samples from mice in each experiment were collected after the second 
vaccination treatment with Ag38-transduced or non transduced cells, at different time 
during the tumour latency period and, in the case of mice completely protected, at 
different times till the end of the observation period. Sera from untreated mice were 
collected as control. 
Flow cytometry analysis was used to evaluate the presence in these sera of antibodies 
directed against antigens expressed on N202.1A mammary carcinoma cells. The 
analyses performed on some representative serum samples are shown in Fig 8.1. 
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Fig. 8.1: Humoral response against parental N202.1A cells in mice protected from 
spontaneous tumour 
Reactivity against N202.1A-associated antigens in some representative serum samples 
from mice vaccinated with Ag38-transduced cells plus IL-12 protected from tumour 
growth (N202.1A-Ag38+IL-12) or from not vaccinated mice (untreated). FACScan 
analysis was performed on N202.1A cells, incubated with serum diluted 1:10 and 
stained by an indirect method using goat FITC-anti-mouse IgG+IgM. Open areas 
indicate cells stained with secondary antibody alone 
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No significant increase in antibody titre directed against N202.1A-associated antigens 
was observed in sera of mice completely protected from tumour development neither 
immediately after vaccination nor during the period of the experiment. 
Therefore, unlike the situation observed in the melanoma model, m which mice 
protected froin parental tumour challenge developed a strong humoral response against 
tumour, in the spontaneous tumour model no production of antibodies directed against 
tumour cells was detectable. 
8.2 CELLULAR RESPONSE 
The activation of a cellular response was then evaluated. To this aim, spleen cells of the 
two .mice completely protected from tumour development were removed and cultured in 
vitro with stimulation of irradiated N202.1A tumour cells, IL-2 at low dose (25 U/ml) 
and syngeneic irradiated splenocytes (feeder cells). 
To select an activated population able to respond to the tumour, these cells were 
maintained in vitro for four weeks with weekly restimulations as above. 
Further analyses were therefore performed to characterise the cell population able to 
survive in this prolonged culture in vitro. 
8.2.1 Characterisation of in vitro long-survived cell population 
The proliferation activity of these cells in the presence of N202.1A tumour cells was 
determined. To this aim, cells were co-incubated for 72 hours with irradiated N202.1A 
tumour cells, IL-2 at low dose and with or without syngeneic irradiated splenocytes as 
feeder. Cultures were then pulsed with 3[H]thymidine and proliferation was estimated 
after 8 hours. Splenocytes obtained from naive mice were incubated in the same 
conditions and used as control. The result of the experiment is reported in table 8.1. 
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Cells from a Cells from a Control protected mouse protected mouse 
splenocytes (A) (B) 
Alone 16967 ± 2044 15797 ± 8499 9832 ± 938 
+Tumour 17841±727 10754 ± 1184 12920 ± 4906 
+Feeder and 83714 ± 13902 52309±1705 15955 ± 9014 Tumour 
Table 8.1: Proliferation of in vitro long-survived splenocytes from protected mice 
Proliferation of cells obtained from two protected mice, after in vitro re-stimulations 
with N202.1A tumour, IL-2 and feeder cells. Data, calculated as mean ± S.D. of 
triplicate determinations, represent [3H] Thymidine uptake ( cpm) of cells cultured alone, 
or in presence of N202.1A tumour cells, or in presence of N202.1A tumour cells and 
feeder cells. Proliferation activity of splenocytes obtained from a nai've mouse was 
evaluated as control. 
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As compared to control splenocytes, cells obtained from mice completely protected 
from spontaneous tumour showed a higher proliferation activity in the presence of 
feeder cells. 
These data, therefore, suggest that the activation of this tumour-responding population 
might be increased by the presence of a subset of immune cells, as a component of 
feeder cells. 
In vitro assays were then performed to investigate the cytotoxic activity of these cell 
populations against the tumour. After incubation with N202.1A tumour cells labelled 
with s1Cr, a standard 4-h s1Cr release assay was performed. 
No cytotoxic activity against tumour cells was detected (less than 6% of lysis 
percentage) in these conditions. . Therefore, the cell population derived from mice 
completely protected from spontaneous tumour were not able to lyse N202.1A tumour 
cells in vitro. 
The type of immune cell subset derived from protected mice was then investigated by 
F ACScan analyses. 
No Natural Killer (NK) cells were present in this immune cell-population, as revealed 
by a first analysis performed using an antibody directed against the NKI.1 surface 
antigen (Fig 8.2A) 
An analysis to evaluate the presence of activated CD4+ or CD8+ lymphocytes and their 
cytokine production was then performed. To this aim, five days after the weekly re-
stimulation, cells were cultured for 21 h with immobilised anti-CD3 mAb and 1 µM 
monensin, added for the last 12 h to inhibit protein transport. Surface marker and 
intracellular cytokine staining was performed using Cy-Chrome-labelled anti-CD8 or 
anti-CD4, FITC-anti-IFN-y and PE-anti-IL-4 mAbs. As shown in figure 8.2B, this 
analysis revealed the presence of mainly a CD3+ CD4+ population producing IL-4. 
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FL2-Height 
Fig. 8.2A: Characterisation of in vitro long-survived splenocytes by F ACScan 
analysis for the presence of NK cells 
Characterisation of splenocytes derived from mice protected from spontaneous 
mammary tumour and survived to prolonged in vitro culture in presence of N202.1A 
tumour cells. Flow cytometry analysis of cells stained with PE-anti-NKl. Open areas 
indicate cells stained with a PE- antibody isotype control. 
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Fig. 8.2B: Characterisation of in vitro long-survived splenocytes by FACScan 
analysis for the presence of CD4+ and CD8+ cells 
Characterisation of splenocytes derived from mice protected from spontaneous 
mammary tumour and exposed to prolonged in vitro culture in presence of N202. l A 
tumour cells. Flow cytometry analysis of cells stimulated with immobilised anti-CD3 
mAb, in the presence of monensin, and triple-stained with Cy-Chrome-anti-CD8 or Cy-
Chrome anti-CD4, PE-anti-IL-4 and FITC-anti-IFN-y mAbs. Analysis of cytokines 
production was performed setting a gate on CD8- (top) or CD4- (bottom) positive cells. 
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8.2.2 Inhibition of in vitro tumour growth 
The ability of this activated cell population to directly inhibit tumour growth through 
the release of inhibitory factor(s) was then evaluated. 
To this aim, the sensitivity of different transgenic tumour cell lines to supernatant 
obtained from culture of these CD3+CD4+ cells was analysed in vitro. Cultures of the 
three different tumour cell lines N202.1A, N202.1E and TT3, each derived from a 
mammary carcinoma spontaneously grown in FVB-neuN transgenic mice, were 
incubated with supernatant diluted 1 :2 recovered three days after the weekly re-
stimulation of CD3+CD4+ culture. After four days of incubation, in vitro proliferation of 
cells was determined using an SRB ( sulforhodamine B) assay. 
As shown in figure 8.3, a decrease, which was very strong in N202.1A and TT3 cells, 
of the proliferation index was observed in all three transgenic cell lines, while no 
inhibition was detected in the growth of an unrelated murine control cell line. 
As with other cytokines, IL-4 has been reported to inhibit proliferation of some tumour 
cell lines (Burke et al., 1999; Gooch et al., 1998). Therefore, since, as revealed by 
F ACS can analysis, this cell population produced IL-4, it was investigated whether the 
inhibitory effect observed on the growth of transgenic tumour cells was mediated by 
this cytokine. 
As shown in figure 8.4, a SRB assay performed after incubation ofN202.1A cells in the 
presence of IL-4 did not reveal any inhibitory effect, even at high dose. 
Therefore, the CD3+CD4+ cell population was demonstrated to directly inhibit in vitro 
tumour growth through the release of inhibitory factor(s). This inhibition was not 
mediated by the release ofIL-4. 
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Fig. 8.3: Inhibition of in vitro tumour growth by supernatant of long-survived 
splenocytes 
A representative experiment showing the sensitivity of N202.1 A, N202.1 E, TT3 and 
B 16 tumour cells to supernatant obtained from culture of CD3+CD4+ cell population, 
diluted 1 :2 (Sup 1 :2). Proliferation index is expressed as a percentage of absorbance in 
the presence of medium alone (Medium). Data are mean ± S.D. of quadruplicate 
determinations. 
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Fig. 8.4: Direct effect of IL-4 on proliferation of N202.1A cell line 
Effect of IL-4 on proliferation of N202.1A tumour cells. Proliferation index is 
expressed as a percentage of absorbance in the absence of IL-4. Data are mean± S.D. of 
quadruplicate determinations. 
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8.2.3 Passive transfer of immunity (Winn test) 
In view of the inhibition of in vitro tumour growth observed in the study above, an 
experiment was then performed to evaluate whether the activated CD4+ T cell 
population transferred in vivo in mice could be able to protect from a tumour challenge. 
After expansion of the culture, CD4+ T cells were subcutaneously injected to naive 
animals mixed with live N202.1A tumour cells. A control group received an injection of 
N202.1 A cells in the presence of splenocytes obtained from a naive mouse in vivo 
depleted of the CD8 T cell population (Fig. 8.5) and in vitro depleted of adherent cells 
by passage over a nylon wool column. Four FVBNeuN mice were treated in each group 
and a ratio of 30:1 between immune cells (3x106) and live tumour cells (lx105) was 
administered in each animal. Mice were then monitored for the development of a 
subcutaneous tumour at the site of injection. 
As shown in Figure 8.6, no differences were observed in the development of tumour 
mass between mice injected with activated CD4+ T cells and control mice injected with 
CDS-depleted splenocytes. No differences in the number of tumour-infiltrating 
lymphocytes were also detected by histologic evaluation between the two groups of 
mice (data not shown). 
8.3 SUMMARY 
The immunological effectors activated in mice protected from spontaneous mammary 
tumour development were investigated. No production of antibodies directed against 
tumour cells was detectable, while a cell population able to survive to in vitro culture 
was derived from these mice. These immune cells, able to· proliferate in the presence of 
tumour cells and lacking an in vitro cytotoxic activity, were characterised as CD4+ T 
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Fig. 8.5: FACScan analysis of in vivo CDS-depleted splenocytes 
FACScan analysis with murme FITC-anti-CD8 antibody on splenocytes from 
FVBNeuN mice depleted of CD8+ T lymphocytes (overlay) or non-depleted control 
mice (filled), performed to verify the depletion of the appropriate subset 
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Fig. 8.6: Passive transfer of immunity (Winn test) 
~Female #1 
-o-Male #2 
-o-Male #3 
----o- Male #4 
-o-Male #5 
-o-Male #6 
~Female#7 
----o- Male #8 
Growth of subcutaneous injected N202.1A tumour in mice transferred with the CD4+ T 
cell population (treated) and in mice transferred with control cells (control). Four mice, 
3 males and 1 female, were treated in each group. 
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cells producing IL-4. A direct inhibition on the growth of FVBNeuN transgenic tumour 
cell lines mediated by the release of inhibitory factor(s) was observed in vitro. This 
effect was not mediated by the release of IL-4, since this cytokine did not inhibit the in 
vitro growth of the transgenic tumour cell lines. 
However, this cell population transferred in vivo in mice failed to protect against a 
subcutaneous tumour challenge. 
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CHAPTER NINE 
DISCUSSION 
The identification in murine and human tumours of various antigens representing 
different histiotypes that serve a,s potential targets for an immune response, has provided 
an opportunity to develop new, and hopefully more effective, anticancer therapies. 
These antigens, derived from endogenously synthesised proteins, are seen as foreign by 
the host, either as a consequence of mutations that arise during malignant 
transformation or because they represent gene products not normally expressed in adult 
tissues. 
The immune system is capable of recognising and responding to tumours via several 
effector mechanisms. Among these different mechanisms, the CTL response seems to 
be the most important; indeed, some data demonstrate that CTLs can be generated 
which specifically recognise tumour antigens presented on the cell surface together with 
MHC class I molecules. However, generally the CD8+ T cell response is likely to be 
inadequate, and strategies for active immunotherapy must attempt to recruit alternate 
cytolytic effector cells (Pardoll, 1996). 
Mitchinson (1970) hypothesised that the combination of poorly antigenic and highly 
antigenic determinants on a common carrier would augment the immune response 
toward the poorly antigenic determinants by. stimulating immune recognition (Kim et 
al., 1992). On the basis of this theory, the thesis explores the use of a gene encoding an 
highly antigenic protein, transduced in tumour cells, in increasing the immune response 
against weak tumour antigens. 
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9.1 TUMOUR MODELS 
I chose to study two murine tumour models which, like human tumours, although they 
express tumour antigens demonstrated poor immunogenicity. Immunogenicity refers to 
the ability of a tumour to elicit an immune response against itself, that can be evaluated 
by resistance against a challenge with live tumour cells following vaccination with 
irradiated tumour cells. 
The first tumour chosen, B 16 murine melanoma, expresses different tissue-specific 
differentiation antigens (Figure 5.8). These antigens correspond to those expressed on 
human melanoma, which have been reported to represent potential targets for an 
immune response in patients. Moreover, like many advanced tumours and metastases in 
humans, murine B 16 melanoma express very low level of MHC class I antigens. 
As a second tumour model, I have chosen a mammary carcinoma tumour that 
spontaneously grows in HER2/neu transgenic mice. This tumour, although expressing 
the potential antigenic target HER2/neu oncoprotein, demonstrated a poor 
immunogenicity. About 30% of human breast carcinomas overexpress HER2 
oncoprotein. An antibody response specifically directed against HER2 oncoprotein has 
been detected in some human breast carcinoma patients (Pupa et al., 1993; Disis et al., 
1997); however the majority of patients seem to be tolerant to the antigen. 
Under the experimental conditions used in this thesis to evaluate protection against 
melanoma or spontaneous mammary carcinoma by vaccination with tumour ·cells, 
parental B16 and N202.1A ".ells show a very poor immunogenicity. Indeed, the majority 
of mice vaccinated with parental irradiated cells developed tumours (Figure 4.2 and 7.2) 
with not significant difference when compared to control not vaccinated mice. 
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9.2 GENE TRANSFER AND EXPRESSION OF AG38 MOLECULE IN 
TUMOUR CELLS 
In an effort to elicit an immune response against tumour antigens, I decided to transduce 
tumour cells with a gene of Mycobacterium tuberculosis. In less than a decade the 
archetypal view that the immune system exists primarily to distinguish "self' from 
"non-self' has been replaced by the paradigm that the immune system functions 
primarily to distinguish "dangerous" from "non-dangerous" antigens (Matzinger, 1994). 
Presumably the immune system has evolved over millions of years to respond to 
bacteria with a rapid activation of defences that are best suited to fight microbial 
infection. Because Mycobacterium tuberculosis is a major target in this fight, 
mycobacterial molecules are promising candidates to be used as adjuvants for the 
development of effective therapeutic or prophylactic tumour vaccines. The immune 
response elicited by mycobacteria might facilitate activation of the immune system 
against tumour antigens and result in the eventual selective destruction of tumour cells 
through a specific immune response. Indeed studies on complete Freund' s adjuvant 
(CF A) indicate that mycobacteria contain several substances that stimulate the immune 
response and promote Thl differentiation (Forsthuber et al., 1996). Moreover, studies in 
different countries have shown . that neonatal Bacillus Calmette-Guerin (BCG) 
vaccination confers some degree of protection against leukaemia and other childhood 
cancers (Grange et al., 1995) and recently a significant reduction in melanoma risk in 
people vaccinated with vaccinia virus or BCG was reported (Koelmel et al, 2000). 
However, the use of BCG as immunoadjuvant in patients with different cancer types has 
produced variable results (Grange et al., 1995). Such variable results are also observed 
when BCG is used in vaccination against tuberculosis (Fine PEM, 1994). There is some 
evidence that a similar mechanism underlies the efficacy of BCG in therapy and in 
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prophylaxis against tuberculosis and tumour prevention (Grange et al., 1990). The BCG 
efficacy appears to depend o·n whether a predominant Thl- or a Th2-type cytokine 
secretion pattern is induced. Several findings, indeed, have suggested that protective 
immunity to infection is associated with pronounced Thl lymphocyte expansion and 
activity with increased production of cytokines typical of this subset. Conversely the 
enhancement of Th2 function is associated with decreased Thl activity and progression 
of disease or infection (Heinze! et al., 1989; Pearce et al., 1991 ). 
One hypothesis for these conflicting results is that BCG could contain both substances 
able to induce a protective immune response and substances which stimulate the 
secretion of immunosuppressive cytokines depending on dose, schedule and the 
individual subject (Fine et al., 1990). Therefore I postulated that using a product of a 
single gene, instead of the whole bacillus, it might be possible to enhance Thl cell 
maturation pathway, avoiding the suppressive effects observed in some patients using 
the whole bacillus. 
To create the cell vaccine I chose the Mycobacterlum tuberculosis Ag38 gene. Indeed, 
the 3 8 kDa antigen is known to be an immunodominant antigen during the development 
of the immune effector mechanism against tuberculosis (Kadival et al., 1987; Verbon et 
al., 1992). This antigen has been demonstrated to evoke the generation of a Thl-type 
response preferentially, as revealed by the secretion of Thl-like lymphokines (IL-2 and 
IFN-y) and by the preferential production of 38 kDa specific IgG2a-type antibody 
(Agrewala et al., 1995). 
Furthermore, analysis of Ag38 gene sequence revealed the presence of 14 CpG motifs, 8 
of which are maintained· in the open reading frame region used to transduce tumour 
cells (Fig. 3 .1 ). CpG motifs, consisting of CpG dinucleotides within specific flanking 
bases, are under-represented and selectively methylated in vertebrate DNA, but are 
present at higher frequency and unmethylated in bacterial DNA. DNA containing these 
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motifs has been reported to induce a rapid direct activation of macrophages to secrete 
IL-12 (Krieg et al., 1998), resulting in the final activation of a Thl-type immune 
response. 
To transduce this gene in tumour cells, I initially chose a PRC/CMV eukaryotic vector 
and conventional transfection strategies. As compared to the use of vectors based on 
retroviruses, I considered these strategies likely to be safer in the context of their use in 
humans. Indeed, although retroviral vectors are extraordinarily efficient gene delivery 
vehicles, the inadvertent production of replication-competent retroviruses and the 
possibility of insertional mutagenesis due to their integration in the eukaryotic gen.ome, 
even if these are very unlikely events, may limit their application in humans. However, 
using the conventional strategies, I failed to achieve good results. Not only were tumour 
cells expressing the bacterial protein obtained with a low efficiency but also the 
expression of the bacterial product in transfected tumour cells was low and very 
unstable (data not shown). 
As a consequence of these preliminary studies a retroviral vector, modified to express 
the· leader and transmembrane portion of Nerve Growth Factor Receptor (NGFR) and 
the stop codon region of human IL-3, was then constructed for my purpose. This 
modification resulted in the transduction of tumour cells with high efficiency and 
resulted in the stable expression of Ag3 8 bacterial protein in both tumour models. 
Furthermore, due to the presence of the NGFR transmembrane sequence, Ag38 protein 
was expressed on the tumour cell surface, allowing me to detect and tag transduced 
cells. 
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9.3 AG38 TRANSDUCTION IN THE VACCINATION AGAINST 
MELANOMA 
At a dose of· 2.5xl05 cells, which induced the subcutaneous growth of tumour in 100% 
of mice injected with parental cells, only 60 % of mice injected with Ag38-transduced 
cells developed tumours (Fig. 4.1 ). Moreover, compared to parental cells, I observed a 
delay in the appearance of tumour and no metastases developed during the observation 
period. 
Significant protection against tumour growth after subcutaneous or intravenous 
injection of parental melanoma tumour cells has been observed in mice vaccinated with 
Ag38-transduced melanoma cells. Indeed, as an overall result from all the experiments 
performed, it was observed that 80 % of mice injected subcutaneously were completely 
protected from tumour growth and 20-30 % of mice intravenously injected failed to 
develop lung metastases. Moreover, a response to Ag38-cell vaccine was also observed 
in mice which developed tumours, since in these mice the onset of tumour growth, as 
well as the mortality, was delayed in comparison with non-immune animals and animals 
immunise with non-transduced-cells (Fig. 4.2 and 4.3). 
Regarding the immune mechanism induced by the vaccine, the presence of Ag3 8 
protein does not seem to work as a chaperone molecule by influencing the ability of 
melanoma cells to present endogenous antigens, as has been observed using tumour 
cells transduced with mycobacterial genes encoding heat-shock protein (HSP). Indeed, 
vaccination with tumour cells transduced with HSP 65 from Mycobacterium leprae 
(Lukacs, 1993) and Mycobacterium bovis (Schweighoffer, 1996) has been reported to 
achieve enhancement of the immune response against tumour antigens, by enhancing 
the expression of MHC class I surface antigens. The HSPs are molecular chaperones 
that mediate the assembly and folding of other proteins (Hartl, 1996). 
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They are also associated in vivo with the entire repertoire of peptides generated within 
the cell, and these non-covalent HSP-peptide complexes are particularly immunogenic 
(Blachere et al., 1995). The B 16 cell lines used in this thesis express very low or · 
undetectable levels of MHC class I antigens in vitro. No increase in the expression of 
MHC class I molecules has detected after transduction of the Ag38 gene into melanoma 
cells (data not shown). Therefore, the effect of Ag38 in this context differs from that 
observed using HSP 65. 
Vaccination with Ag38-transduced melanoma cells induced a preferential Thl response 
(Tab 4.1) The induction of a Thl cytokine secretion pattern by endogenously expressed 
mycobacterial antigen is consistent with results reported by Huygen et al. (Huygen et 
al., 1996) and Zhu et al (Zhu et al., 1997) who, in their studies on tuberculosis vaccines, 
showed that vaccinations with plasmid DNA constructs encoding the 85T or Ag38 
Mycobacterium tuberculosis antigens are a powerful approach to generate a specific 
helper response with a Thl-like phenotype. A Thl-type response might be important in 
the control of tumour growth. Indeed, a Thl response may be effective in activating NK 
cells, cytotoxic T lymphocytes and tumouricidal macrophages, thus increasing the 
killing of tumour cells (Sredni et al., 1996). 
The induction of a Thl-type response might depend on more than one factor. For 
example both the expression on the tumour cell surface of the strong mycobacterial 
antigen and the presence of CpG immunostimulatory motifs in the Ag3 8 encoding gene. 
The presence of mycobacterial protein on the cell surface of irradiated tumour cells can 
improve their uptake by activated antigen-presenting cells (APC), which might 
introduce endocytosed-tumour antigens into both the MHC class II and class I 
processing pathways, effecting cross-priming with weak tumour antigens (Gromme et 
al., 1999; Heath et al., 1999). The· CpG motifs flanked 5' by two purines and 3' by two 
pyrimidines have a potent immunostimulatory activity. Prokaryotic and vertebrate DNA 
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differ in the relative abundance of CpG-dinucleotides and the degree of cytosine 
methylation raising the possibility that these structural differences are used by immune 
cells to discriminate pathogen-derived "dangerous", from "self', DNA. Bacterial DNA 
containing CpG-sequences has been observed to activate antigen-presenting cells 
(APCs) such as macrophages and dendritic cells (Zimmermann et al., 1998; Pisetsky, 
1997; Sparwasser et al., 1997; Sparwasser et al., 1997; Sparwasser et al., 1998) upon 
DNA endosomal uptake, resulting within minutes in activation of the stress kinase 
pathways (Hacker et al., 1998) and NF-kB (Sparwasser et al., 1997; Stacey et al., 1996). 
As a consequence APCs produce cytokines, including IL-12, IL-6, IL-1 and TNF-a, and 
upregulate co-receptor molecules (Sparwasser et al., 1998). Recent work has 
demonstrated the powerful adjuvant effect of CpG-ODNs, which can be used to trigger 
protective and curative Thl responses in vivo (Zimmermann et al., 1998; Lipford et al., 
1997; Lipford et al., 1997; Chu et al., 1997). Therefore, the strong immune response 
against mycobacterial epitopes and CpG motifs might create a microenvironment highly 
concentrated for cytokines, which promotes the activation of minor clonotypes directed 
against weak tumour antigens. In this hypothesis the Ag38 gene might play the role of 
adjuvant, increasing the immune activation and promoting the recognition of poorly 
immunogenic tumour cell. antigens, finally resulting in a specific anti-tumour immune 
response. The property of allowing the recognition of the poorly immunogenic murine 
melanoma B 16 seems to be a characteristic of bacterial products, since vaccination with 
ovalbumin-transfected melanoma does not induce a protective response to non-
transfected parental melanoma B 16 (Fala, Jr. et al., 1995). 
The expansion of clonotypes directed against tumour antigens induced by vaccination 
might promote a rapid immune response against the live non-transduced tumour 
administered after vaccinations. A concerted response involving the activation of 
different populations of immunocytes has to be postulated. Indeed, the depletion of CD8 
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T lymphocytes evaluated in the in vivo experiment (Figure 4.4) did not reduce the 
protection induced by vaccination with transduced cells. 
Mice vaccinated twice with irradiated transduced B 16 cells exhibit low serum antibody 
titres. However, mice immunised with transduced B 16 cells and protected from 
challenge with parental B 16 melanoma cells showed a strong humoral response against 
the parental cell antigens which was detectable at serum dilutions up to 1 : 1000 (Fig. 
5.3). Most of these antibodies were of an IgG2a isotype, which represents the main IFN-
y- dependent isotype in mice (Fig. 5.4) (Snapper et al., 1993). Therefore, the prevalent 
isotype observed during the humoral response after challenge with viable cells is 
consistent with the Thl-type response induced by the vaccine. 
A positive contribution of antibodies to tumour protection was indicated by in vitro 
results showing that antibodies present in the sera of mice surviving the challenge 
mediated cytotoxic effects· on parental melanoma cells through complement activation. 
Moreover, in vivo passive immunisation with a pool of sera from protected mice 
resulted in a decrease in the number of experimental B16 lung metastases (Fig. 5.5 and 
5.6). These findings, although obtained in a small number of mice, suggested the 
possible involvement of antibodies in tumour protection, but do not exclude a role for 
cytotoxic T cells. As the cellular and humoral immune systems work in concert, it 
would be surprising if cancer-associated antigens would induce only a cellular or 
humoral response. Indeed, in humans the frequency of CTL precursors specific for 
melanoma antigens has been observed to be usually very low ( <1/105). Therefore, in 
patients immunised with tumour antigens a CTL response has been detected only after 
in vitro expansion of specific T cells by 1 to 3 restimulations with specific antigen 
(Kawakami et al., 1998). The serological response of the mice was directed 
predominantly to products encoded by endogenous murine leukaemia viruses (Fig. 5.11, 
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5.12). These findings, in light of the high levels of viruses expressed on viable B16 cells 
(Li et al., 1998), are consistent with previous data (Leong et al., 1988). 
A serological response against TRP-2, the antigen found by screening a cDNA library 
from B 16 to be the major target recognised by tumour-reactive T cell clones (Bloom et 
al., .1997), has not been detected (Fig. 5.14, 5.15 and 5.16). Moreover, with in the 
limitations of Western blot analysis, no antibodies directed against other melanocyte 
lineage-specific antigens, such as tyrosinase, TRP-1 and gplOO, were found (Fig. 5.17) .. 
However, it cannot be excluded that the presence of low amount of antibodies against 
these antigens might be detectable by serological analysis of recombinant cDNA 
expression libraries (SEREX) of B 16 melanoma cells using immune serum (Sahin et al., 
1995). Since the presence of antibodies against melanocyte lineage-specific antigens has 
been observed in some melanoma patients (Huang et al., 1998; Okamoto et al., 1998), it 
is plausible that, in the B 16 murine model, their immune recognition is inhibited or 
masked by the presence of viral antigens. 
In order to enhance the anti-tumour immune response, the effect of re-administration of 
irradiated transduced tumour cells (recall) in vaccinated mice immediately after tumour 
challenge was evaluated. Although this study constituted only a single experiment, it 
provided an unexpected result. Thus a detrimental effect was observed during this 
experiment, since a reduction of tumour protection . induced by vaccination was 
observed (Fig. 6.4). The mechanism to explain the adverse effect of re-administration of 
the vaccine after tumour challenge was not investigated. 
Irradiated Ag38-transduced cells administered three times, on days + 1, +8 and + 15 from 
tumour challenge, did not have a therapeutic effect on existing tumour (Fig. 6.5). The 
ability of cancer vaccines to cure existing tumours has been intensively investigated, but 
with limited successes. In most studies, only a minority of tumour-bearing mice were 
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cured, and this limited efficacy was achieved solely when the vaccine was administered 
in the. first few days after challenge (Cavallo et al., 1997). This limited efficacy in 
curing existing tumours is thought to rest primarily in inadequate penetration of tumour· 
mass by the immune cells and in the escape of some tumour cell progeny from the 
immune response. Moreover, presumably, the rapid replication of the live injected 
tumour cells in the experimental models leads to the death of mice before the activation 
of an efficient immune response. 
Different vaccination strategies based on the use of fractions of materials derived from 
Mycobacterium tuberculosis, administered as a general immunostimulant or as an 
adjuvant together with tumour cells, have been evaluated and compared to the use of the 
Ag3 8-expressing cellular vaccine. 
Recombinant Ag38 protein was administered exogenously in incomplete Freund's 
adjuvant or, in order to maintain the protein in the same context of melanoma antigens, 
in the presence of irradiated non-transduced melanoma cells. A low protection against 
tumour challenge was induced by these vaccination treatments (Fig. 6.1 ). The 
administration of DNA plasmid encoding the Ag3 8 antigen was evaluated as an 
alternative strategy. A very low protection against tumour challenge was induced by this 
vaccination (Fig. 6.2). Administration of whole live Bacillus Calmette-Guerin as an 
immunostimulant was also evaluated. A delay in tumour growth was induced in mice 
immunised with BCG before the tumour challenge, as compared to control mice which 
received only tumour challenge (Fig. 6.3). However, the level of protection observed in 
these experiments was less than that evoked by vaccination with Ag38-transduced cells. 
It is plausible that, using a tumour cell endogenously expressing the mycobacterial 
protein, a response against the tumour cell antigens expressed in the same context might 
also be increased, thus resulting in a more selective destruction of tumour cells. 
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9.4 AG38 TRANSDUCTION IN VACCINATION AGAINST A MAMMARY 
CARCINOMA SPONTANEOUSLY GROWING IN TRANSGENIC MICE 
The recent discovery of gene mutations that predispose to cancer now enables 
identification of at-risk individuals with a defined genetic prognosis (Jonsen et al., 
1996). The goal of vaccination in such individuals is the recruitment of the immune 
system to eliminate single transformed cells before tumour nodules develop. In this 
thesis the efficacy of the Ag38-cancer vaccine was evaluated in proto-neu transgenic 
mice. In this strain, the expression of proto-neu induces the development of spontaneous 
focal mammary tumours in all females (Guy et al., 1992) although the stochastic 
development of the tumours and the long latency period indicate the requirement for 
additional events in tumour formation. 
Vaccination of proto-neu transgenic mice with M tuberculosis Ag38-transduced tumour 
cells resulted in a significant delay in tumour onset (Fig. 7.1 and 7.2). Consistent with 
previous data obtained in the experimental melanoma tumour model, endogenously 
expressed· mycobacterial antigen in tumour cell vaccine induced a preferential Thl 
response (Fig. 7.4 ). 
As reported above, the DNA of the M tuberculosis Ag38 gene used for transduction 
contains 8 CpG motifs. Such CpG DNA motifs have been shown to activate monocytes 
and macrophages directly to secrete cytokines, especially IL-12 (Klinman et al., 1996; 
Krieg et al., 1998; Chu et al., 1997). Consistent with these findings, I found detectable 
levels of serum IL-12 in two of five mice after vaccination with M tuberculosis-
transduced (data not shown). It was investigated whether a systemic co-administration 
of rIL-12 together with the non-transduced tumour cells could induce the same anti-
tumour response observed using the transduced tumour cell vaccine. Indeed, an 
adjuvant effect of IL-12, with induction of protective cell-mediated immunity, in a · 
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vaccine against Leishmania has been Qescribed (Afonso et al., 1994), as well as an 
increa~e in both humoral and cell-mediated immune responses in a vaccine against 
schistosomes (Wynn et al., 1996). In oncology, used alone, IL-12 has been shown to be 
effective against many murine tumours (Brunda et al., 1993; Rodolfo et al., 1996). In 
proto-neu-transgenic mice, Boggio et al (Boggio et al., 1998) found that prolonged 
administration of IL-12 delayed tumour onset and reduced tumour multiplicity in 
association with deficient peri- and intra-tumoural angiogenesis and infiltration of 
reactive cells. IL-12 showed anti-tumour activity when systemically administered after 
tumour challenge in mice vaccinated with IL-2 gene-transduced cells or in mice 
vaccinated with B7 costimulatory molecule-expressing tumour cells (Vagliani et al., 
1996; Coughlin et al., 1995; Zitvogel et al., 1996). Recently, an adjuvant effect oflL-12 
on vaccination with irradiated SCK tumour cells engineered to secrete 
granulocyte/macrophage colony-stimulating factor, has also been reported (Kurzawa et 
al., 1998). 
I observed that immunisation with non-transduced tumour cells plus rIL-12 induced just 
a slight delay in tumour onset without the recruitment of anti-tumour T cells, suggesting 
that the anti-tumour response involves more than an enhancement of immunity signaled 
by the CpG motif (Fig. 7.3). Consistent with this observation data, obtained by Roman 
et al (Roman et al., 1997) using bacterial immunomodulatory DNA sequences, showed 
that these sequences activate the precise cytokine network required to induce an initial 
burst of IFN-y in an antigen-independent fashion. In the presence of a protein antigen, 
the differentiation of naive CD4+ T cells toward Thl phenotype can be promoted, 
leading to a second burst oflFN-y production, this time in an antigen dependent fashion. 
However, when I administered the recombinant murine IL-12 together with transduced 
tumour cells, I observed an enhanced effect. Indeed, a clear and significant delay in 
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tumour onset with 2 out of 12 immunised remaining tumour-free was observed at the 
end of the observation period (Fig. 7.3). 
In agreement with the preferential Thl response induced by Ag38-transduced cell 
vaccine, a population of CD3+CD8+ lymphocytes producing IFN~y have been derived 
from spleen cells of vaccinated mice, which were able to proliferate in vitro in the 
presence of tumour cells (Fig. 7.6). These CD3+CD8+ lymphocytes produced IFN-y in 
response to the recognition ofN202.lA tumour cells. However, this production was not 
restricted to the recognition of HER2/neu oncoprotein, expressed on N202.1 A cells, 
since IFN-y production was detectable also in the presence of the non-HER2/neu 
expressing N202.1E cell line (Fig. 7.7). 
The production oflFN-y by the CD3+CD8+ lymphocytes and the strong inhibitory effect 
of this cytokine on the three different transgenic tumour cell lines suggest that induction 
of this cytostatic cytokine at the tumour site might represent at least one of the 
mechanism of action of the vaccine (Fig. 7.8). 
The administration of an anti-IL-12 antibody did not significantly change IFN-y 
production induced by vaccination with Ag38-transduced cells, indicating that 
additional factors related to Ag38 expression are responsible for the greater level of 
IFN-y observed (Fig. 7.5). 
Vaccination with transduced N202.1A tumour cells did not induce an humoral response 
against the vaccine. Moreover, unlike the situation observed in the melanoma model, in 
which a strong humoral response was detectable after challenge, no difference in the 
antibody profile was found between mice that developed spontaneous tumours and mice 
which were protected (Fig. 8.1). 
A cell population able· to respond and to proliferate in the presence of the tumour was 
derived from the spleens of the two mice completely protected from tumour 
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development. These cells passively transferred in vivo in the presence of tumour cells 
did not shown any inhibitory activity on tumour growth (Fig. 8.6). The ability to 
actively proliferate in vitro was a peculiarity only of spleen cells derived from these 
mice. Indeed, spleen cells derived from vaccinated mice which developed tumours were 
able to survive in in vitro culture for some weeks, but did not show an active 
proliferation, while spleen cells derived from unvaccinated mice did not completely 
respond to the tumour and survived in vitro at the most 2 weeks. 
FACScan analysis indicated that these cells were CD4+ T cells and, surprisingly, they 
produced IL-4 (Fig. 8.2B). The presence of cells producing a cytokine representative of 
a Th2 type subset in protected animals is apparently in contrast with the opposed Thl 
phenotype observed in these mice immediately after vaccination. However, recent 
evidence has been derived which is opposed to the idea of an extreme separation 
between a Thl status, as identified by IFN-y production, and a Th2 status, as identified 
by IL-4 production. It is likely that regulatory systems exist to maintain a more 
appropriately balanced cytokine response which involves the simultaneous activation of 
both-types of regulatory cytokines. For example, a recent study by Hochrein et al 
(Hochrein et al., 2000) describes a feedback system mediated by IL-4. As well as the 
well-established positive feedback by which IL-4, as a Th2 cytokine, directly promotes 
Th2 differentiation from ThO cells, these authors have found that IL-4 also has the 
potential to promote Thl differentiation. This is an indirect effect via the action of IL-4 
on dendritic cells to enhance the production and bioactivity of IL-12, the major Thl-
inducing cytokine. Moreover, Klugewitz et al (Klugewitz et al., 2000) recently decribed 
a model of vaccination using the tumour-specific large T antigen against a murine 
kidney sarcoma, which induces a protective immunity dependent both on CDS+ 
cytotoxic and on CD4+ T-helper cells. These authors reported that the phenotype 
analysis of the CD4+ T cells showed a general increase, as response to vaccination, both 
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in Thl and Th2 cells and an increase in percentage of IL-4 producing cells only in 
vaccinated mice which rejected the tumour. It is not unlikely that the presence of 
increased CD4+ T cells producing IL-4 is important for the maintenance of a tumour-
specific CTL response (Santra et al., 1997) and of antigen-inducible IFN-y expression 
among CD8+ T cells in animals protected from tumour growth. 
Consistent with these data, it has recently been reported on the identification of a 
melanoma-specific CD4+ T cell clonal subset with a Thl cytokine profile but releasing 
high amounts of IL- I 0 (Rivoltini et al. 2000). Since cells with such immunological 
features have been found to be present with high frequency in long-term surviving 
melanoma patients, it has been proposed that they are likely to play a role in mediating 
an effective long-lasting immunological control of tumour growth in vivo. 
I observed that inhibitory factors released by the CD4+ T cell population specifically 
inhibited the in vitro growth of different transgenic tumour cell lines (Fig. 8.3). This 
inhibition was not due to the release of IL-4, since this cytokine did not reveal any 
inhibitory effect on the growth of a transgenic cell line (Fig. 8.4). This inhibition 
apparently did not seem to be due to the eventual production of toxic factors in the 
conditioning of the in vitro culture of lymphocytes, since supernatant obtained by the 
culture of control spleen cells from untreated mice, maintained under the same 
conditions, did not reveal any toxicity. Therefore, it could be postulated that this effect 
might be rµediated by other cytokines released by CD4+ T cells. Unfortunately I was not 
able to investigate this issue during this thesis, because of the difficulty of obtaining 
large amounts of supernatant from the lymphocyte cultures, which were maintained in 
wells of small size and at high concentration. Moreover, at the end of my work I 
observed some alterations in the characteristics of these lymphocytes, probably due to 
the prolonged in vitro culture, such as the loss of dependence for their growth on the 
continued presence of tumour cells. 
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9.5 CONCLUSION: ADVANTAGES AND DISADVANTAGES OF THE 
APPROACH 
Most investigations in the field of cancer gene therapy have· been related to the 
antitumour effect of cancer vaccines with transfected cytokine genes, maJor 
histocompatibility antigens and co-stimulatory molecules (Drano ff et al., 1995; 
Porgador et al., 1995; Townsend et al., 1993). Some of these engineered tumour cells 
provide cytokines that bypass the need for helper cells, while the other modified tumour 
cells provide major histocompatibility molecules or co-stimulatory signals for direct 
stimulation of CD8 T cells or CD4 T cells. 
Another approach to stimulating an immune response against tumours, based on 
transduction of a bacterial gene which represents a danger signal, has been evaluated in 
this thesis. Indeed, the immune response normally involves the integrated production of 
a variety of cytokines and the activation of different cell subsets that work in concert 
both locally and systemically. I reasoned that an enhancement of tumour immunity may 
be most effective if I used agents that can orchestrate the immune response, including 
cytokine production and cellular activation simultaneously, in a manner that reflects 
physiological responses. Furthermore, the activation of innate immune mechanisms, 
mediated by bacterial molecules, might induce a more prompt and rapid anti-tumour 
response. Compared to other strategies, such as transduction of cytokine genes or 
costimulatory genes, the use of bacterial genes might induce a wider and more 
physiological immune response. 
In the light of the pivotal role of M tuberculosis genes and their encoded proteins in 
linking innate and cell mediated adaptive immunity, these bacterial substances are 
promising candidates to be used as adjuvants for the development of effective 
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therapeutic or prophylactic tumour vaccines. Indeed, as above described, neonatal 
bacillus Calmette-Guerin (BCG) vaccination has been demonstrated to confer protection 
against leukaemia and other childhood cancers (Grange et al., 1995), and recently a 
significant reduction in melanoma risk in people vaccinated with vaccinia virus or BCG 
was reported (Koelmel et al, 2000). These findings suggest that oncologic disease can 
be prevented by immunologic means but without a specific immunisation. The proposed 
bacterial transduced immunisation procedure could potentially be used for prevention in 
high-risk patients and in an adjuvant setting after surgery. 
An important peculiarity of the vaccination protocol analysed in this thesis is that the 
protection is induced in mice by injections of irradiated tumour cells. This characteristic 
allows the translation of this vaccination protocol to human patients, in which the use of 
non-replicating tumour cells is mandatory. On the contrary, other approaches often 
require, to induce an efficient response, the administration of live engineered cells and a 
major number of injections. For example, it has been reported that B7-expressing 
tumour cells lose their ability to elicit systemic immunity on irradiation (Townsend et 
al., 1994; Cayeux et al., 1996; Katsanis et al., 1996). Other studies have shown that live 
cytokine-secreting tumour cells were superior to irradiated tumour cells in generating 
protective immunity. Most likely, irradiated non-replicating cells secrete a too limited 
amount of cytokine before dying. For example, it has been demonstrated by Drano ff et 
al (Dranoff et al., 1993) that irradiated B 16 cells transduced to express either IL2, IL4, 
IL5, IL6, TNF or IFNy failed to induce immunity to subsequent challenge with live 
parental B 16 cells. A specific anti-tumour immunity was observed only using irradiated 
B16 cells transduced to express GM-CSF (Dranoff et al., 1993). 
As with other transduced vaccines, when translated into the human application, some 
disadvantages limited the applicability of the strategy as designed in this thesis. The 
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creation of a cell vaccine based on transduction of the mycobacterial gene in tumour 
cells requires patient's cultured cells, transduction with problematic vectors, labor-
intense development for scale-up to treat large number of patients. All these 
requirements are expensive, time-consuming and restricted to only a few oncologic 
centres. 
9.6 SUMMARY 
In an effort to increase immunogenicity of the recipient tumour, the Mycobacterium 
tuberculosis Ag38 gene has been transduced in tumour cells. Transduced cells have 
been used as a cellular vaccine and their ability to elicit an anti-tumour response has 
been evaluated against both a transplanted tumour model and against a spontaneous 
tumour model. Protection against both tumours has been observed after only two 
vaccinations with irradiated transduced cells. 
In both models, vaccination with transduced cells induced a preferential Thl response. 
In mice protected from transplanted melanoma tumour growth, a strong humoral 
response against tumour antigens with a prevalent Thi-dependent isotype was observed. 
This response was directed predominantly against endogenous retroviral antigens. 
No hum oral response was induced in mice protected from spontaneous mammary 
carcinoma development, while an activated CD4+ T cell population producing IL-4 was 
derived in vitro from these mice. 
In the light of the pivotal role of M tuberculosis genes and their encoded proteins in 
linking innate and cell mediated adaptive immunity, these bacterial substances are 
promising candidates to be used as adjuvants for the development of effective 
therapeutic or prophylactic tumour vaccines. Furthermore, an enhancement of tumour 
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immunity may be most effective if agents are used that can orchestrate the immune 
response, including simultaneously cytokine production and cellular activation, in a 
manner that reflects physiological responses. 
The elucidation of the clear mechanism induced by these bacterial substances in 
increasing the immune recognition of poorly immunogenic tumours and the evaluation 
of a strategy which employs these substances in a manner more easily translatable into 
human applications will be the future issues resulting from the work of this thesis. 
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